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CHAPTER 1
General introduction and outline of the dissertation 




Although primary brain tumors (PBT) account for a relatively small proportion of all 
forms of cancer,1,2 they account for a disproportionately large share in cancer morbidity 
and mortality.3 PBT pose a direct threat to all facets of human functioning;4 emotional, 
physical, behavioral and cognitive. Still, clinical research has traditionally focused on 
the duration of (progression-free) survival.5 As survival outcomes improved due to 
treatment advances, interest has shifted towards optimizing quality of survival.6,7 
Understanding and managing the symptomatology of PBT is a key aspect of this goal.
Cognitive dysfunction is one of the most common symptoms in both untreated 
and treated PBT patients.8 Although potentially disruptive for the ability to function in 
various facets of daily life9-11 and capacity for medical decision making,12 it is under-
recognized in clinical care.13 Moreover, cognitive monitoring is often not a part of the 
standard care trajectory.14 Several issues in current research may contribute to this 
discrepancy. First, there are caveats in our knowledge on the manifestation of cognitive 
dysfunction in PBT and relevant predictors on patient and disease level. Furthermore, 
the added value of routinely obtained cognitive measures for other purposes, such as 
early prognostic stratification and disease monitoring over time, is not always clear. 
Finally, research methodologies do not always match clinical questions and needs at 
hand, which creates a barrier for translation of scientific findings for care purposes. 
For example, studying patients’ performances on separate cognitive domains does 
not correspond with the clinical need for understanding patients’ functioning across 
domains (i.e., their “cognitive profiles”).
The research comprising this dissertation centers around patients undergoing 
surgical resection of PBT at the Neurosurgery department of Elisabeth-Tweesteden 
Hospital, Tilburg, the Netherlands. The aims of this dissertation were to:
1) Contribute to our knowledge of the nature of cognitive (dys-)function, and 
relevant predictors, in benign and malignant PBT,
2) Illustrate the value of early and repeated postoperative cognitive measures 
for prognostic purposes in malignant PBT, and
3) Improve the alignment between research methodologies and question and 
needs in clinical care.
Cognitive functioning before and after surgical resection of three common classes of 
PBT (glioma, meningioma, pituitary adenoma) is investigated in Part II (Chapters 2-5). 
Part III comprises investigations of the value of postoperative cognitive status for early 
prognostic refinement (Chapters 6) and of longitudinal, personalized neuropsychological 
assessment for disease monitoring (Chapter 7) in glioma.
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Primary brain tumors – epidemiology and burden on health care
The 2016 Global Burden of Disease Study reported that approximately 330.000 
individuals are diagnosed with central nervous system (CNS) cancer on a yearly basis. 
This form of cancer is responsible for 6.9 to 8.3 million disability-adjusted life years 
(DALY), i.e., years of ‘healthy’ life lost due to morbidity and mortality.15 CNS cancer also 
strongly affects patients’ direct environment, as relatives who act as carers are at risk 
of compromised (mental) health.16
CNS cancers that specifically affect the brain can be broadly categorized 
into primary and secondary brain tumors. Primary brain tumors (PBT) comprise a 
heterogeneous class of tumors17 that most often arise from glial tissue, the (glandular) 
pituitary, and, although strictly not part of the brain itself, the meninges. In contrast, 
secondary brain tumors arise when malignant cells from a primary tumor environment 
in another part of the body, most often lung or breast cancer or melanoma,18 metastasize 
to the brain.
The most recent US Central Brain Tumor Registry19 reported an average annual 
age-adjusted incidence rate for the major PBT classes - meningioma, glioma, pituitary 
adenoma - of approximately 8.56, 5.48, and 4.08 per 100.000 individuals respectively. 
Although the absolute incidence of PBT tumors increases with age, they rank higher in 
terms of the relative incidence among cancers within the young adult population (aged 
≤ 39 years) as compared to the older adult population (>40 years). The incidence of PBT 
types further varies by factors such as sex and ethnic origin.19
PBT account for only ±2% of cancers.17 However, they pose a great burden to 
health care,20 not only because of the highly specialized, intensive, and often long-term 
multidisciplinary care that is required, but also due to their significant physical and 
psychological morbidity.15,21 Monthly health care costs can be up to 20 times higher 
in PBT patients compared to demographically similar individuals without cancer.22 
Furthermore, estimates of objective burden for informal caregivers of PBT patients, 
measured in daily hours providing (custodial) care, are relatively high compared to 
other neurological and oncological illnesses.20 Symptoms associated with this burden 
are associated higher health care utilization costs and decreased productivity for 
caregivers.21
Primary brain tumors – classification of major subtypes
The contemporary classification of PBT incorporates various histological (phenotypic) 
features and, for some tumor types, genetic characteristics.23 About two-thirds of PBT 
are non-malignant tumors, that carry a favorable oncological prognosis, while malignant 
PBT account for about one-third of the total PBT population.19
Meningioma
The largest class of non-malignant tumors, making up approximately one third of the 
total PBT population,1 constitutes WHO grade I (benign) and II (atypical) meningioma. 
1
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Meningioma are extra-axial tumors that likely originate from arachnoid meningothelial 
cells and can grow at various sites in the infra- and supratentorial compartments of 
the cranial cavity. Although strictly not malignant, atypical meningioma can show a 
tendency towards local invasion and recurrence after (subtotal) removal.24,25 Diagnosis, 
grading and subtyping is currently primarily based on histological features. The role 
of genetic profiling, e.g, downregulation of genes on chromosome 14q,26 for future 
diagnostics and treatment is being investigated.27
Meningioma are diagnosed about 2.5 times more often in women than men 
(incidence 4.5:100.000 vs 1.8:100.000).28 The true prevalence of meningioma in the 
population is significantly higher than the number derived from diagnosed cases, as 
many cases remain undetected due to their asymptomatic nature. In a study by Vernooij 
and colleagues of incidental findings on MRI scans,29 about 1.1% of female and 0.9% 
of male subjects harbored an asymptomatic meningioma. Extrapolating to the Dutch 
population, the prevalence would be 75.000 to 100.000 cases.28
Pituitary adenoma
Tumors growing from the anterior pituitary (i.e., pituitary adenoma) are officially 
recognized as neuroendocrine tumors. The vast majority of pituitary adenoma are 
non-malignant (<1% are classified as malignant), although up to 35% can show invasive 
features, such as infiltration of the sphenoid sinus.30 As a group, pituitary adenoma are 
the second most common type of non-malignant PBT and make up 16% of the total 
PBT population.17
Anatomical classification can be based on radiological evidence, where the 
tumor can be confined to the sella (microadenomas, < 1cm), or extend above the sella 
(macroadenoma ≥1cm) with various degrees of extension and sellar destruction.31 
WHO classification of adenoma subtype currently adopts a designation that combines 
traditionally used features, including morphology and cellular hormonal content, with 
a transcription factor profile that differentiates between different cell lineages.32 Major 
subtypes include somatotroph (growth hormone producing), lactotroph (prolactin 
producing), corticotroph (ACHT producing), gonadotroph (gonadal hormone producing), 
thyrotroph (TSH producing), plurihormonal (combinations) and null cell (no production 
of adenohypophyseal hormones) adenoma.31,32
Tumors with clinical endocrine activity detected in immunohistochemical analysis 
and serum hormone levels are historically referred to as functioning pituitary adenoma. 
Those that do not secrete hormones or below a clinically relevant level are referred 
to as non-functioning pituitary adenoma (NFPA, 14-54% of cases in varying series).33 
Characteristic of NFPA can be their relatively large size and extension beyond the sella 
through which they can damage and compress adjacent structures, including the optic 
chiasm (causing visual disturbances) and pituitary itself (causing hormonal deficiencies, 
±37-85% of cases).33




About 75% percent of malignant PBT comprise diffuse glioma. Their incidence in Europe 
lies around 6:100.000 individuals,34 and approximately 1100 individuals are diagnosed 
in the Netherlands each year.35
The broad class of glioma comprises various tumors that share histological features 
with different types of glial cells, such as astrocytes (astrocytoma) and oligodendrocytes 
(oligodendroglioma). Histological grading takes into account the presence of nuclear 
atypia (WHO grade II, low grade glioma), increased cell proliferation (WHO grade III, 
anaplastic glioma), and microvascular proliferation and/or necrosis (WHO grade IV, 
glioblastoma). Higher tumor grade is related to more aggressive clinical behavior and 
poorer prognosis. Still, low grade glioma can be particularly disruptive for patients’ lives, 
because their peak age is relatively low (35-44 years36) as compared to, for example, 
glioblastoma (>55 years).37
The most recent WHO classification of CNS tumors23 combines the glioma’s 
histological features with genetic markers that serve further diagnostic accuracy 
and prognostic stratification. It presented a major restructuring and introduced new 
entities based on the combination of these features. For example, a distinction could 
not be reliably made between primary (i.e., de novo) and secondary (i.e., progressed 
from a lower grade) glioblastoma based on histology alone, even though these two 
types proposedly derive from different neural precursor cells and differ with regards 
to survival duration. Isocitrate dehydrogenase gene 1 (IDH1) mutation is, however, a 
distinctive feature of secondary glioblastoma.38 Another example of the added value 
of genetic subtyping for diagnostic purposes concerns combined loss of the short 
arm of chromosome 1 and long arm of chromosome 19 (i.e., 1p/19-codeletion). This 
feature distinguishes oligodendroglial from astrocytic glioma, thereby making diagnosis 
of mixed oligo-astrocytic tumors redundant under the new classification.23 Genetic 
features can also be predictive of treatment response. For example, silencing of the 
O6-methylguanine-DNA methyltransferase [MGMT] gene is a known biomarker for 
response to temozolomide chemotherapy.23
Treatment and prognosis
Benign PBT
The threat of non-malignant tumors like meningioma and pituitary adenoma, and the 
reason for intervention, does not lie in their potential for invasive or aggressive growth. 
Rather, treatment is usually commenced due to the presence of clinical symptoms that 
result from increased intracranial pressure and/or mass effect that subsequently disrupt 
functioning of proximal structures and more distally located regions. Depending on the 
balance between risk and expected benefit, surgical resection is a preferred treatment 
of choice in these symptomatic tumors.27,39 Removal of a meningioma or adenoma 
provides a definitive diagnosis (as tissue is obtained), and aims to relief symptoms and 
1
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obtain optimal local disease control. Local control rates are generally high,40 but depend 
on the presence of atypical or invasive features, the extent of resection and whether 
non-radical resection is followed by stereotactic radiotherapy or –surgery.39,40
Glioma
Like benign PBT, malignant PBT affect both local and global brain function and can 
increase intracranial pressure. However, these tumors pose a major concern because of 
their infiltrative growth that disables complete surgical resection, their location behind 
the blood-brain-barrier that hampers delivery of systemic therapeutic agents, and the 
immune-suppressive nature of the tumor microenvironment.2,41
Treatment for diffuse glioma is not curative, as even low grade glioma progress 
toward higher malignancy over time.42 Surgical resection is the preferred first step 
in a multidisciplinary therapeutic approach for glioma as seen from an oncological 
viewpoint. Still, surgical decision making depends on tumor resectability and needs 
to balance risk (e.g., loss of function) with expected oncological benefit.43 Depending 
on tumor features as well as patient characteristics, such as functional status (i.e., 
the degree of functional impairment) and age, adjuvant treatment strategies can 
significantly prolong survival44 and improve or maintain quality of life.3
The clinical outcome of glioma is highly variable,45 as illustrated by median overall 
survival duration of only 13 months in patients with IDH1-wildtype glioblastoma 
(WHO grade IV46) up to 157 months in 1p-19q co-deleted oligodendroglioma (WHO 
grade II).47 Prognosis appears to be tied more closely to the tumor’s genetic profile 
than its morphology,46,48 although histological grading remains relevant for prognostic 
stratification. Alongside tumor characteristics and treatment, several clinical prognostic 
indicators throughout the care trajectory have shown additional value in predicting 
survival outcome. Some of the major clinical predictors include extent of tumor 
resection,43 which is partly related to tumor location, and perioperative functional 
status (Karnofsky Performance Status, KPS).49,50 Age may also be a prognostic indicator,51 
but its influence is not uncontested, given its relationship with glioma subtype37,45 and 
(adjuvant) treatment decisions,52 as well as non-significant results in patients over 60 
years of age.53
Heterogeneous and burdensome symptomatology
PBT symptomatology is very heterogeneous,54 as it can involve emotional, behavioral, 
physical and/or cognitive dysfunction. Moreover, multiple, different symptoms are 
often present at the same time. A study by Armstrong and colleagues55 found that 
over 50% of PBT patients reported more than ten concurrent symptoms. In the same 
study, the majority of symptoms significantly influenced clinically evaluated Karnofsky 
Performance Status, and 25% of patients reported themselves that symptoms interfered 
with their daily activities.
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Symptom clusters are often already present at time of diagnosis56 as a result 
of mass effect and/or parenchymal infiltration with subsequent damage to neural 
tissue. At this time, symptomatology is significantly related to tumor characteristics. 
For example, low grade glioma most often present with epilepsy (>50% of cases), 57 
whereas focal neurologic deficits and cognitive dysfunction occur more frequently 
with glioblastoma.57,58 Tumor location can also influence pre-treatment symptoms; 
e.g., meningioma located at the skull base often induce specific cranial nerve deficits, 
while those growing at the convexity frequently present with headaches and cognitive 
dysfunction.59 Larger tumor volume and peritumoral edema are also predictors of (the 
degree of) pre-treatment symptomatology.60,61 Symptoms that patients report most 
frequently, irrespective of lesion characteristics and treatment status, tend to be non-
specific in nature, and include fatigue and sleep disturbance.55
Although symptom relief is an important therapeutic aim, some symptoms 
may linger or be exacerbated over the course of and after completion of treatment. 
Moreover, adjuvant modalities (e.g., chemotherapy and radiotherapy) can also elicit 
new deficits,55,62 proposedly due to cellular toxicity and loss that results from oxidative 
stress and DNA damage63 and suppression of progenitor cell proliferation.64,65
Cognitive functioning in patients with PBT
Despite the different pathophysiology, both benign and malignant PBT can induce 
disruption of cognitive functioning. In fact, cognitive symptoms are among the most 
common symptoms found in the PBT population.54 Cognitive functioning is generally 
understood to cover 4 main functional classes, including receptive functions, memory 
and learning, mental (re-)organization and expressive functions. Within each class, 
discrete functions are identified. It is important to note that these classes are primarily 
distinguished on a conceptual level, as in practice they reflect interconnected 
facets.66
Cognitive functioning can be measured in several ways. A broad distinction can 
be made between “objective measurement” - i.e., measuring one’s performance on 
tests that tap into cognitive domains, such as memory, processing speed, and executive 
function - and “subjective measurement” - i.e., by means of self-report or proxy 
report that indicates one’s experience of cognitive functioning,54 such as the ability to 
remember names or navigate in new or familiar environments. Cognitive impairment 
on tests, which is one of the measures of interest in this thesis, is reportedly present 
in the majority of PBT patients.61,67,68 This means that these patients perform below 
a clinically established threshold of dysfunction on one or more neuropsychological 
tests, for example, below the 6.7th percentile based on data from a (healthy) normative 
sample. There may be an additional proportion of patients suffering milder cases of 
disturbed cognitive functioning.69 Alongside its particularly high prevalence, cognitive 
dysfunction is also reported as a primary source of burden by caregivers.70
1
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Developments in and recent insights from research into cognitive functioning
Studied outcomes in PBT have long been restricted to survival and overt neurological 
deficits, such as motor function. As duration of survival improved parallel to advances 
in anti-tumor treatment, a focus on quality of survival and functioning during stable 
disease, and thus cognitive functioning, became more important.6 Still, a conceptual 
review by Wefel and colleagues published in 200471 raised several methodological issues 
in published literature on cognition in PBT patients at the time. These issues included 
heterogeneity in cognitive assessments and patient samples between studies, lacking 
control groups, and the often retrospective nature of investigations. Over the past 15 
years, multiple valuable insights have been generated from the surge in quality studies. 
These insights have confirmed the inadequacy of a singular focus on neurological status 
or survival in research and care. 68,72-80
Possible similarities and differences in cognitive dysfunction between PBT types
One important understanding we can derive from recent research is that some cognitive 
domains, such as executive functioning, may be particularly vulnerable to burden 
across tumor types.14,68,73,78 At the same time, susceptibility to disruption of other 
cognitive functions, such as memory and psychomotor function, may differ between 
diagnoses.75,78,81 It is also argued that the severity of dysfunction is (partly) different 
between diagnoses, where meningioma and low grade (WHO II) glioma are suggested 
to invoke milder disturbances than high grade glioma(WHO III/IV), 68,73 possibly as a 
result of a less disruptive growth pattern, more opportunity for compensation due to 
lower lesion momentum, and less aggressive treatment. Taken together, it appears 
that there may be some overlapping, but also some dissimilar profiles of cognitive 
functioning present between PBT populations. At the same time, the precise nature of 
these cognitive profiles is currently not clear.
Predictors of dysfunction
A second domain where substantial progress has been made is the investigation of 
factors that influence cognitive (dys-)function. The fact that factors on various levels 
- patient, disease, and treatment - can be relevant is now undisputed. Effects of some 
characteristics, such as age,82,83 comorbidity,72 and the presence of epilepsy, 84-86 appear 
to span across PBT populations. Many factors may, however, determine cognitive 
fitness in a disease-specific way, either because they are confined to a specific tumor 
type (e.g., high lesion momentum and systemic treatment specific to diffuse glioma,87, 
and growth in the sellar region specific to meningioma88 and pituitary adenoma) or 
because their effects appear disparate across tumor types (e.g., the influence of the 
affected 88-90 hemisphere on cognition may differ). Despite our knowledge on factors 
that affect cognition on a population level, it remains particularly challenging to 
predicting cognition for individual patients at any phase of the disease.Moreover, there 
is a substantial number of patient (e.g., germline genetic polymorphisms) and disease 
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(e.g., hormonal dysfunction) characteristics of which the effects on cognition in the PBT 
population are still unclear due to a paucity of research.
Advances in the approach to studying cognition
Significant insights have also been presented on best practices for studying cognition, 
in particular the use of individual patient level in addition to group (mean) level 
approaches.91 As a result of thorough comparisons of results generated from both 
approaches, we now know that investigating only group performances is not appropriate 
for individual patients in clinical care,92 because the variability in cognitive performances 
and their trajectories of individual patients is not captured in group-level results.69,92 
For example, within a patient sample that, based on their average group score, deviates 
only mildly from a normative sample, there may be a subgroup of individual patients 
with actual cognitive impairment. Similarly, for cognitive trajectories over time, group 
findings may provide intuitive results in reporting overall improvement after tumor 
resection. However, they do not indicate if there were individual patients who showed 
decline. The importance of incorporating individual level results alongside group results 
is now recommended as standard practice in clinical research.92
The potential value of cognition as predictive measure
Finally, measurement of cognitive function has been shown to have a multifaceted 
value for clinical care, as it relates to various other domains of PBT patients’ daily 
functioning, such as (medical) decision making capability,93 time management and 
coping with physical demands at work,94quality of life, 95 interpersonal functioning,94,96 
and functional independence.97 Moreover, early postoperative cognitive impairment - 
before start of adjuvant treatment - even appears to predict poorer survival outcome98 
and decline in cognitive functioning over time appears to be related to recurrent tumor 
activity99-101 in high grade glioma patients. A similar phenomenon has been observed in 
other neurological afflictions with a progressive nature,102,103 indicating that cognition 
may be useful as an additional, non-invasive proxy measure for (recurrent) disease 
activity.101
Opportunities in research on cognitive functioning in patients with PBT
To this day, cognitive deficits are often overlooked or underestimated in clinical 
practice for various reasons.13,54 The more covert nature of cognitive deficits can partly 
contribute, as it makes them harder to observe during a limited clinical evaluation 
than other symptoms. Moreover, patients’ reporting of subjective experience of their 
daily cognitive functioning is by itself not a sufficient indicator of the actual objective 
level of functioning as measured with tests.104 Objective cognitive evaluation requires 
separate and sometimes lengthy assessments that can be expensive and difficult to 
integrate in regular care trajectories,54 especially as the benefits of obtaining cognitive 
measures for clinical purposes as well as strategies for efficient testing are not always 
1
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clear for clinical staff. In the burgeoning of quality research and insights on cognition in 
PBT, several questions and issues may still be addressed as we aim to solidify cognitive 
monitoring as an integral part of disease management:
First, the level of empirical evidence and the methodological quality of 
research differs between different tumor categories. Relative to meningioma and 
glioma, the literature on pituitary adenoma, for example, remains methodologically 
heterogeneous,105 and there is a lack of prospective investigations of cognition 
surrounding surgical intervention.75 This variance in quantity and quality of empirical 
evidence within the PBT population, may subsequently lead to differences in the quality 
of care provided. Moreover, as mentioned, our understanding of the influence of a 
number of patient and disease characteristics also remains limited to date due to a 
paucity in studies. For example, germ-line genetic determinants of cognitive functioning, 
such as allelic variations of the APOE gene, are relatively scarcely researched in PBT 
patients,106 even though they have been established predictors of cognitive outcomes 
in healthy adults 107,108 and patients treated for non-CNS cancer.109
Second, despite the addition of individual level analyses, most current approaches 
to cognitive profiling in PBT still do not allow us to adequately understand the 
heterogeneity in cognitive functioning, because each cognitive test or domain is 
investigated separately from the others. This approach disregards a part of the nature 
of cognition, namely that cognitive domains show differential interrelations,66,110 
similar to the neural networks that underlie cognitive functions seem to do.66,111,112 For 
example, problems with information processing speed have been shown to influence 
specific complex functions, 113 such as task switching.114 This relationship is proposedly 
a function of their shared mechanisms, including stimulus perception, decision making 
and planning, and performance evaluation.115 The association between information 
processing speed and memory performance appears less strong, indicating that 
these domains may function more distinctly.114 By approaching them separately, we 
cannot retrieve insights into which patterns exist in performances across cognitive 
tests or domains. This subsequently leaves unknown what cognitive profiles exist in 
this apparent cognitive heterogeneity.. Investigations of covert patterns in patients’ 
performances across neuropsychological tests can provide new insights that may be 
more true to the nature of cognition and its evaluation in clinical practice.
The third issue concerns the prognostic value of cognitive measures and how 
this may fit in clinical practice. Although advances have been made in exploring the 
prognostic value of early postoperative cognitive status,98,116 we do not know whether 
poor cognitive status measured at a regular clinical follow up during early adjuvant 
treatment can be used as an early prognostic indicator alongside known clinical factors. 
Moreover, the effect of early cognitive status on survival outcome is reported with 
hazard or odds ratio’s. These statisticsprovide inform us about which patients are more 
likely to experience an event like progression or death during a follow up period, but 
not it does not directly provide knowledge about the difference in time until this occurs. 
In fact, for malignant gliomathat inevitably lead to progression and death, the latter is 
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especially important. A translation of the effects of cognition into differences in survival 
duration is more easily interpretable for clinicians.
Cognitive change may also have value in disease monitoring, as it may reflect 
tumor activity over time.101 Still, capturing those cognitive functions that are most 
sensitive to tumor activity remains difficult, as they may differ between individual 
patients.99 The question of how to capture those domains that are sensitive to changes 
in tumor activity in individual patients is still open, as well as how their assessment can 
be made efficient and integrated into clinical care.
Goal and outline of this dissertation
The research in this dissertation focuses on three objectives:
1) Contributing to our understanding of cognitive (dys-)function and relevant 
predictors thereof in patients with adenoma, meningioma and glioma 
(addressed in Part II),
2) Illustrating the multifarious value of routinely obtained data on cognitive 
functioning for clinical practice, specifically for early prognostic stratification 
and longitudinal disease monitoring of patients with high grade glioma, 
(addressed in Part III), and
3) Improving the alignment of methodologies applied in research and questions 
and needs in the clinical setting, such as the interpretability of results and 
potential for integration in care (addressed in Part II and Part III).
By addressing these objectives, this dissertation aims to contribute to improvement 
of patient informing, and ultimately, facilitation of personalized monitoring, shared 
decision making, and targeted intervention for cognitive symptomatology.
Part II of this thesis comprises Chapters 2-5. In Chapter 2, we investigated the 
course of cognitive functioning of patients with non-functioning pituitary adenoma 
undergoing endoscopic transsphenoidal resection on group- and individual level to 
contribute to our knowledge of the peri-surgical trajectory and tumor-related predictors 
of cognition in this relatively understudied population. In Chapter 3, we examined the 
association between APOE genotypic variation, in particular carrier status of the APOE 
ε4 allele, and the longitudinal course of cognitive functioning in meningioma and glioma 
patients from pre- to 12 months post-surgical follow-up. Chapters 4 and 5 aimed to 
elucidate and predict currently unknown latent profiles of cognitive impairment across 
different neuropsychological tests in patients with diffuse glioma and meningioma.
Part III comprises Chapters 6 and 7. Chapter 6 addresses the relationship between 
cognitive impairment during early adjuvant treatment and survival duration in patients 
with glioblastoma using a clinically intuitive statistical approach, in order to establish 
whether impairment in this phase can be used as a prognostic indicator. In Chapter 7 
we investigated whether brief, longitudinal, personalized cognitive assessment could 
1
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predict disease progression in patients with anaplastic astrocytoma and glioblastoma, in 
order to explore its potential as a non-invasive addition to regular disease monitoring. 
Chapter 8 provides a general discussion of the findings of this dissertation and 
recommendations for clinical and future research practices.
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CHAPTER 2
Cognitive functioning in patients with nonfunctioning 
pituitary adenoma before and after endoscopic 
endonasal transsphenoidal surgery
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Purpose  Patients with nonfunctioning pituitary adenomas (NFPAs) can suffer 
from cognitive dysfunction. However, the literature on longitudinal cognitive follow-up 
of patients undergoing endoscopic endonasal transsphenoidal surgery (EETS) is limited. 
This study was performed to investigate perioperative cognitive status and course in 
patients with NFPAs.
Methods Patients underwent computerized neuropsychological assessment 1 
day before (n = 45) and 3 months after (n = 36) EETS. Performance in 7 domains was 
measured with a computerized test battery (CNS Vital Signs) and standardized using 
data from a healthy control group. We conducted analyses of cognitive performance 
at both time points and changes pre- to post-ETSS on a group and an individual level. 
Linear multiple regression analyses were employed to investigate predictors of cognitive 
performance.
Results  On average, patients scored significantly lower in 6 of 7 cognitive 
domains before and after surgery than controls. Impairment proportions were 
significantly higher among patients (56% before surgery, 63% after surgery) than among 
controls. Patients showed no change over time in group-level (mean) performance, but 
28% of individual patients exhibited cognitive improvement and 28% exhibited cognitive 
decline after surgery. Hormonal deficiency showed a positive correlation with verbal 
memory before surgery. Postoperative performances in all cognitive domains were 
predicted by preoperative performances.
Conclusion Cognitive impairment was present before and after EETS in over half 
of NFPA patients. Individual patients showed diverse postoperative cognitive courses. 
Monitoring of cognitive functioning in clinical trajectories and further identification of 
disease-related and psychological predictors of cognition are warranted.
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INTRODUCTION
An increasing body of evidence indicates that patients with pituitary adenoma may suffer 
from cognitive dysfunction.1,12,28,39 While executive functioning may show improvement 
before other domains, such as episodic memory or perceptual speed,15,31 deficits do not 
necessarily resolve after successful medical treatment.14,24,26,29The degree of cognitive 
dysfunction has been linked tentatively to factors such as age25 and the presence of 
an extrasellar component.31 Although functioning adenomas that cause hormonal 
hypersecretion appear to be related to more dysfunction than nonfunctioning pituitary 
adenomas (NFPAs),31,38,41 studies consistently show that patients with NFPA perform 
worse than healthy individuals.4,6,38
The available literature focusing on or including NFPAs largely comprises 
cross-sectional measurements of cognitive performance in patients who underwent 
varying surgical and nonsurgical treatments.4–6,19,26,28,29,38Prospective studies on 
perioperative cognitive functioning are scarce, but those that exist generally 
reported on short-term postsurgical improvement on a group level despite varying 
measurement methods.15,31,41 A need remains for studies adopting standardized, 
validated measurements of cognitive function before and after surgical intervention. 
Moreover, group-level analyses can leave individual variations unnoticed, thereby 
possibly affecting the applicability of conclusions to clinical practice where patients 
with different characteristics are treated.
Cognitive dysfunction may pose an impediment to recovering regular functioning 
as it is related to mood disturbance,37 work performance,27 and quality of life.23 Adequate 
screening in a clinical setting can help identify disturbance(s) at an early stage and 
guide further monitoring or intervention. Computerized testing offers an opportunity 
to evaluate cognitive function in a standardized and less labor-intensive way than 
traditional paper-and-pencil testing. The method has been shown to be effective in 
detecting cognitive dysfunction across patient groups,7,21,40 whereas the sensitivity of 
well-known screening tools, such as the Mini-Mental State Examination (MMSE), in the 
brain tumor population is challenged.22
To our knowledge, the current study is the first to perform computerized cognitive 
screening over time in prospectively recruited patients with NFPAs undergoing resection. 
We used data from a Dutch control group of healthy individuals as reference for the 
following purposes: 1) to compare patients’ cognitive performance before and 3 months 
after endoscopic endonasal transsphenoidal surgery (EETS), and 2) to investigate change 
in performance, on both a group and an individual level. In addition, we considered 
the influence of tumor expansion and hormonal deficiency on preoperative cognitive 
performance and the influence of hormonal deficiency and preoperative cognitive 
performance on postoperative cognitive performance in exploratory analyses.
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Patients with primary brain tumors underwent neuropsychological assessment 1 day 
before and 3 months after surgery as part of their clinical care between November 2010 
and March 2018 in the Neurosurgery Department of Elisabeth-TweeSteden Hospital. 
Data were used for research purposes after written consent was given by the patients. 
The study was approved by the Medical Ethics Committee of the hospital.
Participants
Prospective cognitive test data from patients with histologically proven NFPAs who 
underwent first-time EETS were collected for this study. Exclusion criteria were age 
under 18 years, a recent history of psychiatric or (progressive) neurological disorder (≤ 
2 years), a history of intracranial neurosurgery, and characteristics that interfere with 
testing (e.g., severe visual deficits that prevent one from taking a computerized test).
Assessment Procedure
Assessments took place on the day of hospitalization (1 day before surgery) and 
when patients returned to the outpatient clinic for postoperative MRI evaluation (3 
months after surgery). Assessments required approximately 60 minutes and included 
computerized evaluation of cognitive function, as well as completion of the Dutch 
version of the Hospital Anxiety and Depression Scale (HADS).36 Sociodemographic 
variables were obtained via structured interview at the first assessment. Clinical data 
(symptoms at the time of presentation, reason for surgical intervention, and postsurgical 
events) were retrieved from medical records.
Measures
Cognitive functioning
Cognitive performance was assessed using CNS Vital Signs, a computerized 
neuropsychological test battery that is largely based on widely used tests, including 
the Symbol Digit Modalities Test and Stroop test.13 The CNS Vital Signs tests used in 
this study took about 30–40 minutes and covered the following 7 domains: Verbal 
Memory, Visual Memory, Psychomotor Speed, Processing Speed, Reaction Time, 
Cognitive Flexibility, and Complex Attention.
Data on repeated CNS Vital Signs performance from 158 healthy Dutch individuals 
were previously collected by Rijnen et al.33 and used to standardize patients’ scores 
at each time point on each domain to z-scores, taking into account the effects of age, 
Binnenwerk_Productie.indd   36 1/18/2021   11:38:49 AM
37
Cognitive functioning in patients with NFPA
education, and sex that were demonstrated to influence CNS Vital Signs performance. 
Follow-up z-scores were also corrected for practice effects in repeated testing.
Radiological Tumor Characteristics
The Hardy-Wilson classification42 was used to categorize the degree of preoperative 
extrasellar expansion (stages A–E) and invasion (grades I–IV). Signs of cavernous sinus 
invasion were classified according to Knosp grade (scores 0–4).18 Evaluations were 
based on coronal section of T1-weighted gadolinium-enhanced 1.5-T MR images. For 
exploratory prediction analyses, we dichotomized the Hardy-Wilson classification for 
suprasellar growth, indicating the presence of extension beyond the optic chiasm (stage 
CD) or its absence.
Hormonal Status
Hormonal assessment was performed as part of perioperative endocrinological care 
before, 1 week after, and 2 weeks after surgery. Measurements included serum levels 
of thyroid-stimulating hormone, free thyroxine, adrenocorticotrophic hormone, 
cortisol, insulin-like growth factor 1, follicle-stimulating hormone, luteinizing hormone, 
prolactin, and testosterone or estradiol. From these measurements, functioning of the 
hormonal axes was established (normal function or hypofunction). For exploratory 
prediction analyses, we specifically used the status of the pituitary-adrenal (cortisol) 
and -thyroid axes (deficiency vs no deficiency), because of their established relationship 
with cognitive functioning.2,10 Occurrences of transient and persistent central diabetes 
insipidus were obtained from the medical records.
Statistical Analysis
Group-Level Analyses: Cognitive Performance and Change
We conducted z-tests to compare the mean standardized z-scores for each of the 7 
cognitive domains of patients to the norms (mean z-score = 0, SD = 1), for both the pre- 
and postoperative time points. The mean z-score of the patient group in each cognitive 
domain reflects the standardized difference (in SDs) between the patient and control 
sample and can be considered as Glass’ delta effect size: (Mpatients − Mcontrols)/SDcontrols. 
Change on group level was investigated using paired sample t-tests, for which Cohen’s 
d effect sizes were calculated: Mdifference/SDdifference.
Individual-Level Analyses: Cognitive Performance and Change
We inspected patients’ individual performances in each domain for both time points. 
Individual z-scores of ≤ −1.5 (1.5 SDs below the mean; 6.7th percentile) were considered 
impaired. z-scores between −1.49 and −1.00 (6.8th–15.9th percentile) were considered 
low performances. We counted impaired and low performances per domain. Proportions 
at each time point were compared for patients versus healthy controls with chi-square 
tests and were compared over time within patients using McNemar’s test. Standardized 
2
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regression-based reliable change indices (RCIs)20,34 were calculated to investigate reliable 
change over time in individual patients, accounting for confounding effects related 
to repeated test administration, including flawed test-retest reliability and practice 
effects. RCI values ≥ 1.645 or ≤ −1.645 (two-tailed 90% CIs) were considered reliable 
improvement or decline, respectively. Descriptive characteristics were computed for 
improvers, stable performers, and decliners. No statistical comparisons of these groups 
were performed, as achieved statistical power with the current group sizes would not 
be sufficient ([1 − β] < 0.8).
Prediction of Cognitive Performance
Power calculation with G*Power 3.1 (based on proposed small to medium effect 
sizes and [1 − β] = 0.8) indicated that a multiple regression analysis allowed for 2 
predictors in this sample. We selected predictors based on reporting of particular 
importance to the NFPA population2,10,31 and primary brain tumor patients undergoing 
resection.32 Therefore, the relationships of preoperative performance (z-score) in each 
cognitive domain with suprasellar expansion and hormonal deficiency (dichotomized 
variables) and the relationships of postoperative performance with preoperative 
performance and postoperative hormonal status were investigated. Normal hormonal 
status and the absence of suprasellar growth were reference categories. Reflect-and-
logarithmic transformation was performed for domains with nonnormal distribution 
of residuals.
All analyses were carried out using SPSS Statistics 22 (IBM Corp.). Adjusted levels 
of significance (α) using the procedure by Benjamini and Hochberg3 were computed 
in the primary analyses to control for erroneous rejection of the null hypotheses in 




Data from 45 patients (Table 1) who underwent preoperative assessment were included. 
Patients’ mean age at the time of surgery was 59.7 years, in a predominantly male 
sample (67%). The distribution of patients according to Hardy-Wilson and Knosp 
classifications was available for 42 patients and is displayed in Table 2.
Transient or progressive visual deficits (e.g., hemianopia and diplopia) were the 
most common primary presenting symptom (31 patients, 69%), followed by headache 
(4 patients, 9%). Eight patients (18%) presented with other symptoms, including fatigue, 
anomia, malaise, and isolated epileptic insult. In 2 patients, the tumor was discovered 
during neuroimaging for a suspected unrelated illness (e.g., suspected transient 
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ischemic attack). Tumor characteristics on MRI—compression of the optic chiasm, 
signs of tumor growth, pituitary (stalk) displacement—were the primary reason for 
surgical intervention (44 patients, 98%). Surgical intervention was indicated because of 
symptom worsening in between radiological evaluations in 1 patient (2%).
Nine patients (20%) did not complete the postoperative cognitive assessment 
(5 canceled the assessment; 1 patient was deceased; and 3 had logistical problems). 
We found no significant differences between patients who completed both cognitive 
assessments and those who underwent the preoperative assessment only, in terms 
of sociodemographic or clinical variables of interest and preoperative cognitive 
performances (all p > 0.05; data not shown).
Table 1. Patient characteristics
Pre-op (n = 45) Post-op (n = 36)
Male (%) 30 (67%) 26 (72%)
Age at time of surgery, yrs
Mean, range 59.73 ± 12.07, 38–84 60.06 ± 12.17, 38–84
Educational level
Low 16 (36%) 12 (33%)
Middle 12 (27%) 11 (31%)
High 17 (38%) 13 (36%)
HADS Anxiety score 6.85 ± 3.90 4.07 ± 3.49*
HADS Depression score 4.44 ± 3.84 3.93 ± 4.67
Postop events/complications
CSF rhinorrhea n/a 4 (9%)
Meningitis secondary to CSF rhinorrhea n/a 2 (6%)
Nasal hemorrhage n/a 1 (2%)
Central diabetes insipidus†
Transient 0 (0%) 8 (22%)
Persistent 0 (0%) 3 (8%)
Anterior pituitary function
Hypocortisolism no. (%, substituted no.‡) 15 (33%, 15) 13 (36%, 13)
Hypothyroidism no. (%, substituted no.‡) 18 (40%, 18) 20 (56%, 20)
Hypogonadism no. (%, substituted no.‡) 35 (78%, 5) 29 (81%, 7)
Growth hormone deficiency no. (%,
substituted no.‡)
16 (36%, 1) 9 (25%, 2)
Values are presented as the number (%) of patients or as the mean ± SD.
*Significant change from pre- to postoperative measurement on a group level (p < 0.01).
†Transient: normalization at time of discharge. Persistent: continued therapy with desmopressin.
‡The number of patients receiving hormonal substitution therapy at pre- and postoperative 
measurements.
2
Binnenwerk_Productie.indd   39 1/18/2021   11:38:49 AM
40
Chapter 2
Table 2. Radiological classifications of NFPAs according to Hardy-Wilson and Knosp grades
Suprasellar Extension (H-W 
grade)
Parasellar Invasion (H-W 
grade)
Cavernous Sinus Invasion 
(Knosp grade)
Category No. Category No. Category No.
A (suprasellar 
cistern)
5 I (normal sella) 0 0 (no extension) 0
B (anterior recess of 
3rd ventricle)
13 II (enlarged sella) 17 1 (no extension beyond 
intercarotid line)
13
C (displacement of 
3rd ventricle floor)
15 III (localized floor 
perforation)
21 2 (no extension beyond 
lateral ICA tangent)
14
D (intradural) 1 IV (diffuse floor 
perforation)
4 3 (extension beyond 
lateral ICA tangent)
8
E (extradural) 8 V (distant spread) 0 4 (encasement of 
intracavernous ICA)
7
H-W = Hardy-Wilson; ICA = internal carotid artery
Group-Level Analyses: Cognitive Performance and Change
Before and after surgery, the patient sample showed significantly lower mean 
performance scores (false discovery rate–adjusted α-level 0.043) than the individuals 
from the normative sample in all domains (all p ≤ 0.02) except Visual Memory (p = 0.61), 
with medium to large effect size (Table 3). Before surgery, Psychomotor Speed showed 
the lowest mean z-score, and thus greatest effect size (−0.90), followed by Reaction 
Time (−0.82). Similar effect sizes were found at 3-month postoperative assessment, 
where Reaction Time (−0.88) and Psychomotor Speed (−0.80) still showed the highest 
effect size. Paired sample t-tests showed no significant change in mean cognitive domain 
scores over time (all p > 0.05).
Individual-Level Analyses: Cognitive Performance and Change
Prior to surgery, 25 (56%) of 45 patients showed impairment in at least 1 cognitive 
domain, and 14 patients (31%) showed impairment in at least 2 domains. Four 
patients showed broad impairment (6 domains). The proportion of impairment among 
patients was significantly higher than in the control group (29% in 1 domain and 14% 
in 2 domains; p = 0.02). The highest proportions of impaired scores were observed 
for Psychomotor Speed (11 patients, 24%) (Table 4), followed by Complex Attention 
and Cognitive Flexibility (each 10 patients, 22%). These were significantly higher than 
those seen in the healthy control individuals (7%, 9%, and 9%, respectively; all p < 
0.05). The postoperative proportion of impairment among patients (23 patients [64%] 
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in at least 1 domain; 11 patients [31%] in at least 2 domains) was not significantly 
different from that of the preoperative proportion (p > 0.05), but it was higher than 
that seen in the control sample at their second assessment (p = 0.02). Reaction Time 
and Verbal Memory showed the highest proportions of impairment after surgery (both 
10 patients, 29%), again significantly higher than that seen in the control sample (7% 
and 5%; both p < 0.05), followed by Complex Attention (8 patients, or 23% vs 11% in 
controls; p = 0.056).
Thirteen (36%) of the 36 patients who underwent both pre- and postoperative 
assessments showed no reliable change in any of the domains. Ten patients (28%) 
showed decline (RCI ≤ −1.645) in one or more domains in the absence of improvement, 
and 10 patients (28%) showed improvement (RCI ≥ 1.645) in the absence of decline. 
Improvement and decline occurred concurrently in 3 patients (1 vs 2 domains, 
respectively, in 2 patients; and 1 vs 5 domains, respectively, in 1 patient). As shown in 
Table 4, we observed individual improvement most often for Reaction Time (7 patients, 
20%), while none of the patients improved in the Visual Memory domain. Reliable 
decline was also most frequently observed in the Reaction Time domain (6 patients, 
17%), followed by Cognitive Flexibility and Visual Memory (both 4 patients, 11%).
Group characteristics of patients whose cognitive performance improved, declined, and 
remained stable are presented in Table 5 (no statistical comparisons). All groups showed 
a decrease of > 2.5 points on the Anxiety subscale of the HADS from pre- to postoperative 
measurement. A decrease in the mean score on the Depression subscale of the HADS 
appeared to be greater among patients with improved cognitive performance (1.78 
points) than among those with declined or stable cognitive performance (0.75 and 0.42 
points, respectively). Seventy percent of those with a declined cognitive performance 
suffered from postsurgical hypothyroidism, compared to 40% in the other groups.
2
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Prediction of Pre- and Postoperative Cognitive Performance
Preoperative performances in the domains were not predicted by the regression 
models that contained both variables of interest—hormonal deficiency and suprasellar 
extension (model p values > 0.05). Hormonal deficiency was, however, an independent 
positive predictor in the model for Verbal Memory (β = 0.36, p = 0.02), whereas 
suprasellar extension was not (p > 0.05).
Postoperative cognitive performances in all domains (Verbal Memory: p < 0.01, 
F(2) = 8.95, adjusted R2 [adjR2] = 0.33; Visual Memory: p< 0.01, F(2) = 8.36, adjR2 = 0.26; 
Processing Speed: p< 0.01, F(2) = 17.24, adjR2 =0.53; Psychomotor Speed: p< 0.01, 
F(2) = 8.82, adjR2 = 0.32; Reaction Time: p< 0.01, F(2) = 10.02, adjR2 = 0.47; Complex 
Attention: p< 0.01, F(2) = 5.46, adjR2 = 0.16; and Cognitive Flexibility: p= 0.01, F(2) = 5.3, 
adjR2 = 0.22) were significantly predicted by the regression models. Preoperative 
performance was the only significant predictor (all p’s< 0.02) for each postoperative 
performance, with standardized predictor coefficients ranging from β = 0.43 for Complex 
Attention up to β = 0.76 for Processing Speed. Postoperative hormonal deficiency was 
not an independent predictor (all p’s> 0.05) for postoperative performances.
DISCUSSION
This study prospectively evaluated cognitive performance and change over time with 
brief computerized testing of 45 patients with NFPA before and 3 months after EETS.
Our results support existing evidence of cognitive dysfunction in NFPA patients 
before15 and after4,25 treatment. As a group, patients showed significantly lower mean 
performance (status) scores than healthy controls in 6 of 7 domains, with moderate 
to large effect sizes, at both time points. Over half of patients showed impairment in 
at least 1 domain (56% before surgery, 63% after surgery). These rates of impairment 
among patients were significantly higher than those among controls.
Cognitive deficits in patients with NFPA may involve a broad range of domains 
instead of primarily concerning Verbal Memory, as previously proposed.1 In accordance 
with Tiemensma et al.,38 we found no difference between patients in our sample and 
the healthy controls on Visual Memory. This may reflect material-specific dysfunction 
(e.g., through left medial temporal structures),17 rather than a general disturbance of 
memory-serving processes, such as sustained neuronal activation.9,30 We must note 
that CNS Vital Signs memory domains, both visual and verbal, tap into immediate 
and delayed recognition instead of free recall, thereby not providing a full-scope 
measurement of memory.
The lack of group-level change in any of the domains in this study stands in 
contrast to available prospective findings in similar patient samples. Hendrix et 
al.15 found performance normalization on measures of psychomotor and processing 
speed (Digit Symbol Substitution Test and Trail Making Test part A) 2 months after 
surgery, although their sample was small (n = 10). Wang et al.41 reported improvement 
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in multiple CAMCOG (Cambridge Cognitive Examination) subdomains at a 3-month 
postsurgical follow-up. The CAMCOG instrument is designed to distinguish mild 
dementia from normal cognitive aging,35 with items that are less difficult than those on 
neuropsychological tests.43 This can engender a low threshold to detect improvement 
and reduce suitability in the NFPA population.
We found markedly different individual courses, with almost equal proportions of 
patients showing no reliable change, improvement only, and decline only in cognition 
(36%, 28%, and 28%, respectively) and a small portion showing both improvement and 
decline (8%) that did not surface in the group-level results, which suggested a stable 
performance over time. Clinicians should be cautious when applying and communicating 
group-level information about postsurgical change to individual patients. Moreover, 
they should consider that different cognitive domains may show different rates of 
individual change.
Exploratory regression analyses of preoperative cognitive status showed 
that preoperative hormonal hypofunction (pituitary-adrenal axis; cortisol and/or 
pituitary-thyroid axis; and free thyroxine) was a positive predictor of verbal memory 
performance. The modulatory influence of circulating cortisol and thyroid hormone 
supposedly follows an inverted U shape, where suboptimal receptor occupancy, not just 
clinical deficiency, has been associated with memory dysfunction.2,8,10 It may be that 
patients with pre-surgical clinical deficiency benefitted from replacement therapy (all 
patients with clinical deficiency in our sample received treatment), resulting in better 
performance than in patients with nonclinical suboptimal serum levels who were not 
receiving pharmacological treatment. We found no support for a significant influence of 
tumor expansion beyond the optic chiasm for cognitive performance, despite research 
suggesting that suprasellar growth can affect cognitive function,31 possibly through 
disruption of adjacent (diencephalic) pathways. We acknowledge that categorization of 
suprasellar growth, as used in this study, although more easily determined in a clinical 
setting, provides a less precise measurement than a volumetric report.
Postoperative cognitive performances were not associated with postoperative 
hormonal status but were consistently predicted by the preoperative performances 
with notable effect sizes. Assessment of “cognitive fitness” as part of the clinical 
trajectory before surgery could be used to inform patients and target specific domains 
for further monitoring after resection.
Due to the sample size, we were limited in the number of candidate predictors 
of cognitive status we could adopt into the regression analyses, and statistical power 
was deemed too low to perform comparative tests of characteristics of the groups of 
patients whose cognitive status improved, declined, and remained stable over time. 
We did not adopt anxiety and depression symptoms in the prediction analyses, but we 
acknowledge that they might have played a role in cognitive performance—e.g., through 
attenuation of attentional control.11,16 Individual patients can entertain variable levels 
of anxiety and depression in the perioperative period, which may have accounted for 
individual variation in cognitive status but also change. Notably, the group of patients 
2
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whose cognitive status improved in our study appeared to show greater reduction 
in depressive symptoms than those whose cognitive status declined and remained 
stable.
The current results were derived from patients undergoing EETS, but findings 
may be generalizable to NPFA patients undergoing resection via the transsphenoidal 
approach with the microscope. Direct generalization of the longitudinal results to 
patients treated using a transcranial (microscopic) method is not warranted. In light of 
previous and current findings, we strongly recommend larger studies be performed to 
predict cognitive status and individual change therein, taking into account preoperative 
cognitive performance, as well as sociodemographic, disease-related (growth 
characteristics, tumor size, hormonal status, postsurgical events), and psychological 
(anxiety, depression) factors.
CONCLUSION
Computerized neuropsychological assessment showed lower cognitive performance in 
nearly all tested domains in patients with NFPA compared to healthy individuals before 
and 3 months after EETS. Impaired performance was found in more than half of the 
patients at both time points. Notably, nearly equal proportions of individual cognitive 
improvement, decline, and stable performance over time were found. Substantial 
individual variation in patterns of cognitive change after EETS thus seems present. This 
study emphasizes the need for the following: 1) cognitive evaluation of NFPA patients 
undergoing EETS to capture early impairment and/or subsequent decline and 2) caution 
in applying group-level results to individual patients, until multifaceted predictors of 
individual perioperative cognition are further established.
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CHAPTER 3
The APOE ε4 allele in relation to pre- and 
postsurgical cognitive functioning of patients with 
primary brain tumors
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Background:  Recent studies suggest a relationship between the APOE ε4 allele 
and cognitive outcome in patients treated for malignant brain tumors. Still, longitudinal 
investigations that include a pre-treatment cognitive assessment are lacking and APOE’s 
effects in patients with benign tumors are understudied. This study investigated pre-
surgical cognitive performance and post-surgical change in ε4 carrying and non-carrying 
patients with glioma and meningioma.
Methods: Neuropsychological test scores (CNS Vital Signs battery [7 measures], 
Digit Span Forward/Backward, Letter Fluency test) were obtained as part of a 
prospective study in which patients with meningioma and glioma underwent cognitive 
assessment one day before (T0, N=505), and three (T3, N=418) and twelve months 
after (T12, N=167) surgery. APOE isoforms were identified retrospectively. E4 carriers 
and non-carriers were compared with regard to pre-treatment cognitive performance 
on group and individual level. Changes in performances over time were compared 
with longitudinal mixed model analysis in the total sample and the subgroup receiving 
adjuvant treatment.
Results:  Carriers and non-carriers did not differ with regard to pre-treatment 
performance. No significant main effect of ε4 carrier status or interaction between time 
(T0 to T12) and carrier status was found on any of the tests in the whole sample nor in 
the sample receiving adjuvant treatment.
Conclusions:  This study found no evidence of increased vulnerability for pre-
treatment cognitive dysfunction or cognitive decline within one year after surgery in 
APOE ε4 carrying meningioma and glioma patients. Investigations that include larger 
samples at longer-term follow up are recommended to investigate potential late 
treatment effects.
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INTRODUCTION
Patients with primary brain tumors are at risk for cognitive dysfunction both before 
and after treatment.1-4 Sociodemographic, clinical and tumor specific factors have been 
related to the variation in the affected domains and/or the severity of dysfunction.5-11 
Research into possible germ line genetic determinants of cognition, such as APOE, in 
this patient population is relatively limited.
The major alleles of the APOE gene - ε2, ε3, ε4 - code for three variants of the 
glycoprotein apolipoprotein E (ApoE2/E3/E4), which is a key player in lipid metabolism 
regulation in the CNS,12 and facilitator of neuronal repair and plasticity processes.13,14 
However, the three ApoE isoforms possess different structural and functional properties 
that determine their effects in case of injury through numerous cellular pathways.14-16
ApoE4 specifically shows negative effects compared to the other isoforms14 as 
it facilitates maladaptive responses to CNS damage and less effectively promotes 
repair processes.17,18 Cognitive outcome in clinical populations including Alzheimer’s 
dementia,19 ischemic stroke,20,21 Parkinson’s disease22 and breast cancer 23,24 appear 
related to ApoE4. ApoE4’s detrimental effects might influence consequences of brain 
tumor growth and damage as well. Similarly to after acute injury,25,26 ApoE4 may facilitate 
an enhanced inflammatory response that results in aggravated disruption of blood-brain 
barrier integrity and increased edema. In addition, less efficient myelin formation27 
may result in lower white matter integrity.28 Moreover, adverse effects more specific 
to anti-tumor treatment, such as oxidative stress and alterations in neurogenesis, may 
also be isoform-dependent.17,29-34
Correa and colleagues were the first to study the role of the APOE ε4 allele in 
cognition in patients treated for CNS tumors.5 In later studies, they found that ε4 carriers 
showed poorer verbal learning and recall35, and were more susceptible to decline of 
attention and working memory36 as compared to non-carriers years after treatment. 
Currently, the absence of prospective longitudinal assessment of cognitive function 
in literature and lacking investigation in other common primary brain tumors, such as 
meningioma, limit our understanding of the role of APOE ε4 in the course of cognitive 
functioning in this population.
Prospective investigation of APOE ε4’s effects on cognition may improve our ability 
to (preoperatively) identify patients with a higher risk for tumor- and treatment related 
dysfunction in clinical practice and inform them accordingly. Moreover, it could allow 
for more tailored planning of treatment to optimize the balance between maximal 
anti-tumor effect while limiting disruption of cognition, and thereby other relevant 
outcomes, such as quality of life.37 In this study, we analyzed APOE genotypes in patients 
with glioma and meningioma who underwent neuropsychological assessment before 
and after surgical (and adjuvant) treatment in order to investigate differences between 
ε4 carriers and non-carriers with regard to 1) pre-treatment cognitive performance 
(status), and 2) cognitive functioning over time (change) up to 12 months after 
surgery.
3





Patients with meningioma or glioma underwent surgical debulking between November 
2010 and September 2017 at the Neurosurgery department of Elisabeth-TweeSteden 
hospital, Tilburg, The Netherlands. NPA was performed as standard clinical care one 
day before (T0) and three months after (T3) surgery. All patients signed for informed 
consent for the use of the T0 and T3 NPA data in research. For research purposes only, 
and with separate informed consent, patients underwent NPA 12 months after surgery 
(T12, from January 2014 onwards). NPA was administered by a neuropsychologist or 
neuropsychologist in training (MSc/graduate level).
Clinically obtained blood samples were analyzed retrospectively if patients had 
not formally objected to usage of samples for purposes other than clinical monitoring. 
Consent was recorded by the Clinical Pathology laboratory. The study was conducted 
according to the principles of the Declaration of Helsinki (Fortaleza rev. 2013), and 
in accordance with the Medical Research Involving Human Subjects Act (WMO). The 
study protocol was approved by the Medical Ethics Trial Committee Brabant (file 
NL41351.008.12).
Sample
Data was used from adult patients with a newly diagnosed diffuse glioma (WHO 
grade II-IV) or meningioma (grade I-II) who had completed at least T0 NPA. Further 
exclusion criteria were: previous intracranial surgery, a recent history (≤ 2 years) of 
severe psychiatric or neurologic disorder, other major medical illnesses in the last year 
(e.g., cancer), no basic proficiency in Dutch, and inability to undergo NPA (e.g., due to 




Age, sex, level of education (low, middle, high) were obtained through standardized 
interview at T0.
Clinical data
Histopathological diagnosis, tumor location, use of corticosteroids, use of anti-
epileptic drugs (AED), and adjuvant treatment were obtained from electronic medical 
records. Adjuvant treatment was dichotomized (chemo- and/or radiotherapy versus 
no adjuvant modality). Preoperative tumor volume was obtained through semi-
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automatic segmentation with either Brainlab Elements software or ITK-snap software, 
and expressed in cm3.
Cognitive data
NPA comprised the formal Dutch translation of the CNS Vital Signs (CNS VS) computerized 
test battery, see Supplementary Table 1 for a description of the seven tests that were 
used: Verbal Memory test (VEM), Visual Memory test (VIM), Symbol Digit Coding test 
(SDC), Shifting Attention test (SAT), Continuous Performance test (CPT), Stroop test I 
and Stroop test III. The local software application of CNS VS was used on a notebook 
computer. Additionally, three paper-and-pencil tests were administered: a Letter fluency 
task41, and, from 2015 onwards, a Digit Span Task (Forward and Backward).42
Standardization of test scores. Patients’ raw scores on CNS VS were converted 
into Z-scores using data from 158 Dutch healthy controls, adjusting for demonstrated 
effects of age, sex, educational level, and, for T3 and T12 data, also for practice effects.38 
Digit Span scores were standardized in a comparable manner using data from a healthy 
control group obtained as part of an ongoing Clinical Trial (CAR study A, ClinicalTrials.
gov reference nr. NCT02953756), and described by Verhaak and colleagues.44 Fluency 
scores were standardized into Z-scores, using published norms.41 These scores 
were standardized for educational level, but not sex or age, since these were not 
demonstrated to influence performance. Z-scores of each patient on each test were 
also dichotomized into impaired (Z-score ≤-1.5) or unimpaired.
APOE genotype
APOE isoforms were determined by the department of Laboratory Medicine using assay 
kits (ViennaLab, Diagnostics GmbH) involving a procedure of DNA isolation, polymerase 
chain reaction (PCR) amplification using biotinylated primers, and reverse-hybridization. 
Obtained genotypes were dichotomized into ε4 carrier (heterozygous or homozygous) 
vs. non-carrier (i.e., ε2 or ε3 carrier).
Psychological data
The Dutch translation of the Hospital Anxiety and Depression Scale (HADS43) was 
administered at each time-point (T0, T3, T12) to screen for symptoms of anxiety and 
depression.
Statistical analyses
Characteristics of APOE ε4 carriers and non-carriers
Potential baseline differences regarding sociodemographic (age, education level, sex), 
clinical (histopathology, frontal lobe involvement, tumor hemisphere, tumor volume, 
use of AED, use of corticosteroids and adjuvant treatment), and psychological (Anxiety 
and Depression) scores between ε4 carriers and non-carriers were investigated in 
the total sample, and stratified according to brain tumor diagnosis. Chi-square tests 
3
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of independence were used for categorical variables, independent samples t-tests 
for continuous variables with normal distributions, and Mann-Whitney U tests for 
continuous variables with skewed distributions (α=.05).
Preoperative cognitive performance
Mean performance of the entire sample was compared to healthy controls using Z-tests. 
Subsequently, mean performances of carriers vs. non-carriers in the patient sample 
were compared for each test with independent samples t-tests and Mann-Whitney U 
tests. The proportions of impairment for carriers vs. non-carriers on each test were 
compared using Chi-square tests. In case of baseline differences on any of the sample 
characteristics previously described, that variable was adopted as a covariate in analysis 
of variance (ANCOVA) or as a layer in Chi-square tests. To inspect potential bias in 
the long-term follow up sample, we compared pre-operative performances (mean 
performances and impairment proportions) of patients who completed T12 assessment 
and those who dropped out before T12.
Cognitive functioning over time
We conducted Linear Mixed Model (LMM) analyses to investigate the course of cognitive 
performances over time (1 model per cognitive test), initially in the total patient sample. 
In the longitudinal LMM, Time (T0,T3,T12) was level 1 and its measurements were 
nested in the patients at level 2. Because only three time points were involved, we 
adopted a linear effect of Time for all models. Intercepts were specified as random 
effects, allowing for individual estimations of the data of each patient. Random slopes 
were added to those models if they significantly improved model fit (likelihood ratio 
test, α=.05). Among the tested correlation structures (autoregressive, continuous 
autoregressive, compound symmetry, general correlation matrix, scaled identity), 
the one providing the best fit based on the Akaike Information Criterion (AIC) for the 
majority of the models was adopted uniformly.
First, we created models with only Time as predictor to investigate the overall 
course of performances without any other predictors. In the final models, we included 
a Time*Carrier status interaction (non-carrier as reference group). We also included 
a Time*Diagnosis interaction to account for possible differences in performance over 
time between meningioma and glioma patients (glioma as reference group). Similar 
models were constructed to investigate the effect of carrier status for the T0-T3 interval 
and T3-T12 interval separately, using Time as factor instead of a continuous variable 
(no random slopes). Within the group of patients who received adjuvant treatment 
-regardless of diagnosis-, we performed ancillary analyses, again of Time*Carrier 
status.
We used the restricted maximum likelihood (REML) algorithm to estimate model 
parameters. Global fits of the models (models with only Time as predictor vs the final 
models) were compared using AIC, and tested with likelihood ratio tests in case of a 
significant effect of carrier status. Analyses of the data45 were performed using SPSS 
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software (version 24) and Rstudio software (lme4 and nlme packages46,47). We adopted 
a correction for multiple testing (taking into account the 10 tests we performed to 
investigate all cognitive measures) per main analysis (pre-treatment performance, post-
treatment change with Time only, and post treatment change with APOE carrier status) 
using the False Discovery Rate correction procedure by Benjamini and Hochberg48 
(original α=.05).
RESULTS
Characteristics of APOE ε4 carriers and non-carriers
Figure 1 shows a flow chart of patient inclusion. Baseline characteristics of the sample 
are displayed in Table 1. There were no significant differences for any of the inspected 
sociodemographic, psychological or clinical variables between APOE ε4 carriers and 
non-carriers in the total sample (p’s >.05). In the meningioma group, there was a 






Pa�ents with T0 NPA data and APOE 
genotyping N=505 
Pa�ents with T3 data 
N=418 
 
Pa�ents with T12 data N= 167 
No T3 (N = 87) 
- Lost to follow up/transfer = 20 
- Clinical rehabilita�on = 1 
- Poor clinical status = 20 
- Deceased = 11 
- No show / cancelled = 30 
- Difficul�es with logis�cs = 3 
- Re-resec�on = 1 
- Resec�on cancelled = 1 
 
No T12 (N=251) 
- Lost to follow up/transfer = 136 
- Clinical rehabilita�on = 1 
- Poor clinical status/recurrent disease = 16 
- Planned > 15 months a�er surgery = 22 
- Not willing = 44 
- Deceased = 8  
- Undergoing salvage treatment = 4 
- Treatment arm of RCT on cogni�ve 
rehabilita�on† = 21 
Pa�ents with T0, no T3 
data N=3  
 
† NCT Number: NCT03373487  
Pa�ents who underwent clinical care T0 NPA  
N= 548  
Recruitment: Nov 2010-Sep 2017 
Excluded before analysis (N =43) 
- Objec�on to usage of NPA data or blood = 9 
- NPA (largely) invalid = 18 
- Re-resec�on = 13 
- Diagnosis not glioma/meningioma  = 1 
- Biopsy only = 1 
- Comorbidity = 1 
 
Figure 1. Flow chart of patient inclusion and attrition.
3
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Table 1. Baseline characteristics of included patients (T0)














Age M±SD 53.2 ± 14.8 53.2 ± 13.8 55.9 ± 12.7 57.0 ± 11.6 54.9 ± 13.9 55.3 ± 13.1
Female, n (%) 28 (44) 71 (36) 41 (64) 135 (76) 69 (54) 206 (55)
Education, n(%)
Low 20 (31) 57 (29) 25 (39) 63 (35) 45 (35) 120 (32)
Middle 19 (30) 69 (34) 14 (22) 57 (32) 40 (31) 126 (33)
High 25 (39) 73 (37) 25 (39) 58 (33) 43 (34) 131 (35)
Clinical
Diagnosis, n(%)
LGG WHO II 21 (30) 59 (30) n/a n/a 19 (15) 59 (16)
HGG WHO III/IV 45 (70) 140 (70) n/a n/a 45 (35) 140 (37)
MEN WHO I n/a n/a 61 (95) 166 (93) 64 (50) 178 (47)
MEN WHO II n/a n/a 3 (5) 12 (7)
Frontal involvement 34 (53) 101 (51) 31 (48) † 114 (64) † 65 (51) 215 (57)
Lesion hemisphere
Left 30 (47) 81 (40) 24 (38) 68 (38) 54 (42) 149 (40)
Right 33 (52) 117 (59) 36 (56) 87 (49) 69 (54) 204 (54)
Bilateral 1 (1) 1 (1) 4 (6) 23 (13) 5 (4) 24 (6)














AED use, n(%) 32 (53) 83 (43) 58 (33) 42 (23) 47 (38) 125 (34)
Corticosteroid use, n(%) 29 (48) 107 (56) 21 (33) 15 (23) 50 (41) 165 (45)















Concurrent Rtx/Chtx 36 (56) 117 (59) 0 (0) 0 (0) 36 (29) 117 (31)
Psychological
HADS Anxiety M±SD 7.0 ± 4.5 6.9 ± 4.3 7.1 ± 4.3 7.1 ± 4.3 7.0 ± 4.4 7.0 ± 4.2
HADS Depression M±SD 5.3 ± 3.7 4.8 ± 3.4 5.8 ± 4.7 6.1± 4.9 5.6 ± 4.3 5.4 ± 4.2
Information was available for AED use at T0 n=124 (ε4 carriers) vs. 367 (non-carriers), Corticosteroid use 
at T0 n=128 vs. 367, Adjuvant Tx: n= 126 vs 372
† significant difference between carriers and non-carriers within the diagnostic group, p<.05.
‡ Temozolomide, Lomustine or PCV (Procarbazine-Lomustine-Vincristine)
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Baseline cognitive performances in the total sample
Z-tests showed that our sample performed worse than healthy controls on all NPA 
measures (all p’s <.001, data not shown). As a group, patients who returned for T12 
follow up showed better pre-surgical performances than those who did not return 
for T12 on all tests (p’s<.05, data not shown) except Finger Tapping, Continuous 
Performance, Fluency and Digit Span Forward and Backward. The baseline proportion 
of impaired performances was also lower among patients who returned for T12 follow 
up for Symbol Digit Coding, Shifting Attention, Stroop III and Fluency tests (p’s<.05, 
data not shown).
Baseline cognitive performances of ε4 carriers and non-carriers
No significant differences were found between carriers and non-carriers in mean 
performance on any of the tests under the adjusted α (BH-corrected α=.005), see Table 
2. No significant differences were found between carriers and non-carriers with regard 
to the proportions of impaired performances (BH-corrected α=.005), see Figure 2.
Cognitive functioning over time of ε4-carriers and non-carriers
Table 2 and Figure 3 show group performances on each test for carriers and non-carriers 
over time. Table 3 shows results of the LMM. We found a positive effect of Time for 
scores on the Verbal Memory test, Symbol Digit Coding test, Shifting Attention test, 
Stroop test I and II, and Fluency test (BH-corrected adjusted α=.03, range β=.02 to 
β=.05, p’s<.01). In the final models, we found no significant main effects of ε4 carrier 
status nor Time*ε4 carrier status interactions (BH-corrected α=.005). No significant 
effects were found for Time*Diagnosis, except for Fluency performance in the T0-T3 
interval. Meningioma patients showed more improvement than glioma patients on 
this test (p=.001), see Table 3. Analyses in the group of patients who received adjuvant 
treatment (chemotherapy and/or radiotherapy) revealed no significant main effect of 
carrier status or Time*carrier status interaction (data not shown), p’s >.10.
3
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Figure 3. Mean performances ± SEM over time on each test stratified by ε4 carrier (light) vs. non 
carrier (dark) for the total sample.
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DISCUSSION
The current prospective longitudinal study investigated whether patients with 
glioma or meningioma carrying the APOE ε4 allele showed greater vulnerability for 
cognitive dysfunction before treatment (1 day before surgery) and worse cognitive 
functioning over the course of treatment (3 and 12 months after surgery) as compared 
to non-carriers. We found no evidence for significantly worse pre-treatment cognitive 
performance, i.e., a lower group performance or higher prevalence of impairment, 
in ε4 carriers. Overall (without distinction based on APOE genotype), patients 
showed significant improvement from the pre-surgical to the 12 month postsurgical 
measurement on tests tapping into verbal memory (Verbal Memory test), psychomotor 
speed (Symbol Digit Coding test), and executive functioning (Shifting Attention test, 
Stroop test, and Verbal fluency). We found no significant differences in performance 
over time between carriers and non-carriers on any of the tests.
As previous investigation of APOE’s effects in brain tumor patients did not include 
a pre-treatment measurement, it remained unknown to what extent worse cognition in 
carriers after treatment was actually related to preexisting dysfunction.49 We expected 
a small negative effect in the ε4 allele carriers before start of treatment, based on 
ApoE4’s modulation of cerebrovascular function16,26 and white matter integrity50 in 
response to injury. The lack of differences in pre-treatment performances between 
carriers and non-carriers may be related to the temporal pattern of brain tumor injury. 
Brain tumor growth involves diffuse infiltration and/or compression over a period of 
years, as opposed to acute damage. Especially in case of tumors with lower lesion 
momentum, APOE ε4 carriers may exert greater compensatory neural recruitment or 
“cognitive effort” that may be reflected in altered functional connectivity,28 but not a 
poorer test performance. We also note that large standard deviations were present for 
most of the (computerized) test scores at baseline. Substantial within-group variation 
is not uncommon in brain tumor patients, but it could have complicated detection of 
potential small effect sizes from an allelic variation.
Based on longitudinal research in treated (non-)CNS cancer patients, we expected 
ε4 carriers to show worse performances over time (i.e., less recovery) compared to 
non-carriers on tests of executive functioning, (working) memory and processing 
speed.24,35,36,51,52 A myriad of pathways,48 including vascular abnormalities, sub-efficient 
myelin regulation, increased oxidative stress and treatment-related toxicity, 17,30,31,34 
could contribute this difference in cognitive outcome. Our results did, however, not 
illustrate poorer trajectories of cognitive functioning in the total sample nor in the 
subgroup that received adjuvant treatment.
We note some methodological differences between studies that might account for 
the different findings. The longitudinal study by Correa and colleagues36 that reported a 
ε4-related risk for decline in Digit Span performance, obtained cognitive measurements 
at later time-points (first assessment 4±3.4 years after completion of treatment and 
second assessment 5.2±0.8 years after that). Similarly, a study by Ahles and colleagues 
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included long-term survivors of breast cancer 8.8±4.3 years post-treatment [23]. Our 
measurements were obtained up to 12 months post-surgery (about 9 months after 
completion of radiotherapy, and about 3 months after completion of chemotherapy, 
depending on clinical and tumor characteristics). A longitudinal study by Ahles and 
colleagues [51] investigating changes from pre up to 18 months post-chemotherapy 
in breast cancer patients also found no main effect of APOE. Late cognitive effects of 
treatment-induced processes that continue >6 months after radiation, such as capillary 
loss [53] and apoptosis [54], may be captured better at later follow ups than those in 
our study.
We applied correction for multiple testing, thereby holding a more stringent cut 
off for significant effects than other studies. Still, differences for baseline proportions 
of impairment Digit Span Backward and Shifting Attention tests were relatively large 
(>10% more impairment in carriers as compared to non-carriers) and could have 
been considered significant under an unadjusted significance level. In addition, mean 
performances for Letter Fluency appeared higher in carriers than non-carriers at 
baseline, but similar at 12 month follow up, which indicates more improvement in non-
carriers. These tests measure different facets of executive function, and a significant 
difference for Digit Span Backward was also found in previous research [36]. Future 
investigations may therefore focus primarily on executive measures.
While our sample sizes at pre- and first post-surgical measurement were large, 
41 ε4 carriers and 126 non-carriers remained for the relevant time-point 12 months 
post-surgery. This left us unable to include additional variables that might moderate the 
relationship between APOE and long-term cognition For example, preclinical research 
has shown that adverse cognitive effects of radiation in ε4 carriers may manifest 
particularly in females.[34] Our adjuvant treatment sample naturally comprised a large 
proportion of high-grade glioma that occur more commonly in males.[55] In addition, 
mixed results regarding the effect of APOE ε4 on cognition have been found for different 
age groups, i.e., a positive effect in middle-aged or younger adults versus a negative 
effect in older adults.[27,56] Our sample reflected the prevalence of brain tumors across 
age groups.
The degree to which APOE ε4 moderates cognition in patients with brain tumors 
remains somewhat inconclusive. While APOE ε4 might be related to a cognitive 
phenotype [27] conflicting results have also been reported in other neurological 
samples, such as TBI [57]. Still, elucidating the effect of APOE allelic variation on 
cognition is important, especially for patients with low grade or benign tumors who are 
expected to return to daily activities, such as work, that are associated with cognitive 
fitness [58] after treatment. We identify multiple potential areas of interest for future 
research. First, although APOE has received most attention in studies on cancer-related 
cognitive function [59] other genetic polymorphisms should also be recognized and 
investigated further as potential (interacting) markers for risk of cognitive dysfunction.. 
For example, COMT and BDNF have been associated with cognition independently 
[47,60,61] as well as in interaction with APOE genotype.60,62 Several genes associated 
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with DNA repair, oxidative stress and inflammation have also been described.59 APOE 
may also be investigated as a moderating factor for the effect of behavior on cognitive 
outcomes. For example, longitudinal findings by Ahles and colleagues51 suggested that 
the association between APOE and cognition over the course of oncological treatment 
may be moderated by smoking behavior. In addition, individuals who carry ε2/3 alleles 
have been reported to benefit more from engaging in complex cognitive activities - as 
opposed to cognitively less challenging activities - than those who carry ε4.63 Finally, 
E4 carrying men with low levels of physical activity appear to be more at risk for 
cognitive decline as compared to their non-carrying counterparts.64 Individual brain 
tumor patients receiving cognitive or physical rehabilitation might benefit to different 
extents based on APOE genotype.
CONCLUSION
The current prospective longitudinal study was the first to investigate the association 
between APOE ε4 carrier status and both pre- and post-treatment cognition in patients 
with primary brain tumors. We found no statistical evidence for a negative effect of 
ε4 on pre-treatment cognitive performance nor cognitive functioning over time up 
to 12 months after surgery. Research with larger samples at longer-term follow up 
and investigations of the potential for APOE to interact with other (genetic) patient 
characteristics to influence cognitive outcome are warranted.
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Supplementary Table 1 Description of used CNS VS tests
Test Content Score computation
CNS VS Verbal Memory 
(VEM) Test
Fifteen words are presented, one at a 
time. Subject subsequently identifies 
presented words among new words by 
pressing the space bar (immediate and 
delayed recall).
Total items correct 
(hits and passes)
CNS VS Visual Memory 
(VIM) Test
Fifteen abstract images are presented, 
one at a time. Subject subsequently 
identifies presented images among 
new images (immediate and delayed 
recall).
Total items correct 
(hits and passes)
CNS VS Symbol Digit Coding 
(SDC) Test: Psychomotor 
speed
Symbols and corresponding numbers 
are displayed in the upper part of the 
screen. Subject matches symbols with 
correct numbers in a grid on the lower 
part of the screen for two minutes.
Correct responses – 
incorrect responses
CNS VS Stroop Test part I 
(Stroop I): Simple reaction 
time
Part 1: subject presses space bar when 





CNS VS Stroop Test part 
III (Stroop III): Inhibitory 
control
Part 3: subject presses space bar if 
the color of the word does not match 
the meaning of the word (incongruent 
trials, e.g., the word “green” is 




CNS VS Shifting Attention 
Test (SAT): Cognitive 
flexibility
Subject matches geometric objects 
by either shape or color to one of two 
figures in the lower part of the screen 
for two minutes, using the left and 
right shift keys. The assignment and 
figures differ per trial.
Correct responses – 
Errors
CNS VS Continuous 
Performance Test (CPT): 
Vigilance
Capital letters are presented on the 
screen, one at a time. Subject responds 
to only target letter “B” by pressing the 
space bar (total test time 5 minutes, 
uninterrupted).
Average reaction 
time of responses to 
target letter
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Pre-surgical patterns of cognitive impairment in 
patients with diffuse glioma revealed by latent 
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Background  Despite the substantial heterogeneity in cognitive performances 
among glioma patients, studies aiming to elucidate patterns underlying these 
performances are lacking. Using Latent Class Cluster Analysis (LCA), we investigated 
1) subgroups of patients based on patterns in pre-surgical performances across 
neuropsychological tests, and 2) patient and disease characteristics in relation to group 
membership.
Methods  Glioma patients (n=382, WHO grade II-IV) underwent brief 
computerized neuropsychological assessment one day before surgery. We selected 
nine test measures, of which the scores were standardized into Z-scores. We used the 
dichotomized performances (impaired [Z-score ≤-1.5] versus unimpaired [Z-score >-1.5]) 
in a bias-adjusted three-step LCA.
Results   Cluster 1 illustrated patients with low probabilities of impairment on 
all tests (n=164).This cluster was characterized by younger age, low mean tumor volume, 
a high proportion of low grade tumors, and anti-epileptic drug use. Cluster 4 (n=50) 
illustrated patients with impairment across all tests, and was characterized by a large 
proportion of high grade and frontal lobe tumors. Clusters 2 (n=81) and 3 (n=64) both 
showed executive function impairment, but Cluster 3 additionally showed processing 
and psychomotor slowing and visual memory impairment. Cluster 2 was characterized 
by younger age and left hemispheric tumors, but Cluster 3 by higher age and high mean 
tumor volume. Cluster 5 (n=23) showed isolated visual and verbal memory impairment 
and was characterized by right hemispheric tumors and high mean tumor volume.
Conclusion  Subgroups of patients showing distinct pre-surgical cognitive 
impairment profiles were identified. Routinely obtained characteristics may help to 
identify patients at risk for specific dysfunctions.
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INTRODUCTION
Cognitive dysfunction is an undisputed symptom of diffuse glioma that arises as a 
result of (the combination of) multiple tumor-related processes.1-5 It has been shown 
consistently that executive functioning and memory domains are particularly vulnerable 
to disruption before treatment.6-11 Still, deficits can be present in all cognitive domains 
in varying degrees5,10 and the number of affected domains varies substantially between 
patients,8 indicating considerable inter-individual cognitive heterogeneity. As cognition 
shapes numerous facets of daily life, such as decision making ability,12 quality of life 13,14 
and interpersonal functioning,15 an in-depth understanding of the nature of (disease-
related) dysfunction is imperative for integrative care.
Approaches to cognitive profiling of glioma patients commonly involve the 
comparison of (mean) cognitive test performances to normative samples, complemented 
with the investigation of clinical impairment rates among separate tests and individual 
patients. A systematic review of 23 studies concluded that about two thirds of the 
population presents with clinically relevant cognitive impairment prior to treatment.5 
This proportion may be even higher in glioblastoma3,7,10 as a result of higher lesion 
momentum.16-18
Taking into account the varying rates of impairment in the glioma population,5,8 
as well as the differential interrelations between cognitive functions in general,19,20 we 
can expect the large group of patients with cognitive dysfunction to branch off into 
multiple subgroups of patients showing distinct profiles of cognitive (dys-)function. 
However, such profiles cannot be revealed by studying tests or domains separately. To 
adequately understand cognitive heterogeneity glioma patients, research that aims to 
elucidate patterns in patients’ performances across various neuropsychological tests 
is needed.
By using a clustering approach, as done previously for other cancer-related 
symptomatology,21 patient subgroups can be identified based on such underlying 
patterns. In addition, this method allows us to investigate known patient- and disease-
specific correlates of test performances for their value in predicting performance 
patterns, and thereby help to identify which patients are at risk for which type of 
dysfunction. Finally, cluster analysis can also reveal to what degree neuropsychological 
tests contribute to the discrimination between different patterns, and thus their 
suitability for use in a specific population.
We employed latent class cluster analysis (LCA) to investigate whether distinct 
subgroups of patients could be identified based patterns in their performances on 
measures of a computerized neuropsychological test battery. We subsequently explored 
if group membership was related to patient and disease characteristics that are routinely 
obtained and largely known at time of diagnosis.
4




Study design and data
Data were gathered as part of a prospective longitudinal study in which patients 
with primary brain tumors undergo neuropsychological assessment (NPA) one day 
before (T0) and three months after (T3) surgical debulking as part of usual care at the 
Neurosurgery department of Elisabeth-TweeSteden Hospital (Tilburg, the Netherlands). 
The project was approved by the local Medical Ethics Committee Brabant (file number 
NL41351.008.12). Data were used for research purposes with patients’ written 
consent.
For the current study, we used the pre-surgical cognitive data from patients 
undergoing resection between November 2010 and June 2019 for histologically 
confirmed diffuse glioma (grade II-IV). Exclusion criteria included age <18, presence 
of progressive neurological disease, psychiatric or acute neurological disorder 
within the past two years, and reduced testability (e.g. lack of proficiency in Dutch, 




Sociodemographic information including age, sex, educational attainment (categorized 
into low, middle, and high) was collected via semi-structured interview at the start of 
the assessment.
Clinical
Information regarding tumor location, anti-epileptic drug (AED) use and corticosteroid 
use at time of assessment, first resection (versus re-resection), and clinical presentation 
(symptoms reported at time of diagnosis) were retrieved from the electronic medical 
charts. Tumor volume before surgery (expressed in cm3) was determined through semi-
automatic segmentation (BrainLab Elements25 and ITK-Snap software26) on T1-post 
contrast enhanced (grade III and IV tumors) or T2-FLAIR series (grade II and III tumors). 
Histology, grade, isocitrate dehydrogenase type 1 (IDH 1) gene mutation status (wild 
type vs. mutated), and 1p-19q deletion status (co-deletion vs. no co-deletion) were 
retrieved from pathological reviews.
Cognitive
We used the computerized Central Nervous System Vital Signs test battery (CNS VS)27 
for screening of cognitive functioning. Content of each administered test and the score 
computations of the nine measures used as indicators are displayed in Supplementary 
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table 1. We used baseline data from CNS VS assessment in healthy controls as described 
by Rijnen28 for normative purposes. Standardized Z-scores, adjusted for age, sex, and 
educational attainment, were computed for all valid raw test scores of each patient. 
The continuous Z-scores were used for descriptive purposes. We dichotomized 
performances on each test into impairment (Z-score <-1.5; below the 7th percentile 
based on the control group) or no impairment. Impairment rates were used for both 
descriptive purposes and as indicators for the main analyses. Re-resection vs first 
resection candidates were compared with regard to the proportions of impairment on 
each test with Chi-square tests of independence.
Statistical analyses
Clustering of cognitive data
We performed Latent Class Cluster Analysis (LCA)29 in Latent Gold.30 LCA is a model-
based technique that classifies cases into homogeneous groups based on their response 
patterns on a number of indicators. The underlying assumption is that cases (here: 
patients) belong to not directly observable (latent) classes. These classes can be seen as 
subgroups or clusters of patients that are homogeneous with regard to their response 
patterns (here: their impaired or unimpaired performances on cognitive tests). The 
assumption of LCA is that the observed responses of patients assigned to the same 
class arise from the same probability distribution.29 Each patient is assigned a posterior 
membership probability for each identified cluster. This posterior probability reflects 
the probability (0-1 scale) of the patient “belonging” to that specific group. Ultimately, 
each patient is assigned to the group for which they show the highest probability (i.e., 
their “modal class”).
For the LCA, we adopted the bias-adjusted three-step modeling approach 
developed by Vermunt.31In the first step, we built a latent class model using test 
performances (impairment vs. no impairment) as indicators and chose the optimal 
number of latent classes. In the second step, posterior membership probabilities were 
saved and patients were assigned to classes. In the third step, we predicted posterior 
membership probabilities with external covariates (predictors) in a multinomial 
regression while correcting for classification error. The steps are described in detail 
in below.
Determination of the optimal number of clusters
Due to the lack of theoretical evidence for any number of distinct cognitive classes 
in the glioma population, we adopted an exploratory approach to determine the 
optimal number of clusters and performed six separate LCA’s of 1 through 6 clusters. 
We selected the most parsimonious model that also showed the best fit for the data 
based on a combination of fit statistics. Measures of global fit included: Log-Likelihood 
(LL), Bayesian Information Criterion (BIC), Akaike Information Criterion (AIC) and model 
4
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classification error (i.e., the proportion of incorrectly classified cases). We performed 
statistical comparisons of global fit by testing the difference in log-likelihood between 
the nested (restricted) and the source (larger) model, e.g. 2-cluster vs. 3-cluster model, 
using a bootstrapped estimate of the p-value. We used bivariate residuals (BVR) as 
local indicator of fit32 and followed the guideline that values higher than 2 indicate 
that the model at hand cannot explain the association between two indicators33 and 
may therefore violate the assumption of local independence. Bootstrapped estimates 
of the p-values for the BVR in the models were tested against a False Discovery Rate 
(FDR) corrected alpha level 34 using original α=.05. Classifications of the optimal model 
were saved to be used for the prediction analysis.
Predicting posterior membership probabilities with external covariates
Latent Gold uses multinomial logistic regression to predict cluster membership 
probability with external covariates (predictors), while correcting for the model’s 
classification error that can otherwise bias the regression results. External covariates 
were chosen based on theory3,4,7,10,35-37 and clinical relevance: age and tumor 
volume as continuous variables, right vs left hemispheric tumor, non-frontal vs frontal 
tumor location, non-temporal vs temporal tumor location, low grade vs high grade 
(histological), IDH-1 wild-type vs mutation, treatment of epilepsy with AED and a 
clinical presentation that involved cognitive complaints, as dichotomous variables. We 
also inspected the presence of a nonlinear effect of age38 by including an age*age 
interaction. We adopted proportional classification. We used the Maximum Likelihood 
(ML) method for parameter bias correction, which is recommended for covariates. 
Cases with missing values any of on the predictors were kept in the model.
RESULTS
Pre-surgical measurements from 444 patients with histopathologically confirmed grade 
II-IV glioma were identified. Sixty-two patients were excluded from analysis because 
of medical history or comorbidity (n=17), invalid testing (e.g., due to disorientation, 
confusion, emotionality or severe fatigue, n=38), technical problems with the laptop 
(n=1), and early NPA interruption, e.g., the patient completed only the interview or one 
test after which they expressed the wish to stop (n=6). The final sample comprised 382 
patients, see Table 1.
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Age (years) m±SD 53±14 43±13 50±15 58±12
Male 251 (66) 65 (60) 25 (63) 161 (70)
Education
Low 109 (29) 21 (19) 16 (40) 72 (31)
Middle 128 (33) 38 (35) 12 (30) 78 (33)
High 145 (38) 53 (49) 12 (30) 80 (34)
Re-resection 34 (9) 13 (12) 7 (18) 14 (6)
+ chemo- and radiotherapy 4 (1) 1 (1) 5 (13) 12 (5)
+ chemotherapy only 1 (0) 1 (1) 0 (0) 0
+ radiotherapy only 18 (5) 0 (0) 2 (5) 1 (0)
Histology
Astrocytoma 326 (85) 64 (58) 29 (72) 233 (100)
Oligodendroglioma 56 (15) 45 (41) 11 (28) 0 (0)
IDH-1 mutated (n=272) 127 (47) 93 (86) 19 (66) 15 (11)
1p/19q co-deleted (n=136) 48 (35) 38 (47) 7 (35) 0 (0)
Frontal lobe involvement† 193 (51) 80 (73) 23 (58) 90 (39)
Temporal lobe involvement† 145 (38) 32 (29) 11 (28) 102 (44)
Parietal lobe involvement† 73 (19) 10 (9) 6 (15) 57 (24)
Occipital lobe involvement† 38 (10) 3 (3) 4 (10) 31 (13)
Lesion hemisphere
Left 150 (39) 55 (49) 12 (33) 83 (36)
Right 227 (60) 54 (48) 26 (67) 148 (64)
Bilateral 4 (1) 3 (3) 0 (0) 1 (0)
Tumor volume (cm3) Med, range 37, 1-200 45, 1-200 37, 1-180 35, 1-163
Cognitive complaints at presentation‡ 57 (15) 5 (5) 7 (18) 45 (19)
AED use 188 (49) 88 (81) 18 (45) 82 (35)
Corticosteroid use 208 (55) 26 (23) 18 (45) 164 (70)
Values are n(%) unless stated otherwise
† added up percentages may be larger than 100 due to multilobar tumors
‡ reported as a primary symptom at time of presentation
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The mean performance on each test and the proportion of impaired performers are 
displayed in Table 2. Overall, 25% of patients (n=97) showed no impairment (on any of 
the tests), 19% (n=73) on one test, and 56% (n=212) on at least two tests. Prevalence 
of impairment per test ranged from 24% (Verbal memory) to 42% (Stroop task III). Re-
resection and first resection candidates did not differ significantly with regard to the 
impairment proportions on the individual tests (p>.05, data not shown).
Table 2. Pre-surgical cognitive test performances in the total sample




Verbal memory test (VEM, n=363) Verbal memory -0.67 ± 1.31 87 (24)
Visual memory test (VIM, n =375) Visual memory -0.55 ± 1.39 94 (25)
Symbol Digit Coding test (SDC, n =371) Psychomotor 
speed
-0.96 ±1.40 119 (32)
Finger Tapping test (FTT, n =356) Simple motor speed -1.01 ± 1.61 108 (30)
Shifting Attention test (SAT, n =349) Cognitive flexibility -0.91 ± 1.60 113 (32)
Continuous Performance test (CPT, n =375) Sustained 
attention
-0.73 ± 1.64 95 (25)
Stroop test I, reaction time (Stroop I, n =375) Simple 
processing speed
-1.30 ± 2.41 122 (33)
Stroop test III, reaction time (Stroop III rt, n=355) 
Executive control; speed
-1.53 ± 2.35 149 (42)
Stroop test III, correct answers (Stroop III cor n =355) 
Executive control; accuracy
-1.25 ± 2.97 89 (25)
Identification of the number of cognitive clusters in the data
Global fit measures
Supplementary table 2 provides an overview of the investigated models and their 
evaluative global fit parameters. The 4- and 5-cluster models appeared to be the 
models that fitted the data best. The 4-cluster model showed a better global fit to 
the data compared to the 3-cluster model, as indicated by the significant reduction 
in L2 (conditional bootstrap, p=.01, se=.01). The 5-cluster model provided similar AIC 
and lower LL values compared to the 4-cluster model, but not a significant increase in 
global fit (p=.41, se=.02).
Local fit measures
Inspection of the BVR indicated one value ≥ 2 (relationship SAT – VEM) in the 4-cluster 
model only. Neither the 4- or 5-cluster model showed significant BVR values under 
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the FDR corrected significance level (p’s ≥.01 in both models, α=.001), indicating no 
significant violation of the local independency assumption. In both models, all test 
scores significantly contributed to the cluster discrimination (all p’s <.05). The variance 
in test performance explained by the clustering itself (test R2) ranged between 18% 
(VEM) and 55% (Stroop I) for the 4-cluster model, and between 23% (FTT) and 56% 
(Stroop III rt) for the 5-cluster model (data not shown). The most notable difference in 
explained variance between the 4- and 5- cluster solution was observed for VIM (23% 
versus 38% respectively). Based on the local fit (BVR values and test R2) as well as a 
theoretically relevant additional cluster that was identified in the 5-cluster model (see 
the Characteristics section), we adopted this model for further analyses. The model is 
described in detail below.
Characteristics of the 5-cluster model
Table 3 shows the conditional probabilities of impaired and unimpaired performances 
on each test as well as the overall conditional probabilities (in the total sample). For 
example, patients in Cluster 1 patients showed a 93% chance of unimpaired performance 
and 7% of impaired performance on VEM, while the probabilities in the overall sample 
were 76% and 24% respectively. Probabilities < 0.30 were considered low, 0.30-0.40 
low-moderate, 0.40-50 moderate, 0.50 - 0.60 high-moderate and > 0.60 high.
Figure 1 depicts these probabilities in cluster profiles, again indicating how likely 
patients in each group were to be impaired on the tests. Cluster 1 (n=164, 43% of 
the total sample) illustrated a “cognitively intact” group with very low chances of 
impairment on all tests (conditional probabilities ≤0.13), while Cluster 4 (n=50, 13%) was 
characterized by high chances of impairment on all tests (all conditional probabilities 
≥0.6, “global impairment” cluster). Cluster 2 (n=81, 21%) illustrated high-moderate 
impairment probabilities for SAT and Stroop III reaction time (0.56, 0.51) and low to 
low-moderate probabilities for the other measures (“executive” cluster). In Cluster 
3 (n=64, 17%), we identified high probabilities for Stroop III (both measures) as well 
as Stroop I impairment (≥0.90), but low-moderate probabilities for SAT impairment 
(0.38). High-moderate impairment probabilities were present for SDC, FTT and VIM 
measures, overall indicating a “speed-motor-visual” profile. Cluster 5, the subgroup not 
revealed in the 4-cluster solution, (n=23, 6%) represented a “memory”-based cluster 
showing high impairment probabilities for both memory tests (VEM and VIM, >0.70), 
low-moderate probabilities for psychomotor tasks (SDC and FTT) and low probabilities 
for all other tasks.
Relationship between cluster membership and external variables
Table 4 provides an overview of the cluster-specific probabilities of the predictors and 
corresponding parameter statistics. Figure 2 depicts the probabilities in a profile. Age 
(linear term, Wald =13.1, p=.01; quadratic term, Wald =13.3, p=.01), tumor volume 
4
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(Wald =9.0, p=.01), tumor lateralization (Wald =24.2, p<.01), and AED use (Wald=13.0, 
p=.01) were identified as significant predictors of cluster membership. The following 
between-cluster differences were observed:
Age. Mean age was significantly lower in Clusters 1 (47.4) and 2 (51.4) as compared 
to Cluster 3 (64.2; p=.03 and p=.04 respectively).
Tumor volume. Mean tumor volumes (cm3) in Clusters 1 (46.6) and 2 (45.5) were 
significantly lower than in Clusters 3 and 5 (53.5 and 82.7, p’s ≤.02).
Hemisphere. Left hemispheric tumors were most common in Cluster 2 (cluster-
specific probability 0.70; 70% of the cluster). This was significantly higher than in all 
other clusters (p’s ≤.01). They were least common in Cluster 5 (3%), this proportion was 
also significantly lower than in Clusters 1 (43%, p<.01) and 4 (31%, p=.02) respectively. 
Cluster 3 also contained fewer left hemispheric tumors (14%) compared to Cluster 1 
(p=.03).
AED use. Use of AEDs before surgery was highest in Cluster 1 (probability 0.70; 
70%) and significantly higher than in Cluster 4 (probability 0.24, p<.01).
Although there was no significant overall effect of the following variables, we 
observed significant between-cluster differences for frontal tumor location (Cluster 4 
> Cluster 2, p=.03), and lesion grade (LGG proportion in Cluster 1 > Cluster 4, p=.048). 
We found no significant effects (overall or between-cluster comparisons) for temporal 
involvement, IDH1 gene mutation status or presentation with cognitive complaints 
(p’s >.05).
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DISCUSSION
To our knowledge, this study is the first to characterize subgroups of glioma patients 
based on distinct pre-surgical patterns of cognitive impairment with latent class cluster 
analysis (LCA). Using nine measures of a computerized neuropsychological screening, 
five groups were identified.
The largest cluster (Cluster 1; 43% of the total sample) consisted of a “cognitively 
intact” group of patients with low chances of impairment on all tests, irrespective 
of the cognitive domain. The remaining majority of patients (57%) were, however, 
assigned to clusters that indicated the presence of varying patterns of clinically relevant 
dysfunction. In accordance with literature reporting a high prevalence of executive 
functioning impairment,5 we found particular susceptibility to impairment on such 
measures in multiple clusters (Clusters 2 and 3). Whereas Cluster 2 patients (21% of 
the total sample) showed isolated executive dysfunction, Cluster 3 (17%) additionally 
showed susceptibility to impairment on measures of processing (Stroop part I) and 
(psycho-)motor speed (Symbol Digit Coding, Finger Tapping) and visual memory. Taking 
into account that slowed processing speed is more pronounced as tasks become more 
complex39, and that CNS VS memory tests and Stroop tests all have a time restriction for 
item presentation, slowing may have been the fundamental problem in this cluster. We 
found a global pattern of disruption in Cluster 4, indicating that 13% of patients suffered 
cognitive impairment across the board. Cluster 5 (6%), illustrated a susceptibility to 
verbal and visual memory impairment only.
 All test measures contributed significantly to the discrimination of the clusters. 
Still, it was evident that the reaction time measures from the Continuous Performance 
test and Stroop part I, that tap into simple (sustained) attention and processing speed, 
showed quite low probabilities for impairment on most clusters except those reflecting 
extensive dysfunction (3 and 4). We also did not find a cluster with isolated impairment 
on these measures. Based on these findings, a question remains whether the threshold 
for clinically relevant dysfunction of these more basic functions was only reached if 
a patient’s cognitive profile was already at a troublesome level (i.e., more complex 
functions were already disrupted) or if disruption of these functions also disrupted 
performance on more complex domains.
 Multiple patient and disease characteristics showed independent associations 
with cluster membership. Younger patients (mean age 47.4 years) with low tumor 
volumes who received treatment for epilepsy characterized the “intact” cognitive 
phenotype (Cluster 1). Notably, the proportion of high-grade glioma was 51% here, 
whereas the proportion in the total sample was 71% and in the “globally impaired” 
Cluster 4 even 86%. The significant difference between Cluster 1 and 4 with regard to 
high grade tumor proportion supports literature reporting more extensive cognitive 
disruption with high grade tumors.7 In the current study, the effect was based on 
histological grading, as IDH1 mutation, in contrast to previous reporting investigating 
separate test performances,10,16,36 did not reveal predictive value. We note that IDH1 
4
Binnenwerk_Productie.indd   89 1/18/2021   11:38:54 AM
90
Chapter 4
mutation status was only available for 71% of our patients, and this may have led to limited 
ability to detect a significant (limited) effect. The proportion IDH1 wild-type tumors was 
relatively high in Cluster 3. The influence of this feature may therefore be restricted to 
(a limited combination of) specific domains. Cluster 4 was further characterized by a low 
proportion of patients receiving treatment with AED. Mean age was relatively high (58.5 
years) but not significantly different from other clusters. It is worth noting that tumor 
location measures (hemisphere, frontal and temporal lobe) did not differ significantly 
between Clusters 1 and 4, that appeared to be at either end of the cognitive spectrum.
 Isolated executive impairment (Cluster 2) was associated with low tumor 
volumes, similarly to “intact” Cluster 1. However, mean age of Cluster 2 (51.4 years) 
was more comparable to that of the total sample (52.8 years). Cluster 2 presented 
with a large proportion of left hemispheric tumors (70%, significantly higher than all 
other clusters), while frontal tumors were less common (40%), in particular compared 
to the globally impaired Cluster 4. Cluster 3 composition (“speed, motor, visual”) was 
characterized by older patients (mean 64.2 years) harboring right-sided lesions (86%) 
with above average volumes. Isolated verbal and visual memory impairment (Cluster 
5) was observed in patients with high tumor volumes located in the right hemisphere 
(97% of this group). High chances of verbal memory impairment along with a high 
proportion of right hemispheric tumors is a striking finding. In the absence of an 
empirical lateralization index for verbal ability, we hypothesize that Cluster 5 patients 
may have been susceptible to a broad memory deficit regarding both verbal and visual 
information. In contrast, Cluster 3 patients, who also largely harbored right hemispheric 
tumors, showed vulnerability for dysfunction on the visual memory measure only.
The patient and disease factors that showed independent contributions towards 
prediction of the clusters have previously also been described as predictors of separate 
test or domain performance.4,7,8,40-42 However, our findings reveal that some 
characteristics – patient age, tumor grade, epilepsy treatment - may help to discriminate 
an intact (Cluster 1) from a broadly impaired (Cluster 3/4) cognitive profile, while others - 
tumor volume, hemisphere and frontal location – may contribute mostly to discrimination 
between impaired profiles (Clusters 2-5). We note that, although some factors may be 
interrelated (e.g., age, AED use, histology), their effects were independent.
We acknowledge several limitations to our current study. First, NPA was integrated 
into clinical care and combined with hospital admission and MRI one day before surgery. 
Performing the cognitive screening earlier would be more appropriate for informing 
patients timely and allowing the clinical team to act on the profile. Still, we believe 
our results are generalizable to a somewhat earlier time-point, as the prevalence of 
impairment (overall and on separate domains) were largely comparable to previous 
reporting5, except for memory, where impairment was less prevalent in our study. 
We attribute this difference to the test itself rather than timing, because CNS VS 
memory tests measure immediate and delayed recognition, but not free recall. A 
second limitation therefore is that, although we did identify a memory cluster in our 
data, our analyses may still provide an underestimation of the prevalence of memory 
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impairment and may reflect problems with a specific memory sub-modality. Patients at 
our neurosurgery department undergo assessment as part of standard care unless they 
have symptoms that impair testability. As we investigated diffuse glioma only, we cannot 
infer whether the impairment patterns are glioma-specific or if they are also present in 
CNS tumors with other histopathological features and growth patterns. For example, 
patients with brain metastases may show more (psycho-)motor impairment43 and 
patients with meningioma may show a larger “intact” cluster than glioma.44 Finally, we 
chose a limited number of (cortical) location categories that were believed to be most 
relevant based on literature, and did not distinguish between degrees of subcortical 
involvement. Involving subcortical nuclei as well as white matter integrity would fit in 
a framework of cognitive profiles and could be studied in a larger patient sample.
The current study is explorative and provides new insights into (the prediction of) 
cognitive profiles in glioma patients that we can gain from non-traditional methods. 
Our study concerns pre-surgical cognition, but longitudinal clustering applications allow 
for the estimation of patients’ chances for transitioning from one profile to another 
profile (i.e, qualitative changes in cognitive functioning) over the course of treatment. 
In addition, investigating cognitive profiles in relation to other outcomes, such as quality 
of life,45 and survival outcome, 46 may also give us new information beyond that of 
individual tests. A main goal to serve clinical practice would be the development and 
validation of a tool that uses routine patient and disease characteristics to estimate 
cognitive profiles, as done with previously machine learning in other neurological 
diseases with a strong cognitive component.47 Clinicians could adapt information 
provision based on the expected profile, e.g., providing succinct (written) information 
or involving caregivers in case of isolated memory problems, or taking more time for 
a consultation in case of speed-related problems, but also to target patients for more 
elaborate NPA (e.g., adding specific modules to a core assessment battery), specific 
intra-operative testing during awake surgery, or referral and/or tailoring to/of cognitive 
rehabilitation in case of a high likelihood of impairment(s).
CONCLUSION
Using tests from a brief computerized cognitive screening, LCA revealed five clusters 
of glioma patients with different patterns underlying their test performances. Patient 
and disease characteristics that were predictive of cluster membership can be derived 
without extensive effort in the consultation room or from diagnostic MRI and are largely 
known at time of diagnosis. Whereas some patient and disease factors previously 
related to test performances (age, AED use, lesion grade) seem valuable in distinguishing 
an “intact” from a (broadly) impaired profile, some factors relating to tumor location 
(hemisphere, frontal lobe involvement) and tumor volume may be useful mostly for 
distinguishing different patterns of impairment.
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SUPPLEMENTARY TABLES
Supplementary table 1. Description of neuropsychological tests and their scores used as indicators
Test Content Score used as indicator
Verbal Memory 
(VEM)
Fifteen words are presented, one 
at a time. Subject subsequently 
identifies presented words among 
new words. Delayed recall at end of 
assessment.
Total items correct for the 




Fifteen abstract images are 
presented, one at a time. Subject 
subsequently identifies presented 
images among new images. Delayed 
recall at end of assessment.
Total items correct for the 
immediate recall and delayed 
recall
Finger Tapping Test 
(FTT)
Subject presses space bar as quickly 
as possible for 10 secs (index finger, 
three trials per side).
Taps right average + taps left 
average
Symbol Digit Coding 
(SDC)
Subject matches symbols presented 
on the screen with corresponding 
number for two minutes, using the 
numbers on the keyboard.
Correct responses – incorrect 
responses
Stroop Part I 
(StroopI)
Subject presses space bar when a 
word is presented on screen.
Average reaction time correct 
responses Part 1
Stroop Part III 
(StroopIII)
Subject presses space bar if the 
color of the presented word does 
not match the meaning of the word.
*Average reaction time correct 
responses
(StroopIII rt)




Subject matches geometric objects 
by shape or color for two minutes.
Correct responses – Errors
Continuous 
Performance Test (CPT)
Subject responds to target letter 
among distractors for 5 minutes.
Average reaction time to 
target letter
Supplementary table 2. Overview of model characteristics – measures of global fit






2-Cluster -1683.38 3479.72 3404.75 19 363 0.05 0.82 <.01 (0.00)
3-Cluster -1665.39 3503.20 3388.78 29 353 0.16 0.65 <.01 (0.00)
4-Cluster -1650.73 3533.33 3379.45 39 343 0.19 0.65 .02 (0.01)
5-Cluster -1642.32 3575.96 3382.64 49 333 0.18 0.67 .41 (0.02)
*Comparison of the global fit of the restricted vs larger model, e.g., 2-cluster model compared to the 
3-cluster model. P-values are estimated using the bootstrap of L2
4
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Profiles and predictors of cognitive impairment 
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Purpose  Cognitive dysfunction in patients with meningioma can affect various 
domains, but it is unclear what specific patterns of dysfunction exist. We performed 
Latent Class Cluster Analysis (LCA) to identify and predict pre- and postsurgical patterns 
in performances across neuropsychological tests.
Methods Patients with meningioma underwent computerized 
neuropsychological assessment one day before (T0, n=402) and three months after (T3, 
n=347) surgery. Performances on nine test measures were standardized into Z-scores 
and dichotomized into impaired (Z-score ≤.1.5) and unimpaired (Z-score >-1.5). We 
performed bias-adjusted three-step LCA’s for both time points, using impairment status 
on the measures as indicators. Patient and disease characteristics were used to predict 
cluster membership.
Results  At T0, we identified four patient clusters showing distinct impairment 
profiles, which we labelled “cognitively intact”, “(psycho)-motor-executive”, “executive-
processing speed”, and “globally impaired”. At T3, we identified five clusters that 
were labelled as “cognitively intact”, “verbal memory”, “executive-speed” (combining 
executive, psychomotor and processing speed impairment), “(psycho-)motor-attention”, 
and “diffuse”. For both time points, younger age and high education predicted the 
“intact” profile, and bilateral tumor location predicted multi-domain dysfunction. 
AED use and location variables (left hemisphere localization, falx, skull base) predicted 
membership of impaired clusters at T0. Low depressive symptoms predicted the 
“intact” profile at T3.
Conclusion We identified multiple subgroups of patients characterized by distinct 
cognitive impairment profiles. Profiles were partly different before versus after surgery, 
and were related to patient and disease factors. Future studies should further explore 
the different types of change patients appear to show in their cognitive profiles.
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INTRODUCTION
Cognitive functioning is increasingly recognized as a relevant outcome for brain tumor 
patients undergoing treatment.1 This is an important development, as cognitive 
impairment is among the most common symptoms in this population2-4 and is related 
to various patient- tumor- and treatment-related factors.5 The severity of dysfunction 
in patients with benign tumors, such as meningioma, is reportedly more mild than 
in patients with malignant tumors characterized by parenchymal infiltration, such as 
high grade glioma.6 Still, the majority of meningioma patients suffer from cognitive 
dysfunction7,8 that does not necessarily resolve after treatment.9-11
The overall cognitive profile of patients with meningioma is heterogeneous, 
with deficits presenting in various domains. Multiple studies report that dysfunction 
is most pronounced on measures of executive function and (verbal) memory,7,8,12,13 
whereas others report particular disruption of other functions, such as psychomotor 
speed.14-16 These cognitive deficits can interfere with many facets of daily functioning17-23 
and quality of life.13 Having an adequate understanding of the nature of cognitive 
dysfunction and being able to predict different dysfunctions is therefore imperative 
to optimize (shared) decision-making and balance disease and functional outcome for 
individual patients. Furthermore, it may aid in improving long-term outcomes,1 such as 
health care utilization24 and work performance,25 on a greater scale.
Studies on cognition in brain tumor patients generally investigate patients’ 
performances on separate tests or domains.7,8,10-13,15,16,26,27 This approach informs us 
about the degree to which different cognitive functions are affected before and over 
the course of treatment. Still, studying performances on cognitive tests or domains 
separately does not provide an account of which patterns exist in patients’ performances 
across cognitive domains. In addition, it disregards interrelations between (dysfunction 
on) domains.28 In a recent study, we identified five subgroups of glioma patients showing 
distinct patterns of pre-surgical cognitive impairment across neuropsychological tests 
with Latent Class Cluster Analysis (LCA).29 It is still unclear if (such) impairment patterns 
can be found in patients with other brain tumors, such as meningioma, that show 
different lesion26,30 and population9 characteristics.
Exploring impairment patterns in various PBT population could help to improve 
peri-surgical and follow-up care. The existence of disease-specific cognitive profiles 
would warrant tailoring of cognitive monitoring and patient informing within the 
population. If similar cognitive profiles manifest across diagnoses, a more centralized 
approach would be appropriate. It is also important to know if cognitive profiles before 
tumor resection and after tumor resection in the same population are the same or 
not, i.e., if the type of dysfunction is likely change. In this study we employed LCA to 
investigate 1) whether meningioma patients could be classified into subgroups based 
on patterns in their performances across different cognitive tests before and three 
months after resection, and 2) which patient and disease factors predicted membership 
of the groups.
5




Study design and patients
Data were gathered for the purpose of a prospective longitudinal study in patients 
with primary brain tumors who undergo neuropsychological assessment (NPA) one 
day before (T0) and three months after (T3) surgical debulking as part of usual care 
at the Neurosurgery department of Elisabeth-TweeSteden Hospital (Tilburg, the 
Netherlands). The study was approved by the local Medical Ethics Committee Brabant 
(file number NL41351.008.12). Data were used for research purposes with patients’ 
written consent.
We used neuropsychological data from patients undergoing resection between 
November 2010 and November 2019 for grade I-III infra- or supratentorial meningioma 
who had completed T0 measurement. Exclusion criteria were age <18, presence of 
progressive neurological disease, psychiatric or acute neurological disorder within the 
past two years, and reduced testability (e.g. lack of proficiency in Dutch, estimated 
premorbid IQ <85). The current sample is described in part in previous studies.8,9,31
Measures
Sociodemographic
Age and sex were obtained from electronic medical charts. Educational level (categories: 
low, middle, high) was obtained by means of a semi-structured interview at the start 
of the T0 assessment.
Clinical
We obtained the following clinical parameters from the electronic medical charts: tumor 
grade, symptoms reported by patients at time of diagnosis, use of corticosteroids and 
anti-epileptic drugs [AED] at T0 and T3, extent of resection assessed with Simpson 
grade. From symptoms that patients reported at time of diagnosis, we specifically 
included cognitive complaints for analyses. Tumor localization data were retrieved from 
surgery reports and categorized first into infratentorial vs. supratentorial location. In 
case of supratentorial location, further classification included intraventricular, skull 
base, convexity, parasagittal and falx location. Tumor lateralization contained three 
categories: left, right, bilateral. Tumor volume (cm3) was determined through semi-
automatic segmentation (BrainLab Elements and ITK-Snap software) on T1-weighted 
contrast enhanced MRI. Anxiety and depression symptoms were evaluated with the 
Hospital Anxiety and Depression Scale (HADS) at time of assessment.32
Cogntive
We assessed cognitive performances at each time point with the computerized 
neuropsychological test battery CNS Vital Signs (CNS VS), that is largely based on 
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conventional neuropsychological tests.33 Assessment with CNS VS covered seven tests 
(some of which consisting of multiple subtests), took 30-45 minutes and was supervised 
by a trained test administrator. Supplementary table 1 shows the content of each 
administered test as well as the score computations of the nine test measures that 
were used in the analyses. Raw scores were standardized into sex- age- and education-
adjusted Z-scores, using data from repeated assessment in our previously obtained 
sample of healthy controls as reference. Z-scores at T3 were also controlled for practice 
effects that were demonstrated in the healthy sample.34 For the main analyses, we 
dichotomized performances on each test for each individual into impaired (Z-score 
≤-1.5; below 6.7th percentile) or unimpaired (Z-score >-1.5). Continuous Z-scores were 
used for descriptive purposes.
Statistical analyses
Descriptive characteristics were computed in SPSS v24. Latent Class Cluster Analysis 
(LCA) was performed in Latent Gold35 v5.1. LCA is a model-based technique that classifies 
cases (here: patients) into homogeneous subgroups based on their responses on a 
set of indicators (here: performances on the nine CNS Vital Signs test measures). The 
underlying assumption of LCA is that cases belong to latent, i.e., not directly observable, 
classes (clusters), and that the response patterns of cases in the same cluster arise from 
the same probability distribution.36 LCA assigns every patient a posterior membership 
probability for each identified cluster that reflects the probability of the patient 
“belonging” to that cluster. Every patient is then assigned to the group for which they 
show the highest probability (i.e., their “modal class”). In the following section, we 
provide a brief overview of the applied procedure. For a more detailed description, we 
refer to our previous paper.29
Three-step approach
We adopted the bias-adjusted three-step approach proposed by Vermunt37 for the T0 
and the T3 data separately. In step 1, we performed six separate LCA’s that assumed 1 
through 6 clusters, using the nine test performances (impairment vs. no impairment) 
as indicators, to explore the optimal number of clusters. The estimated models were 
compared on a combination of global and local fit statistics that are described in detail 
in our previous study.29 We calculated an adjusted significance level for analysis of the 
Bivariate Residuals (BVR) using the approach by Benjamini and Hochberg.38
Patients’ posterior membership probabilities for each cluster of the optimal model 
(i.e., the model that was both the most parsimonious model and showed the best fit 
to the data) were saved, and patients were assigned to their clusters (step 2). Cluster 
profiles were interpreted based on the conditional probabilities for impairment on 
the tests. These probabilities reflect the chance of impairment on a measure given 
membership of a particular cluster. Probabilities < 0.30 were considered low, 0.30-
0.40 low-moderate, 0.40-50 moderate, 0.50 - 0.60 high-moderate and > 0.60 high. In 
5
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step 3, we performed a multinomial multivariate logistic regression to predict cluster 
membership probability with external covariates (predictors), while correcting for the 
model’s classification error that can otherwise bias results.
External covariates used to predict cluster membership were chosen based on 
theory9-11,13,15,39,40 and clinical relevance for each timepoint. T0 candidate predictors 
included: Age, tumor volume (both as continuous variables), and high (vs low/middle) 
education, AED use, cognitive complaints reported as a symptom at presentation (vs. no 
cognitive complaints), atypical (vs. benign) tumor, lateralization (right vs left vs bilateral), 
and location (infratentorial, convexity, falx, anterior skull base) as categorical variables. 
T3 candidate predictors included: Age, Hospital Anxiety and Depression Scale Anxiety 
facet and Depression facet at T3 (as continuous variables), and high education, atypical 
tumor, lateralization, and location with the same categories as at T0. Lateralization was 
converted to dummies with right sided lesions as reference group.
Proportional classification was used for the prediction. Parameter bias adjustment 
was done using the Maximum Likelihood (ML) method.41 Cases with missing values on 
the predictor variables were kept in the model. Conditional probabilities (probability of 
showing a characteristic, given membership of a cluster) were reported for categorical 
predictor variables and group means for continuous predictor variables.
RESULTS
We identified 466 meningioma patients who underwent T0 measurement as part of 
regular care and did not meet any of the exclusion criteria. Seventy-seven patients 
were excluded from the analyses due to invalid or largely incomplete NPA (n=64), e.g., 
due to motor dysfunction or trouble understanding the instructions, leaving a total 
of 402 patients of whom data were included at T0. Of this group, fifty-five did not 
complete T3 assessment. Reasons for dropout included: lost to follow up/no show 
(n=22), patient cancelled the appointment (n=12), readmission or poor clinical status 
(n=12), neuropsychological follow-up elsewhere (n=4), patient deceased (n=3), resection 
cancelled (n=1), patient lived abroad (n=1). Table 1 describes the characteristics of the 
included samples at T0 and T3. Table 2 shows the mean cognitive test performances 
and rates of impairment on the tests.
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Table 1. Sample characteristics
T0 N=402 T3 N=347
Age (years) M±SD, range 57.2±12.1 (23-84) 56.8±11.9 (23-84)
Male, n (%) 109 (27) 91 (26)
Education,
Low 153 (38) 128 (37)
Middle 118 (29) 101 (29)
High 132 (33) 118 (34)
Previous treatment
Radiotherapy/radiosurgery 11 (3) 8 (2)
Surgical resection 8 (2) 7 (2)
Embolization 1 (0) 1 (0)
WHO Grade
WHO I (benign) 370 (92) 321 (92)
WHO II (atypical) 31 (8) 26 (8)
WHO III (malignant) 1 (0) 0 (0)
Lateralization
Left 164 (40) 143 (41)
Right 190 (48) 163 (47)
Bilateral 48 (12) 41 (12)
Location
Infratentorial 42 (10) 35 (10)
Intraventricular 7 (2) 6 (2)
Convexity 143 (36) 118 (34)
Parasagittal 19 (5) 15 (4)
Falx 52 (13) 48 (14)
Skull base 159 (40) 145 (42)
Volume (cm3, n=238) Med, range 31.0, 4.5-150.2 31.1, 4.5-150.2
Cognitive complaints at presentation 48 (12) 39 (11)
Anti-epileptic drug use at time of NPA 105 (26) 108 (32)
Extent of resection (n=326)
Total (Simpson I-III) n/a 290 (89)
Subtotal (Simpson IV) n/a 36 (11)
5
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Table 2. Cognitive test performances in the sample at T0 and T3
T0 n=402 T3 n=347












Verbal memory test (VEM) 
(n =387/340)
-0.68±1.34 97 (25) -0.85±1.39 101 (30)
Visual memory test (VIM) 
(n =386/342)
-0.50±1.24 78 (20) -0.32±1.23 60 (18)
Symbol Digit Coding test (SDC) 
(n =390/339)
-1.07±1.39 138 (35) -0.81±1.18 81 (24)
Finger Tapping test (FTT) 
(n =390/341)
-1.00±1.64 135 (35) -0.62±1.43 73 (21)
Shifting Attention test (SAT) 
(n =380/329)
-0.98±1.72 127 (33) -0.81±1.56 84 (26)
Continuous Performance test (CPT) 
(n =386/341)
-0.57±1.50 76 (20) -0.81±1.32 84 (25)
Stroop test part I reaction time/rt 
(n =389/344)
-1.07±2.48 110 (28) -1.01±2.56 92 (27)
Stroop test part III reaction time/rt 
(n =381/340)
-1.48±2.27 166 (44) -1.02±1.76 105 (31)
Stroop test part III correct answers 
(n =380/338)
-1.49±3.88 88 (23) -0.30±1.09 20 (6)
† The number of patients with a valid performance at T0/T3 is presented for each test
Identification of the number of cognitive clusters in the data
T0
Global fit measures. Supplementary table 2 shows the global fit statistics for all 
models (assuming 1 through 6 clusters) of the T0 and T3 data. Global model fit 
increased significantly from the 2-cluster to the 3-cluster solution (p<.01, Standard 
Error [SE] = 0.00), and from the 3-cluster to the 4-cluster solution (p=.04, SE=0.01). 
The 5-cluster model did not show a significantly improved global fit to the data (p=.16, 
SE=.02) and had a similar class separation (Entropy R2 ) and classification error compared 
to the 4-cluster model.
Local fit measures. We investigated the local fit of the 4-cluster and 5-cluster 
model. Both did not show significant BVR under FDR corrected α level (.001), data not 
shown. All of the test measures contributed significantly to the cluster discrimination 
(all p-values <.01) in both models. The test R2 (variance in performance on the test 
explained by the clustering) ranged from 0.14 (VEM) to 0.67 (Stroop IIIrt) for the 
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4-cluster model and from 0.17 (VEM) to 0.70 (Stroop IIIrt) for the 5-cluster model. 
Taking into account the similar global and local fit measures, we adopted the 4-cluster 
solution for the T0 data.
T3
Global fit measures. Global fit of the model increased significantly from the 2- to 3 
cluster (p<.01, SE=0.00), from the 3- to the 4-cluster solution (p<.00, SE=0.00), and from 
the 4- to 5-cluster solution (p=.04, SE=.01). Entropy R2 was also in favor of the 5-cluster 
solution (0.83) as compared to the 4-cluster solution (0.67).
Local fit measures. We investigated the local fit of the 4-cluster and 5-cluster 
model. Only the 4-cluster model showed significant BVR values (relationship FTT-VEM 
and VIM-VEM, FDR corrected α=.003). Verbal Memory, FTT and Stroop III correct 
measures did not contribute significantly to the cluster discrimination in the 4-cluster 
model, p’s>.05. In the 5-cluster solution, only the Stroop III correct measure (p>.05) 
did not contribute significantly. R2 of the tests ranged from 0.11 (VIM) to 0.64 (Stroop 
IIIrt) for the 4-cluster model, and 0.14 (VIM) to 0.79 (VEM) for the 5-cluster model. 
Substantial increases in explained variance from the 4- to 5-cluster solution were 
observed for VEM (0.45 to 0.78 respectively) and FTT (0.17 to 0.44). Based on the global 
and local fit measures, we adopted the 5-cluster model for the T3 data.
Clusters and profiles of cognitive impairment
T0
Conditional probabilities of impaired performances on each measure per cluster are 
shown in Table 3 and depicted in Figure 1. For example, patients who were assigned 
to Cluster 1 showed a 5% (low) chance of impairment on the Symbol Digit Coding 
test (SDC), while in Cluster 2, patients showed a 73% (high) chance of impairment 
(conditional probabilities 0.05 and 0.73 respectively).
The cognitive profile of Cluster 1 (n=181, 45% of the sample) was characterized 
by low conditional probabilities (≤ 0.15) of impairment on all measures, indicating an 
“intact” cognitive phenotype. Cluster 4 (n=54, 13% of the sample) was characterized by 
high chances of impairment across all test variables (all conditional probabilities >0.6), 
except VIM that showed a slightly lower chance (0.56), indicating a “global impairment” 
cluster. Cluster 2 (n=89, 22% of the sample) showed impairment probabilities >0.50 
on SDC and FTT, and probabilities around 0.50 for SAT, and Stroop IIIrt. This cluster 
was identified as a “(psycho-)motor-executive” phenotype. Cluster 3 (n=78, 20% of the 
sample) was characterized by very high probability of impairment on Stroop III rt (0.96), 
high-moderate (0.50) for Stroop III correct measure, and moderate on Stroop Irt (0.40) 
(“Executive-processing speed” Cluster).
5




Table 4 and Figure 2 show the conditional probabilities for impairment on the tests per 
cluster at T3. Similar to T0, we observed an “intact” Cluster 1 (n=172, 50% of the sample) 
with impairment probabilities < 0.10 for all tests. Cluster 2 (n=58, 17% of the sample) 
was characterized by isolated VEM impairment (probability 0.96, “verbal memory”). 
Clusters 3, 4 and 5 showed multi-domain dysfunction. Cluster 3 (n=50, 15%) showed 
high impairment probabilities (>0.60) for Stroop IIIrt and SAT measures alongside 
moderate probabilities for SDC and Stroop I, indicating a profile with pronounced 
executive dysfunction together with psychomotor and processing speed problems 
(“executive-speed”). A “(psycho-)motor-attention” profile presented in Cluster 4 (n=35, 
10% of the sample). This cluster showed particularly high probability for impairment 
on FTT, and (high-)moderate probabilities (0.41-0.58) for impairment on SDC, SAT and 
CPT. The most widely impaired cluster (Cluster 5, n=31, 9% of the sample) showed 
high impairment probability (>0.60) for VEM, and Stroop I and IIIrt, CPT, SAT and SDC. 
Impairment probabilities for the other measures (FTT, VIM, Stroop III correct), varied 
from low-moderate to (high-)moderate (0.28-0.56). This cluster was evaluated as a 
“diffuse” profile without pronounced motor slowing.
Figure 3 depicts the distribution of patients from the T0 clusters over the T3 
clusters (for descriptive purposes, no statistical comparisons). As can be seen, the 
majority (68%) of patients classified in the “intact” Cluster at T0 were classified in the 
“intact” Cluster at T3, while the other 32% was classified in one of the impairment 
clusters. Although between 26-38% of patients assigned to an impaired cluster at T0 was 
assigned to the “intact” cluster at T3, the majority of patients was thus still classified 
in an impaired cluster at T3.
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T3 "healthy" T3 "verbal memory" T3 "execu�ve-speed" T3 "(psycho-)motor a�en�on T3 "diffuse





T3 “intact” T3 “diffuse”
Figure 3. Patient classifications at T3 (stacks), given membership of clusters at T0 (X-axis). E.g., 
68% of patients classified in the “intact” cluster at T0 were also classified in the “intact” cluster 
at T3 (green stack), 22% were classified in the “verbal memory” cluster at T3 (yellow stack), etc.
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Prediction of cluster membership
Table 5 shows the results of the prediction analysis for the clusters at pre- and post-
surgical assessment (overall predictor effects are presented, effects associated with 
paired comparisons between clusters are described in the text).
T0
Patient and clinical and variables. Age, high education and cognitive complaints at 
presentation were significant overall predictors of cluster membership. Paired 
comparisons revealed that mean age was significantly lower in Cluster 1 (“intact”) 
as compared to all other clusters (p’s <.05). There were no significant differences 
between Clusters 2 ((“psycho-)motor executive”), 3 (“executive-processing speed) and 
4 (“global”). Cluster 1 showed a significantly greater proportion of patients with high 
education as compared to Cluster 3 and 4 (p’s ≤.01), but not Cluster 2. The proportion 
of cognitive complaints at presentation was lower in Clusters 1 and 2 compared to 
Clusters 3 and 4 (p’s≤.01). Finally, AED use was not an overall significant predictor, but 
paired comparisons revealed that AED use was significantly lower in Cluster 2 than the 
other clusters p’s<.05.
Tumor-specific variables. Paired comparisons revealed that the proportion of left 
sided tumors was significantly higher in Cluster 4 as compared to Clusters 1 and 3, 
p’s<.05, and bilateral tumors were more prevalent in Cluster 3 than in Cluster 1, p’s≤.01). 
Tumor volume was significantly lower in Cluster 1 than Cluster 4, p=.01. Adhesion to 
the falx was less common in Cluster 4 than Cluster 1, p=.02. Adhesion to the skull 
base was less common in cluster Cluster 3 than Cluster 1 as well as 4 (p=.02 and p=.03 
respectively).
T3
Patient and clinical and patient variables. Age, high education and HADS depression 
score were significant overall predictors of cluster membership. Mean age in Clusters 1 
(“intact”) and 2 (“verbal memory”) was significantly lower than in Clusters 3 (“executive-
speed) and 4 (“(psycho-)motor-attention”), all p’s <.05. The proportion of patients with 
high education was significantly higher in Cluster 1 than all other clusters (p’s <.05). 
Mean HADS Depression score was significantly lower in Cluster 1 than in Clusters 2 and 
5 (“diffuse”) p’s<.05.
Tumor-specific variables. The proportion of bilateral tumors was significantly 
higher in Cluster 5 than Cluster 1, p<.05). There were no significant effects (overall or 
between clusters) of any of the other tumor-specific variables.
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DISCUSSION
In this study, we performed LCA on neuropsychological test data of patients with 
meningioma one day before and three months after surgical resection in order to 
elucidate and predict patterns in (impaired) performances across tests. We identified 
four patient clusters showing distinct profiles of cognitive impairment at the pre-surgical 
assessment, and five clusters at the post-surgical assessment.
Clusters before surgery involved two apparently contrasting profiles; an “intact” 
profile (Cluster 1, 46% of the sample) with low chances of impairment across tests, and 
a “globally impaired” profile (Cluster 4, 14%), with high chances of impairment across 
tests. We also observed a “(psycho-)motor-executive” impairment profile (Cluster 2, 
18%), with particular susceptibility to impairment on multiple measures of (psycho-)
motor and executive function, and a profile characterizing impairment of executive 
function with additional, although somewhat lower, susceptibility to processing speed 
impairment (Cluster 3 “executive-processing speed”, 22%).
After surgery, an “intact” profile remained with similar impairment probabilities 
and cluster size (50%) as the one before surgery. Cluster 2 (17%) appeared as a relatively 
mild impairment profile, showing a “verbal memory” phenotype with susceptibility 
only for this measure. There were no separate “(psycho-)motor-executive speed” and 
“executive-processing speed” clusters after surgery. Rather, Cluster 3 (14%) involved 
varying degrees of susceptibility to impairment on measures of executive, psychomotor 
and processing speed in one profile, and was labelled as an “executive-speed” profile. 
Cluster 4 (10%) involved an apparent “(psycho-)motor-attention” phenotype, where 
particular motor speed (finger tapping) dysfunction went along with impairment on 
measures of psychomotor function, shifting attention and sustained attention. Cluster 
5 (9%, “diffuse impairment” profile) showed the susceptibility to impairment across 
most tests, but with relatively spared accuracy on Stroop III (executive measure), visual 
memory and finger tapping performances.
 Patients’ cognitive functioning can be expected to improve after resection, 
as main drivers of dysfunction, such as intracranial pressure and compression,7 are 
relieved. However, stable functioning, (transient) decline in functions and new deficits 
are also observed.10,27 The results from the descriptive analysis of the clusters at T0 
and T3 support this variance in trajectories on separate tests. For example, two-thirds 
of patients classified as “intact” at T0 in our study were also classified as “intact” at 
T3, indicating stable intact performance. One third of the “intact” patients developed 
some degree of impairment before the three month follow up. Furthermore, 26-38% of 
patients who were classified to an impaired cluster before surgery (Clusters 2-4) were 
assigned to the “intact” cluster after surgery. This suggests that, although a portion 
of patients with an impaired pre-surgical profile showed recovery after surgery, the 
majority still harbored an impaired profile. Our data also showed change that does 
not appear to fit in the categories of stability, deterioration or improvement, as some 
patients appeared to show a qualitatively different profile at T3 (e.g., 19% of patients 
5
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in the pre-surgical “(pyscho-)motor-executive” profile showed an isolated “verbal 
memory” profile post-surgery).
The contribution of the tests towards profile discrimination were somewhat 
different at the pre- versus postoperative assessment. Notably, the accuracy measure of 
Stroop III no longer contributed significantly to discrimination of clusters after surgery. 
Response speed on the same test did, however, contribute significantly. The explained 
variance in VEM over time went up from 14% to 78%, probably due to the identification 
of the isolated verbal memory impairment cluster. From these findings, it seems that 
sensitivity of tests to detect cognitive profiles may depend on the phase of the disease, 
especially when we take into account that sample characteristics at both time points 
were similar. The contribution of various tests to the discrimination of different cognitive 
profiles should be investigated further in order to determine which tests or domains 
are useful at different time points.
Several patient, clinical and tumor factors often obtained as part of standard 
clinical evaluation predicted the clusters. In line with earlier findings on (separate) test 
performances,7,42 Cluster 1 (“intact”) was characterized by young age and relatively 
small tumors before surgery. As much as 50% of patients completed a higher education. 
In contrast, Cluster 4 (“globally impaired”) had the highest mean age (66 years) of all 
clusters, and only 17% attained higher education. These two seemingly contrasting 
profiles were further distinguished by tumor factors and symptomatology; the 
proportion of left sided lesions, cognitive complaints at time of presentation and mean 
tumor volume were higher in Cluster 4, while adhesion to the falx was less common. 
Cluster 2 (“(psycho-)motor-executive”) before surgery was mostly characterized by 
particularly low proportion of patients reporting cognitive complaints at presentation 
and low AED use. The exact role of AED use as predictor of this specific cognitive profile 
is unclear. Based on the known effects of tumor-related epilepsy and its treatment on 
local and widespread networks underlying cognition,13 one may expect that AED use 
would be lowest not in Cluster 2, but the “intact” Cluster 1. AED use in the “intact” and 
“global impairment” clusters was actually comparable, and similar to the total sample 
proportion. We hypothesize that patients in Cluster 2 may have had other symptoms 
at presentation that we did not include in our analysis. Cluster 3 (“executive-processing 
speed”) comprised a relatively low proportion of patients with high education (15% of 
the cluster, compared to 33% in the total sample), a low proportion of skull base tumors 
and a relatively high proportion of bilateral tumors compared to other clusters.
After surgery, the “intact” Cluster 1 was still characterized by young age and a 
high proportion of patients with high education, but also a low proportion of bilateral 
tumors, especially compared to Cluster 5 (“diffuse impairment”). In addition, Cluster 
1 showed the lowest mean HADS Depression score of all clusters, which is consistent 
with previous reporting indicating an association between mood and performance 
on separate cognitive tests43 that may be mediated by behavioral and biological 
processes.44-46 The composition of Cluster 2, with a relatively mild “verbal memory” 
profile, was mostly comparable to Cluster 1, with the exception of educational level 
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and HADS Depression score. Cluster 5 (“diffuse”) harbored a high proportion of 
bilateral tumors. Although distinguished from the milder clusters 1 and 2, there were 
no significant differences in characteristics between the clusters with multi-domain 
impairment (Clusters 3, 4 and 5).
Taken together, younger age and high education seem related to a better cognitive 
profile before and after surgery, even after correction for their usual effects in the 
healthy population, whereas bilateral tumor localization appears to be a predictor of 
multi-domain impairment at both time points. Most tumor localization variables (left 
hemisphere, falx, skull base) and AED use predicted pre-surgical, but not post-surgical 
profiles. There are inconsistent findings about whether and which effect meningioma 
localization has on cognition surrounding or after treatment,10-12,15 but the current results 
support the notion that cognition after resection of meningioma may be more related 
to patient factors47 that may be static (sociodemographics) or dynamic (depression). 
At the same time, we also note that, within the localization categories adopted in this 
study, tumors at specific anatomical sites can invoke different symptoms (e.g., headache 
in case of sphenoid wing tumors48, hormonal dysfunction resulting from tuberculum 
sellae tumors49) that may have been differentially related to cognition.
We observed some notable similarities in the results of the current LCA with 
our previous findings on pre-surgical impairment profiles in patients with glioma.29 In 
particular, it appears that similar percentages of meningioma and glioma patients harbor 
a cognitive profile without impairment (about 50% of patients) and global impairment 
(13 % of patients). This finding suggests that the prevalence of (severe) impairment may 
similar, despite different disease and population characteristics.
We acknowledge limitations concerning our assessment. CNS VS memory tests 
measure immediate and delayed recognition, but not free recall, and may provide 
underestimation of memory dysfunction compared to previous research.7 At the same 
time, the identification of a “verbal memory” cluster at post-surgical measurement 
supports previous reporting that a subgroup of meningioma patients show dysfunction 
on a non-computerized verbal memory test functioning after surgery.10 Furthermore, as 
we made a selection of test measures of the CNS VS battery based on clinical relevance, 
the profiles identified in our study are logically limited these specific measures. 
Furthermore, we did not adopt mood in the pre-surgical prediction model to preclude 
overfitting of the model, but we cannot exclude that mood influenced pre-surgical 
cognition. A second limitation concerns the approach to clustering. We explored the 
nature of cognitive (dys-)function at different time points. Our results indicate that a 
portion of patients shifted from one cognitive profile to another, thereby showing a 
better, worse, or qualitatively different profile after resection. Still, we are limited in our 
ability to identify which patients showed what type of change in their profile. Methods 
exploring latent patterns over time can be of particular value for exploring this issue.
Similar to other illnesses characterized by heterogeneous cognitive phenotypes, 
e.g., dementia,50 we may ultimately work towards development of individual risk profiles 
based on routinely obtained characteristics. A tool like this may improve clinician’s 
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ability to anticipate and inform about patients’ chances of specific (changes in) cognitive 
profiles, and to target intervention timely. Since such tools require validation in large 
clinical cohorts, an opportunity opens up for more collaboration between neurosurgical 
centers on neuropsychological research. Alongside short-term outcomes, investigations 
would ideally involve long-term trajectories as well (e.g., one and two years after 
surgery) where (modifiable) patient characteristics, such as lifestyle factors that have 
been linked to cognition, such as exercise,51 may be of interest.
CONCLUSION
About half of meningioma patients showed a cognitive profile with impairment(s) before 
and after resection. Impairment profiles were partly different for both time points, 
indicating different natures of cognitive dysfunction. Whereas some patients showed a 
better or worse cognitive profile after surgery, there was also a subgroup that showed 
a completely different profile. Tumor localization factors and AED treatment predicted 
pre-surgical profiles, whereas younger age and high education showed a protective 
effect against dysfunction both before and after surgery. Low depressive symptoms 
were related an intact profile after surgery, warranting extra vigilance towards mood 
disturbances at clinical follow ups. Future studies should further explore the different 
types of change patients may show in their cognitive profiles over time, and work 
towards clinically useful prediction tools.
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Supplementary table 1. Neuropsychological tests and their scores used as indicators for the LCA’s
Test Content Score used as indicator
Verbal Memory (VEM) Fifteen words are presented, one at a 
time. Subject subsequently identifies 
presented words among new words. 
Delayed recall at end of assessment.
Total items correct for 
the immediate recall 
and delayed recall
Visual Memory (VIM) Fifteen abstract images are presented, 
one at a time. Subject subsequently 
identifies presented images among 
new images. Delayed recall at end of 
assessment.
Total items correct for 
the immediate recall 
and delayed recall
Finger Tapping Test 
(FTT)
Subject presses space bar as quickly as 
possible for 10 secs (index finger, three 
trials per side).
Taps right average + 
taps left average
Symbol Digit Coding 
(SDC)
Subject matches symbols presented on 
the screen with corresponding number 
for two minutes, using the numbers on 
the keyboard.
Correct responses – 
incorrect responses
Stroop Part I (StroopI) Subject presses space bar when a word 
is presented on screen.
Average reaction time 
of correct responses 
Part 1
Stroop Part III 
(StroopIII)
Subject presses space bar if the color of 
the presented word does not match the 
meaning of the word.
*Average reaction time 
of correct responses 
Part 3 (StroopIII rt)
* Number of correct 
responses
(StroopIII cor)
Shifting Attention Test 
(SAT)
Subject matches geometric objects by 
shape or color for two minutes.





Subject responds to target letter among 
distractors for 5 minutes.
Average reaction time 
to target letter
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Supplementary table 2. Overview of model characteristics for T0 and T3 data







2-Cluster -1776,58 3667,10 3591,17 19 383 0,06 0.79 .00 (0.00)
3-Cluster -1736,44 3646,77 3530,88 29 373 0,11 0.74 .00 (0.00)
4-Cluster -1723,45 3680,76 3524,90 39 363 0,16 0.69 .04 (0.01)
5-Cluster -1713,12 3720,06 3524,24 49 353 0,16 0.71 .16 (0.02)
6-Cluster -1702,46 3758,70 3522,91 59 343 0,16 0.72 .09 (0.01)
T3
2-Cluster -1447,11 3005,36 2932,22 19 328 0,07 0.73 .00(0.00)
3-Cluster -1431,51 3032,65 2921,01 29 318 0,09 0.75 .00(0.00)
4-Cluster -1417,30 3062,73 2912,61 39 308 0,17 0.67 .00 (0.00)
5-Cluster -1405,04 3096,71 2908,09 49 298 0,09 0.80 .04 (0.01)
6-Cluster -1394,98 3135,07 2907,96 59 288 0,07 0.83 .11 (0.01)
† Comparison of the global fit of the restricted vs larger model. e.g.. 2-cluster model compared to the 
3-cluster model. P-values are estimated using the bootstrap of L2
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Purpose  Cognitive functioning is increasingly investigated for its prognostic 
value in glioblastoma (GBM) patients, but the association of cognitive status during early 
adjuvant treatment with survival time is unclear. The aim of this study was to determine 
whether cognitive performance three months after surgical resection predicted survival 
time, while using a clinically intuitive time ratio (TR) statistic.
Methods Newly diagnosed patients with GBM undergoing resection between 
November 2010 and February 2018 completed computerized cognitive assessment 3 
months after surgery with the CNS Vital Signs battery (8 measures). The association 
of cognitive performance (continuous Z-scores and dichotomous impairment status; 
impaired vs. unimpaired) with survival time was assessed with multivariate Accelerated 
Failure Time (AFT) models that also included clinical prognostic factors as well as 
covariates related to cognitive performances.
Results  114 patients were included in the analyses (median survival time 16.4 
months). Of the clinical factors, postoperative Karnofsky Performance Status (TR=1.51), 
surgical (TR=2.20) and non-surgical (TR=1.94) salvage treatment, and pre-surgical tumor 
volume (cm3, TR=1.003) were significant independent predictors of survival time. 
Independently of the base model factors and covariates, impairment on Stroop test I 
and Stroop test III estimated 23% and 26% reduction of survival time (TR=0.77, TR=0.74) 
respectively, as compared to unimpaired performance.
Conclusion These findings suggest that impaired performances on tests of 
executive control and processing speed in the early phase of adjuvant treatment can 
reflect a worse prognostic outlook rather than an early treatment effect, and their 
assessment might allow for early refinement of current prognostic stratification.
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INTRODUCTION
To date, functional performance status (PS) appears to be one of the few clinical 
factors consistently allowing for prognostic stratification in the glioblastoma (GBM) 
population.1-3 Despite methodological issue ,4,5 it has shown superior predictive value 
compared to characteristics such as macroscopic extent of resection1 and patient 
age.3,6 Still, prognostic heterogeneity remains within clinically defined risk groups7 and 
identification of other patient-related markers could advance clinical monitoring and 
decision-making.
Measures tapping into functional domains that underlie PS, such as fatigue and 
cognitive functioning, have been evaluated increasingly for their prognostic value in 
glioma.8,9 Poorer cognitive performance in treatment- naive patients appears to predict 
worse survival outcome.10,11 However, not all patients can be tested (validly) in the 
short period between diagnosis and start of treatment, and although pre-treatment 
cognitive dysfunction may reflect tumor status,9,12 its nature or severity may be affected 
by distress from the diagnosis9,13 tumor laterality,14 or motor symptoms.12,13
After commencement of anti-tumor treatment, the overall cognitive profile 
of GBM patients remains characterized by high levels of impairment.15 Multiple 
investigations have explored the significance of post-surgical cognitive (dys-)function 
for survival, mostly by targeting cognitive assessment between surgical debulking and 
start of (chemo-)radiation. These studies have suggested a contribution of (impaired) 
cognitive performance, especially executive functioning, to the estimation of hazard 
rates in (older) patients.16-20 It remains unknown, however, whether cognitive status 
during early adjuvant treatment with radio- and/or chemotherapy bears value in 
predicting survival outcome.
Furthermore, although the commonly reported hazard ratio(HR)10,17-20 statistic 
provides information about the rates of death during follow up among patients with 
different cognitive performances, it does not directly translate into an estimation of 
differences in survival time. Considering the poor prognosis associated with GBM, 
readily interpretable information about survival duration can be of particular interest 
to clinicians. The accelerated failure time model (AFT)21 allows for the immediate 
derivation of a time ratio (TR) that indicates if a variable is related to shorter or longer 
survival time, e.g., in months, which is arguably more clinically intuitive.
The current study employed AFT modeling to investigate whether cognitive 
performance three months after surgical resection predicts survival time in GBM 
patients, with the aim of contributing to our understanding of the prognostic value of 
cognitive performance during adjuvant treatment and early refinement of prognostic 
models.
6





Data was obtained as part of a prospective longitudinal study in which patients with 
primary brain tumors underwent neuropsychological assessment (NPA) one day before 
(T0) and three months after surgery (T3) as part of usual care at Elisabeth-TweeSteden 
Hospital (Tilburg, the Netherlands). This study was approved by the local Medical Ethics 
Committee Brabant (file number NL41351.008.12).
Patients
For the current study, patients who underwent surgical resection of histopathologically 
confirmed GBM between November 2010 and February 2018, and who completed NPA 
at T3 were considered for inclusion. All included patients provided written informed 
consent. We excluded patients if at least one of the following criteria was met: age 
<18, diagnosis of a progressive neurological disease, psychiatric or acute neurological 
disorder within the past two years, previous intracranial surgery, or impaired testability 
(e.g., lack of proficiency in Dutch, estimated IQ <85, serious visual or motor deficits). 
Part of the current sample has been described previously.15,22
Cognitive functioning
We measured cognitive performance with a computerized neuropsychological test 
battery (CNS Vital Signs, CNS VS).23 Content of the tests that were used are displayed 
in Supplementary Table 1. Test validity was evaluated by the test administrator at 
time of testing and documented in a separate observation document. Invalid test 
performances were excluded. We used data from repeated assessment with CNS 
VS in healthy controls24 for normative purposes. Based on these data, we computed 
Z-scores that were adjusted for age, sex and educational attainment for each test 
performance (M=0, SD=1). A Z-score ≤-1.5 (performance below the 7th percentile) was 
considered impaired, and Z-score between -1 and -1.49 (performance between 7th and 
16th percentile) was considered low. Valid scores were not truncated. The proportion 
of impaired performances relative to number of valid test scores per patient
was calculated for descriptive purposes.
Clinical measures
We retrieved the following data from the electronic medical charts: tumor location, 
macroscopic extent of resection, KPS, anti-epileptic drug (AED) use, corticosteroid 
use, adjuvant treatment protocol, salvage treatment, and treatment-related events 
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(e.g., allergic reaction, infection, thrombocytopenia). Isocitrate dehydrogenase type 1 
(IDH1) gene mutation status was retrieved from pathological reports. We determined 
presurgical tumor volume (expressed in cm3) through semi-automatic segmentation 




Survival time was defined as the time between debulking and either date of death or 
last known contact before February 1st 2019 (in months). A survival curve displaying the 
proportion of patients surviving as a function of time was plotted.
Cognitive performance
We compared the mean performances of patients on each test to that of healthy 
controls with Z-tests.
Accelerated failure time models
We used the Accelerated Failure Time (AFT) model to investigate differences in 
survival time between groups. The AFT model provides a baseline survivor function 
and an acceleration coefficient that indicates whether a covariate “accelerates” or 
“decelerates” time until death. The exponentiated coefficient constitutes a time ratio 
(TR). TR<1 or TR>1 indicates that a variable is related to shorter or longer survival 
time respectively, e.g., a TR of 0.70 means that patients with a certain characteristic 
are estimated to have a median survival time that is 70% of patients without that 
characteristic.
Data distribution. We fitted models that assumed different distributions 
(Exponential, Weibull, Lognormal, Log-logistic, Gamma and Gauss). The model that 
fitted the data best, while being parsimonious, was selected based on a comparison of 
fit statistics (Akaike Information Criterion, AIC).
Base model. An initial base model included known clinical predictors of survival, 
including age at time of surgery, pre-surgical tumor volume (cm3), extent of resection 
(macroscopic total vs subtotal), KPS (at T3) (≤ 80 vs 90-100), adjuvant treatment 
protocol (chemoradiation vs other), treatment-related events, and salvage therapy 
(none [as reference category], non-surgical, surgical). We kept variables that significantly 
predicted survival time (α=.05) in the base model.
Cognitive models. We added the performances on the tests (continuous Z-scores 
and dichotomous impairment status; not impaired vs. impaired) to the base model 
separately. Before running the cognitive models, we investigated potential covariates 
(clinical and sociodemographic variables that differed between impairment groups 
or were related to the Z-scores) : sex, low educational level, high educational level, 
affected hemisphere, frontal involvement, corticosteroid use at T3, AED use at T3, and 
6
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the clinical factors that were not significant predictors in the base model. Covariate 
analyses included ANOVA’s and (non-)parametric correlations (Z-scores), in addition to 
independent samples t-tests and Chi-Square tests (impairment status). If significantly 
related to the test performance (α=.05), the covariate was added to the AFT model 
containing the relevant cognitive test score. We performed multiple testing corrections 
with the False Discovery Rate procedure by Benjamini and Hochberg [25] (separate 
corrections for the Z-score models and the impairment models).
Multivariate estimation of median time to event (MTTE). For a direct comparison 
of survival probabilities of patients who showed similar clinical characteristics, but 
different cognitive performances, we computed estimations of MTTE for the significant 
models and their predictors. Survival curves were plotted to visualize survival differences 
over time.




One hundred and fourteen patients with T3 data were included in the analyses (see 
Supplementary Figure 1 for a flowchart, including reasons for dropout before T3 and 
exclusion). Table 1 displays the sample characteristics.
Cognitive functioning
Average time between surgery and T3 measurement was 3.03 months (95% CI 2.95–
3.12 months). Table 2 provides group performances (mean Z scores) and impairment 
counts for all tests at T3. The number of valid performances ranged between n = 107 
and n = 113. Invalid performances were the consequence of technical problems during a 
test, external distraction, not understanding or repeatedly forgetting the instructions of 
a test, color blindness (Stoop test III and Shifting Attention test only) and mild unilateral 
motor disturbances (Finger Tapping test and Shifting Attention test only).
Eighty-seven percent (n = 99) of patients displayed some degree of impairment 
(on at least one of the tests they completed); 38% (n = 43) on less than one third of 
the tests, 16% (n = 18) on at least one third, but less than half of the tests, and 33% of 
patients (n = 38) showed impairment on at least half of the tests.
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Table 1. Patient characteristics
N=114
Male 83 (73%)












Frontal involvement 41 (36%)
IDH1 wild-type n=66) 62 (94%)
KPS at T3† (n=111)
80 or below 32 (29%)
90-100 79 (71%)
AED use at T3 (n=111) 41 (37%)
Corticosteroid use at T3 (n=113)
Macroscopic extent of resection
46 (41%)
Gross total (<90%) 70 (61%)
Gross subtotal (>90%) 44 (39%)
Adjuvant treatment‡
Chemoradiation (followed by TMZ monotherapy) 104 (91%)
Radiotherapy only 9 (8%)
No adjuvant treatment 1 (1%)
Treatment-related event 12 (11%)
Salvage therapy (n=113)
No salvage therapy 62 (55%)
Non-surgical (e.g., TMZ, lomustine, XRT) 29 (26%)
Surgical (with or without additional treatment) 22 (19%)
Values presented n (%) unless stated otherwise
† ECOG/WHO functional status instead of KPS was reported for 6 patients. This score was converted to 
KPS (ECOG 0 = KPS 90-100, ECOG 1 = KPS 80 or below). TMZ= temozolomide
‡ all patients had started adjuvant treatment before T3 NPA
6
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Table 2. Mean cognitive test scores (group level) and impairment counts






Verbal memory test (VEM) 
(n=109)
-0.82 ± 1.27** 33 (30%) 13 (12%) 63 (58%)
Visual memory test (VIM) 
(n =111)
-0.52 ± 1.04** 18 (16%) 22 (20%) 71 (64%)
Symbol Digit Coding test 
(SDC) (n =112)
-1.17 ±1.27** 46 (41%) 14 (13%) 52 (46%)
Finger Tapping test (FTT) 
(n =112)
-0.94 ± 1.53** 34 (31%) 16 (14%) 62 (55%)
Shifting Attention test 
(SAT) (n =107)
-1.37 ± 1.79** 42 (39%) 10 (9%) 55 (52%)
Continuous Performance 
test (CPT) (n =113)
-1.32 ± 2.59** 39 (35%) 16 (14%) 58 (51%)
Stroop test part I (n =112) -1.66 ± 2.78** 47 (42%) 5 (4%) 60 (54%)
Stroop test part III (n =109) -1.77± 1.93** 56 (51%) 11 (10%) 42 (39%)
† Z-score ≤-1.5, ‡ -1.49 ≤ Z-score ≤-1, § Z-score ≥ -0.99
** Significant difference from healthy control group (Z-tests, p<.001)
Survival
The lognormal distribution provided the lowest AIC among the tested models, 
indicating the best fit for the data. Figure 1 displays the survival probability over time 
(no predictors). The median survival time was 16.4 months (95% CI 13.90–18.85). At 
the defined time-point, 91 of 114 patients were deceased (79.8%).
Base model
Of the included clinical variables, T3 KPS of 90–100 (p < 0.001), salvage therapy 
(non-surgical and surgical) (p’s < 0.001), and pre-surgical tumor volume (p = 0.02) 
were significant positive predictors of survival time (TR= 1.51, 1.94, 2.20, and 1.003 
respectively). Age, extent of resection, adjuvant treatment protocol, and treatment-
related events were not related to survival time (p’s > 0.05).
Cognitive model—continuous Z-scores
Based on analyses of the covariates, we adopted the following variables as covariates 
in the cognitive models: age at time of surgery (SDC, SAT, Stroop I, Stroop III), sex (SAT), 
right hemispheric tumor (VIM), and corticosteroid use at T3 (FTT). None of the eight 
continuous Z scores showed a significant independent relationship with survival time 
under the adjusted alpha level after B–H correction (α = 0.006; see Table 3). None of 
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the included covariates showed a significant independent contribution to prediction 
of survival time.
Figure. 1 Survival probability over time and estimated median survival time (censoring is indi-
cated with +)
Cognitive status—impairment
Covariates for impairment status included age at time of surgery (SDC, Stroop I, 
Stroop III), sex (VIM), low educational level (SDC), right hemispheric tumor (Stroop I), 
corticosteroid use at T3 (VEM), extent of resection (VIM), and frontal involvement (CPT). 
Salvage treatment was significantly associated with less SDC, SAT, Stroop I and Stroop 
III impairment (p < 0.05), but was already part of the clinical model. As shown in Table 
3, addition of impairment status and relevant covariates to the base model showed 
that impaired performance on Stroop I (p < 0.01, TR = 0.77) and Stroop III (p < 0.01, 
TR = 0.74) were independent negative predictors of survival time (i.e., decreasing 
survival duration) under the adjusted alpha level (α = 0.013). Tumor volume was not an 
independent predictor for survival time in the Stroop I and III models (p > 0.013), while 
KPS and salvage treatments remained significant (p’s < 0.01). None of the covariates 
showed a significant contribution to the prediction of survival time.
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Table 3. Multivariate analyses of cognitive performances and survival time
Variable Coefficient (95% CI) SE TR p Model AIC
Base model
KPS 90-100 at T3 (vs. ≤ 80) 0.41 (0.21-0.64) 0.11 1.51 <.001 614.3
Salvage treatment (vs. none)
Surgical 0.78 (0.53-1.04) 0.13 2.20 <.001
Non-surgical 0.66 (0.45-0.91) 0.12 1.94 <.001
Volume (expressed in cm3) 0.003 (-0.001-0.005) 0.001 1.003 .02
Cognitive model – Z-scores
Z-score VEM 0.05 (-0.02-0.12) 0.04 1.05 .14 585.2
Z-score VIM† -0.02 (-0.11-0.08) 0.05 0.98 .71 599.2
Z-score SDC † 0.08 (0.00-0.16) 0.04 1.08 .06 602.3
Z-score FTT † 0.02 (-0.05-0.07) 0.01 1.01 .68 599.1
Z-score SAT † -0.01 (-0.06-0.05) 0.03 0.99 .73 578.4
Z-score CPT 0.01 (0.00-0.03) 0.02 1.01 .72 607.2
Z-score Stroop I† 0.01 (-0.02-0.04) 0.02 1.02 .53 610.1
Z-score Stroop III † 0.06 (0.00-0.11) 0.03 1.06 .03 590.7
Cognitive model – Impairment
Impairment VEM† -0.19 (-0.39-0.00) 0.10 0.83 .07 577.0
Impairment VIM† 0.15 (-0.12-0.42) 0.13 1.17 .24 600.2
Impairment SDC† -0.13 (-0.33-0.06) 0.10 0.88 .19 603.6
Impairment FTT -0.11 (-0.29-0.11) 0.10 0.90 .30 604.1
Impairment SAT† 0.06 (-0.12-0.27) 0.09 1.07 .52 579.6
Impairment CPT† -0.11 (-0.30-0.08) 0.10 0. 90 .28 607.4
Impairment Stroop I† -0.26 (-0.46--0.08) 0.10 0.77 <.01 603.2
Impairment Stroop III† -0.31 (-0.48--0.09) 0.10 0.74 <.01 586.3
† model contained covariate(s), see Results section
SE=Standard error, TR = Time Ratio
Multivariate estimation of median time to event (MTTE)
We estimated survival probabilities for patients with similar clinical characteristics, but 
different impairment status, using the predicted covariance matrices of all significant 
variables in the Stroop I and Stroop III models. For example, a comparison is shown 
below of patients with KPS 90–100 (n = 79) who did not receive salvage therapy after 
progression, and either did show impairment (i.e., survival probability for patient 1, 
denoted by p1) or not (i.e., survival probability for patient 2, denoted by p2).
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p1 = (KPS at T3=90-100, salvage therapy=none, cognitive status = impaired)
p2 = (KPS at T3 =90-100, salvage therapy=none, cognitive status = unimpaired).
Stroop III test
Estimated MTTE for p1 was 12.1 months, compared to 16.1 months for p2, reflecting an 
estimated shorter survival time of 4.0 months for the impaired performer.
Stroop I test
Estimated MTTE for p1 was 12.3 months, compared to 15.9 months for p2, reflecting 
an estimated shorter survival of 3.6 months for the impaired performer.
We repeated this procedure for patients with KPS 90–100, who received non-surgical 
salvage therapy (MTTE = 22.8 vs 30.5 months for Stroop III impaired vs. unimpaired 
performers, 22.5 vs. 28.9 months for Stroop I impaired vs. unimpaired performers), 
and surgical salvage therapy (MTTE = 23.7 vs. 31.7 months for Stroop III impaired vs. 
unimpaired performers, 24.2 vs. 31.2 months for Stroop I impaired vs unimpaired 
performers). See Figure 2 for multivariate survival plots for the described scenarios. 
We did not perform estimations for patients with KPS ≤ 80 (n = 32) due to the lower 
sample size.
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DISCUSSION
This study investigated to what extent cognitive performance three months after surgical 
resection was related to survival time in patients with GBM. We assessed the predictive 
value of cognition with AFT models while controlling for significant clinical prognostic 
factors (KPS, pre-surgical tumor volume, and salvage therapy) and covariates. Eighty-
seven percent of patients showed impairment on at least one test, while 33% showed 
impairment on at least half of the tests. In line with available literature, we found 
that impairment on a test of executive functioning17,19 (Stroop test III) independently 
predicted worse survival. We found a similar effect of processing speed (Stroop test I) 
impairment. Specifically, estimated median survival time was 26% shorter for patients 
with impairment on Stroop III compared to those without, and 23% shorter for patients 
with impairment on Stroop I compared to those without, translating into decreases of at 
least 4.0 and 3.6 months respectively in patients of good postoperative functional status 
(KPS 90-100), depending on salvage treatment. The continuous performance scores 
(Z-scores) did not reach the adjusted significance level, indicating that the prognostic 
bearing of cognition was limited to performances beyond a clinical threshold.
Taking into account previous reporting that patients with stable disease tend 
to show stable cognitive performance during early adjuvant treatment27 and that 
dysfunction arising before 6-month follow up appears related to poorer survival 
outcome,28 our results suggest that specific cognitive impairments during chemo-
radiation reflect a worse prognostic outlook rather than an early treatment effect 
(otherwise due to e.g., acute encephalopathy29,30 or treatment-induced fatigue31).
Notably, we found a relationship between cognitive impairment three months 
after surgery and salvage treatment, but they both exhibited independent associations 
with survival time. Treatment decisions are partly based on the patient’s functional 
performance,3 which itself is associated with cognition,5 and clinicians might favor more 
radical treatment in patients with good cognitive status.9 Incorporating information 
about salvage treatment in studies involving cognition and survival outcome is 
therefore warranted. We note that the prognostic bearings of salvage treatment as 
well as postsurgical KPS appear larger than that of postsurgical cognitive impairment. 
Nevertheless, cognitive measures acquired in addition to routine clinical follow up may 
facilitate early refinement of prognosis. Submitting vulnerable patients to exhaustive 
assessment for this purpose may not be not necessary, as performance on a limited 
range of tests, those assessing executive functioning in particular,9 appear relevant.
Executive functioning encompasses and relies on various functions. Part III 
of the Stroop test measures executive control ability; making decisions on relevant 
information among distracting cues. As it engages multiple functions such as top-down 
attention, response selection, inhibition and evaluation, executive control recruits a 
distributed network involving the dorsolateral prefrontal cortex and anterior cingulate 
cortex.32 Stroop I does not involve executive control, as it mainly reflects the speed at 
which subjects identify that a target is present (simple processing speed). However, 
6
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slowed processing speed contributes to executive functioning deficits33 and decreased 
processing speed together with memory and executive dysfunction has been suggested 
as a marker for more advanced disease.34 The Trail Making Test part B, a test that has 
been shown to carry particular value in predicting survival,11,17 also puts a demand on 
executive function in addition to mental speed.35,36
We did not find significant predictive roles for other tests that strongly depend 
on information processing speed, such as the Symbol Digit Coding (SDC) test. This 
might be attributable to the requirements of the test in CNS VS, where the subject 
presses different numbers on the keyboard based on the item. This involves computer 
familiarity and visuospatial scanning of the keyboard. Stroop I and III require the same 
simple motor response (pressing the space bar) to targets presented in the middle of 
the screen, which limits those factors. From our results, it does remain unclear whether 
processing speed underlay the prognostic effect of both Stroop tests, or if executive 
control exhibited a unique influence. Adopting different tests with varying speed and 
executive components might help to explore distinct contributions.
We acknowledge other limitations in this study that could also be addressed in 
future research. Firstly, we used cognitive status and KPS at one time-point instead of 
change therein. As a result, we cannot infer whether poor cognitive (and functional) 
performance reflected aggressive deterioration after surgery or a poor status that was 
already present. Future investigations might therefore include a short-term repeated 
measure of KPS and a cognitive classification that creates subgroups of patients that 
go from unimpaired pre-operative to impaired post-operative performance, indicating 
fast cognitive deterioration, and those who show impaired pre- and post-surgical status, 
indicating stable problematic functioning. Due to restrictions in sample size (valid T0 
NPA and/or T0 KPS were not available for all patients), we were unable to perform these 
analyses in the current sample. In addition, we did not adopt IDH1 mutation status in 
our analyses, as it was available for only 66 patients. IDH1 mutation status is a major 
factor in distinguishing GBM subtypes37 and predicting clinical outcome,38 but has also 
been related to cognition.39 The high proportion of wild type tumors in the available 
subsample was in line with data presented in the 2016 WHO Classification.40 Still, we 
cannot conclude that our results are directly applicable to the small proportion of IHD1 
mutated glioblastoma. Finally, conducting NPA three months after surgery coupled 
with regular care appointments has benefits from a logistical standpoint and allows for 
major stress from diagnosis and surgical intervention to subside. We have, however, 
observed in our study that this is a subgroup of patients who are clinically able and also 
willing return at this time.
Survival outcomes of patients with brain tumors in relation to cognition have 
primarily been reported using the hazard function, summarizing a predictor’s effect in 
terms of rates of death in different groups. Models based on the survival curve, such 
as AFT,21 may be more useful if a predictor is thought to convey a delay in the event 
occurring rather than an effect on the event itself occurring, and its derivative (Time Ratio) 
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is arguable more clinically interpretable.41 The AFT model as used here therefore appears 
to be an appropriate alternative to the commonly used Proportional Hazards model.
CONCLUSION
In conclusion, patients with GBM who displayed impairment on tests of executive 
functioning (Stroop III) and processing speed (Stroop I) three months after surgical 
resection had significantly reduced survival time (26% and 23% shorter respectively) 
compared to patients who did not show impairment. As KPS remains a principal clinical 
prognostic factor at the three-month time-point, targeted assessment of cognitive 
status incorporated as part of clinical follow-up care might allow for early refinement of 
disease monitoring. Further exploration of the prognostic value of different (speeded) 
measures of executive functioning and use of AFT models are recommended.
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SUPPLEMENTARY MATERIALS
Supplementary table 1 Description of used CNS VS tests
Test Content Score computation
CNS VS Verbal Memory 
(VEM) Test
Fifteen words are presented, one at a 
time. Subject subsequently identifies 
presented words among new words by 
pressing the space bar (immediate and 
delayed recall).
Total items correct 
(hits and passes)
CNS VS Visual Memory 
(VIM) Test
Fifteen abstract images are presented, 
one at a time. Subject subsequently 
identifies presented images among 
new images (immediate and delayed 
recall).
Total items correct 
(hits and passes)
CNS VS Finger Tapping Test 
(FTT): Motor speed
Subject presses the space bar as 
quickly as possible for 10 seconds with 
the index finger (three trials for the left 
and the right hand).
Taps right average + 
taps left average
CNS VS Symbol Digit Coding 
(SDC) Test: Psychomotor 
speed
Symbols and corresponding numbers 
are displayed in the upper part of the 
screen. Subject matches symbols with 
correct numbers in a grid on the lower 
part of the screen for two minutes.
Correct responses – 
incorrect responses
CNS VS Stroop Test part I 
(Stroop I): Simple reaction 
time
Part 1: subject presses space bar when 




CNS VS Stroop Test part 
III (Stroop III): Inhibitory 
control
Part 3: subject presses space bar if 
the color of the word does not match 
the meaning of the word (incongruent 
trials, e.g., the word “green” is 
presented with a red font).
Average reaction 
time correct items
CNS VS Shifting Attention 
Test (SAT): Cognitive 
flexibility
Subject matches geometric objects 
by either shape or color to one of two 
figures in the lower part of the screen 
for two minutes, using the left and 
right shift keys. The assignment and 
figures differ per trial.
Correct responses – 
Errors
CNS VS Continuous 
Performance Test (CPT): 
Vigilance
Capital letters are presented on the 
screen, one at a time. Subject responds 
to only target letter “B” by pressing the 
space bar (total test time 5 minutes, 
uninterrupted).
Average reaction 
time of responses to 
target letter
6



















GBM patients with T3 NPA  
N=122 
(November 2010 - February 2018) 
Included   
N=114 
Excluded (n=8)  
- Psychiatric comorbidity (n=2) 
- Medical comorbidity (n=2) 
- Resection of a recurrent tumor (n=2) 
- Estimated premorbid IQ <85 (n=1) 
- Declined use of data for research (n=1) 
Censored  
n= 23 
- Alive at time of last clinical follow up 
before February 2019 (n=22) 
- Unknown status after last contact due to 
outside referral (n=1) 






GBM patients with presurgical NPA  
N=179 
(November 2010 - December 2017) 
No T3 NPA (n=57) 
- Deceased (n=11)  
- Clinical status (n=20) 
- Complications/re-admission (n=4) 
- Patient declined  T3 (n=13) 
- Logistical (n=6) 
- No show (reason unknown) (n=2) 
- Surgery cancelled (n=1) 
 
Supplementary figure 1. Overview of patient inclusion
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CHAPTER 7
Predicting disease progression in high-grade glioma 
with neuropsychological parameters: the value of 
personalized longitudinal assessment
Journal of Neuro-Oncology. 2019;144:511–518.
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Purpose  Progressive disease in patients with high-grade glioma may be 
reflected in cognitive decline. However, the cognitive functions most sensitive to 
progression may differ between patients. We investigated whether decline on a 
personalized selection of tests predicted progressive disease according to RANO criteria 
in high-grade glioma patients.
Methods Starting one day before surgery, patients underwent 
neuropsychological assessment every three months during standard treatment and 
clinical follow-up. We first made a personalized selection of three tests that showed 
the highest Reliable Change Index (RCI) values, i.e., most positive change, at the first 
post-surgical assessment for each patient. In subsequent follow up, a decline of RCI≤−1 
on at least two of the three tests in the selection was considered cognitive decline. 
We performed a discrete Cox proportional hazards model including a time-dependent 
coefficient cognitive decline (vs. stability) and covariate age to predict progressive 
disease.
Results  Twenty five patients were included. Cognitive decline on the 
personalized test selection preceded or had occurred by the time progression was 
established in 9/15 patients with RANO confirmed progressive disease (60%). Decline 
was absent in 8/10 patients (80%) with stable disease during participation. The 
independent hazard ratio for progression in case of cognitive decline was 5.05 (p< 
0.01) compared to stable performance.
Conclusions Using only three patient-specific neuropsychological tests, we 
found a fivefold increased chance of disease progression in case of cognitive decline 
as compared to stable performance. Brief, patient-tailored cognitive assessment may 
be a noninvasive addition to disease monitoring without overburdening patients and 
clinical care.
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INTRODUCTION
Identification of reliable prognostic indicators for disease progression and overall 
survival is a principal aim in care for patients with high-grade gliomas (HGG), for 
treatment planning and to inform patients. Age and performance status (PS) are 
generally considered the major prognostic factors from a clinical perspective.1–3 These 
characteristics, however, may be interrelated with or confounded by other factors, such 
as therapeutic strategy or varying disease symptoms,1, 4 that are not always accounted 
for. Interest in the prognostic value of cognitive functioning in the clinical management 
of glioma patients is growing. 1, 5–9 Cognitive functioning depends on neuronal synchrony 
across brain regions.10 Invasive growth, reactive changes in peritumoral tissue and 
increased intracranial pressure may all disrupt network functioning needed for cognitive 
performance.11
Cognitive status before surgery or oncological treatment has been reported 
as a predictor of (progression-free) survival time7 independent of age and Karnofsky 
PS (KPS),9 as well as within RPA-RTOG classes.12 Furthermore, Meyers8 reported that 
performance decline over time on one of nine cognitive tests preceded radiological 
evidence of progressive disease (PD) in HGG in 85% of cases and by a median of 4 to 
7 weeks. In a heterogeneous sample of patients with brain tumors, Armstrong and 
colleagues5 showed that a decline of one standard deviation (SD) on the standardized 
mean of three to five tests per patient selected based on tumor location, was 
accompanied by a fivefold increase in chance of PD.
Cognitive deterioration over time might thus provide information about tumor 
activity during the course of the disease.5, 8, 13, 14 A targeted test selection, e.g., tumor 
location-based,5 may increase efficiency of assessment. However, dysfunction of specific 
cognitive domains may not be reliably determined by location alone15, 16 as tumors affect 
cerebral functioning outside their location.17
In this study, we argue that disease-related cognitive dysfunction in HGG, and 
individual differences therein, may also be detected by considering the manner in which 
a patient’s performance changes early after tumor resection. We hypothesize that the 
functions that show the largest recovery shortly after surgery are the ones that suffered 
the largest burden from tumor-related edema and mass effect, and that these same 
functions may deteriorate first amid recurrent disease activity. In a sample of newly 
diagnosed HGG, we constructed a personalized test selection for each patient, based on 
a subset of three neuropsychological tests that demonstrated most improvement within 
three months after resection. We subsequently investigated whether deterioration on 
this selection coincided with, and predicted PD.
7





Patients undergoing resection at the Elisabeth-TweeSteden Hospital, Tilburg, the 
Netherlands, between August 2015 and September 2017 for histopathologically 
confirmed WHO grade III anaplastic astrocytoma (AA) or WHO grade IV glioblastoma 
(GBM) were included. Patients received clinical follow up either at Elisabeth-TweeSteden 
Hospital or Catharina Hospital, Eindhoven, the Netherlands. Exclusion criteria were age 
<18, presence of progressive neurological disease, psychiatric or acute neurological 
disorder within the past 2 years, previous intracranial surgery, reduced testability 
(e.g. lack of proficiency in Dutch, estimated IQ<85). All participants provided written 
informed consent.
Study procedure and design
At the neurosurgery department of Elisabeth-TweeSteden Hospital, patients with brain 
tumors undergo neuropsychological assessment (NPA) as part of clinical care 1 day 
before (T0) and 3 months after (T3) neurosurgical treatment. Around T3, patients were 
asked to participate in this prospective longitudinal study by a neuro-oncology nurse 
practitioner, and underwent three monthly NPA and MRI, for up to 24 months after 
surgery (T24; 9 NPA’s in total) or until confirmed progressive disease (PD) at their clinical 
follow-up site. NPA and MRI were performed on the same day, but NPA was always done 
before the patient was informed of the results of the MRI. Approval for the study was 
given by Medical Ethics Committee Brabant (File No. NL41351.008.12).
Measures
Sociodemographic and clinical measures
Sociodemographic information was gathered through semi-structured interview at 
T0. Clinical information (tumor characteristics, extent of resection, KPS, medication, 
adjuvant treatment) was retrieved from electronic charts. Pre-surgical tumor volumes 
were determined through semi-automatic segmentation using BrainLab Elements18 
software on T1-post contrast enhanced series.
Neuropsychological assessment
The Dutch translation of the CNS Vital Signs (CNS VS) computerized test battery consists 
of seven tasks based on conventional paper-and-pencil tests.19 Completion using the 
local software application on a notebook computer took 30–40 min. Two additional 
paper-and-pencil tasks were administered: Digit Span task20 and a Letter Fluency task.21 
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An overview of task content and score computation is provided in the supplementary 
Table. Trained test administrators conducted assessments.
MRI-cerebrum and time until PD
Evaluations of the three monthly MRI scans were conducted by a trained neurologist 
(MB) under supervision of a senior neurologist (CT), both unaware of patients’ cognitive 
status. The baseline for comparison follow up MRI scans (at T3, T6, etc.) was the first 
post-operative scan (≤48 h after surgery). We adopted the response assessment 
criteria for HGG by the RANO Working Group22 for disease status evaluation: (1) ≥25% 
increase of the product of the Journal of Neuro-Oncology (2019) 144:511–518 513 1 
3 maximum diameters of contrast-enhancing lesions (2) significant increase of lesions 
in T2-weighted/ FLAIR series (3) presence of new contrast-enhancing lesions outside 
radiation field (4) significant clinical deterioration not attributable to medication or 
comorbid conditions, or (5) clear progression of a non-measurable lesion.
Cognitive change as a personalized predictor
Reliable change
Regression-based Reliable Change Indices (RCI), aimed at determining whether change 
between assessments in individual patients reflected relevant change, controlling for 
confounding factors related to repeated testing (e.g. flawed test–retest reliability, 
practice effects),23, 24 were computed for each of the 10 test scores. A positive RCI 
value indicates improvement, a negative RCI value indicates decline. RCI’s were based 
on repeated testing data of healthy Dutch individuals from Rijnen24 (CNS VS), Schmand21 
(Letter Fluency), and an ongoing study in the ETH (Digit Span test); CAR study A, 
ClinicalTrials.gov reference nr. NCT02953756.
Personalized selection and criterion for cognitive decline (CD)
For each patient, the three tests with the highest RCIs between T0 and T3 were selected. 
We opted to select three tests in accordance with previous similar studies,5, 8 and with 
the goal of a small selection of tests for potential future clinical purposes. All follow-up 
RCI’s were calculated using T3 NPA as baseline (T6–T3, T9–T3, etc.). CD was defined as 
RCI ≤ −1.00, reflecting a standardized difference score of −1, on at least two of the three 
selected tests at any follow up interval.
Statistical analyses
Using the Survival package in Rstudio, a discrete Cox proportional hazards model with 
two covariates was performed (α=0.05): a dichotomous time-dependent covariate (CD 
vs. stable performance) and age at time of surgery. Cases who dropped out before PD, 
completed follow up (T24) progression-free, or showed stable disease at the end of the 
study (August 2018), were censored. Median time to PD and to CD were computed. 
7
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Z-scores, corrected for age, sex and educational level based on a healthy control 
sample25 were computed to investigate whether patients had cognitive impairment 
before surgery (Z ≤−1.5). Group-level characteristics of patients with PD, without PD, 




Thirty-five of 70 (50%) patients eligible for participation were included in the study. 
Unwillingness, anticipated intensity of repeated NPA, and follow-up care in a non-
participating center were reasons for declining participation. Ten out of 35 patients 
were excluded from analyses, because of invalid or incomplete T0 NPA (n=6), or absent 
T6 data (consent withdrawal; n=3, referral to non-participating treatment center; 
n=1). Analyses showed no differences in age, tumor volume, extent of resection or 
pre-operative KPS between excluded patients and the final sample. The final sample 
comprised four AA and 21 GBM.
Mean age at time of surgery was 53 ± 14 years. See Table 1 for an overview 
of sample characteristics and Table 2 for the personalized test selection per patient. 
All patients started adjuvant chemoradiation according to protocol.26 Twenty-one 
patients completed treatment as planned during study participation. Temozolomide 
monotherapy was discontinued in four patients, either on patient’s request (n=1, around 
T6), because of PD during (n = 2, around T6) or due to treatment-related toxicity (n=1, 
between T6 and T9)
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Table 1. Sample characteristics
Characteristic N=25
Male n (%) 17 (68%)
Age at time of surgery (M±SD, range) 53±14, 19-76
Educational level†
Low n (%) 3 (12%)
Middle n (%) 12 (48%)
High n (%) 10 (40%)
Diagnosis
Glioblastoma 21 (84%)
Anaplastic astrocytoma 4 (16%)
Tumor volume (cm3), median (range) 36.8 (4.4–161.5)
KPS before surgery, mode (range) 90, 80-100
Tumor lateralization n (%)
Right 15 (60%)
Left 10 (40%)








Corticosteroids before surgery 17 (68%)
Anti-epileptics before surgery 8 (32%)
Macroscopic extent of resection
Gross total resection (>90%) 17 (68%)
Gross subtotal resection (<90%) 8 (31%)
†Classified according to Verhage education coding system26
7
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Cognitive change and progressive disease
In 23 out of 25 patients, all three selected tests with the highest RCI from T0 to T3 were 
positive scores (>0), indicating improvement after surgery. In two patients, the selection 
also contained tests with negative values (highest RCI’s were 0.62, 0.23, and −0.25 in 
one patient, 1.76, −0.18, and −0.20 in another patient).
 Fifteen out of 25 patients (60% of the sample) showed PD according to RANO 
during follow up (see Table 3 for evaluations of PD). Eleven out of 25 showed CD during 
follow up. Within the “PD group”, the median time-point to PD was T9, while within the 
“CD group”, the median time-point to CD was T6. CD preceded (n=4) or was present 
at time of (n=5) PD in nine out of 15 patients with PD. See Fig. 1 for a visualization 
of individual follow-up periods and the timing of CD relative to PD. Five of the six 
patients who showed stable cognitive performance according to our criterion, despite 
PD, showed RCI≤−1 on one of their selected tests at time of PD, while showing no RCI≤−1 
on their unselected tests.
In 10 of 25 patients (40%), PD did not occur during study participation. Eight out 
ten (80%) were stable performers throughout follow up (median follow up time-point 
T12, range T6–T24). Two patients showing CD despite stable disease did so at T6 and 
T9 respectively.
Table 3 shows descriptive characteristics of the four groups (no statistical 
comparisons). The group demonstrating both CD and PD was the only group in which 
KPS below 90 was observed at time of final NPA. AED use was high among these patients 
compared to the other groups, but the majority (four out of six) used medication 
because of a pre-surgical insult. The other two started AED therapy due to a seizure 
during follow up (both in the interval prior to PD). The group with stable disease and 
stable cognitive performance appeared relatively young and to comprise fewer males 
compared to the other groups.
Cox proportional hazards model
The Cox proportional hazards model showed a hazard ratio (HR) for PD of 5.05; 
95% CI 1.50–17.02, p< 0.01 (model χ2 [1] = 13.6, p< 0.01, c-index = 0.80), suggesting 
a 405% increase in chance of RANO-confirmed PD if patients met the criterion of CD 
compared to stable cognitive performance, independent of age. Age itself was not a 
significant predictor (HR=1.04, p>0.1) of PD.
7
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Table 3. Descriptive characteristics and RANO22 evaluations grouped by disease status and 
cognitive status on personalized test selections. Percentages are calculated within each group.
Progressive disease (n=15) Decline on tests Stable on tests
n=9 n=6
Age before surgery 60.0±7.6 58.3±10.7
Low education 0 (0%) 1 (16.7%)
High education 4 (44.4%) 3 (50%)
Male 7 (77.8%) 5 (83.3%)
Impairment on ≥1 selected test at T0 5 (55.6%) 5 (83.3%)
Tumor in left hemisphere 4 (44.4%) 1 (16,7%)
Macroscopic total resection 6 (66.7%) 3 (50%)
Time to CD (Median) T6 n/a
Time to PD (Median) T6 T12
KPS <90 at time of PD 5 (55.6%) 0 (0%)
AEDs at time of PD (%, n at T3) 6 (66.7%, 5) 1 (16.7%)
Corticosteroids at time of PD 2 (22.2%) 0 (0%)
RANO evaluation
New contrast-enhancing lesion outside radiation field 0 (0%) 1 (16.7%)†
Increase ≥25% in the sum of the products of 
perpendicular diameters
5 (55.6%) 3 (50%)
Clinical deterioration not attributable to medication or 
comorbidity (≥12 weeks post-chemoradiation)
1 (11.1%) 0 (0%)
Significant increase in T2/FLAIR non-enhancing lesion 0 (0%) 0 (0%)
Clear progression of a non-measurable lesion 3 (33.3%) 2 (33.3%)
Stable disease (n=10) Decline on tests Stable on tests
n=2 n=8
Age before surgery 55.5±3.54 40.3±15.6
Low education 0 (0%) 2 (25%)
High education 1 (50%) 4 (50%)
Male 2 (100%) 3 (37.5%)
Impairment on ≥1 selected test at T0 2 (100%) 7 (87.5%)
Tumor in left hemisphere 1 (50%) 4 (50%)
Macroscopic total resection 2 (100%) 6 (75%)
Time to CD (Median) T6 n/a
Time to PD (Median) n/a n/a
KPS <90 at time of censoring 0 (0%) 0 (0%)
AEDs at time of censoring (%, n at T3) 0 (0%, 0) 2 (25%, 2)
Corticosteroids at time of censoring 0 (0%) 0 (0%)
† Only case of non-local tumor recurrence
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Figure 1 Follow up duration per patient and time of CD (●) Lines stop at time of RANO PD (bold 
line) or end of participation (dotted line; censoring).
DISCUSSION
This study investigated whether post-surgical cognitive decline (CD) on a personalized 
selection of three neuropsychological tests concurred with and predicted progressive 
disease (PD) according to RANO22 in 25 patients with GBM or AA.
Decline in cognitive performance—deterioration of at least one RCI point on 
at least two of the three selected tests—concurred with, or manifested one or two 
interval(s) before, RANO-confirmed PD in nine out of 15 (60%) of recurrences. Of the 
six patients with PD who did not meet our criterion for CD, five showed RCI≤ −1on one 
of their selected tests, but no such decline on their unselected tests. Further consistent 
with our hypothesis and previous reporting,27 eight out of 10 patients with stable disease 
remained cognitively stable throughout participation. The predictive model showed a 
405% increase in chance for PD (HR=5.05) in case of CD, independent of age.
Our findings support existing reports of (change in) cognitive functioning as 
a clinical marker of disease activity in patients with brain tumors.5, 8, 13, 28 Gradual, 
widespread impairment of network functioning over time may underlie the sensitivity of 
cognitive performance to disease progression. Using a uniform test selection in patients 
with recurrent HGG, Meyers and colleagues8 reported a higher proportion of patients 
showing CD (48/56 patients, CD was defined as RCI≤−1.645 on one of nine tests) before, 
or at time of, PD compared to our study. It could be that CD emerges sooner in patients 
with progression of already recurred HGG. Still, the described criterion for decline was 
based on a more stringent cutoff, but for only one test, and time between CD and 
7
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actual PD seemed to vary considerably among patients. Their reported prediction model 
(requiring decline on one of three uniform tests) yielded a HR for PD of 2.0 in case of 
CD.
The hazard ratio of CD (one standard deviation in mean performance) on a tumor 
location-based selection of three to five tests found by Armstrong5 in a sample of 
34 patients with glial and non-glial tumors, of which 11 demonstrated recurrence, 
was comparable to the one we found. As stated, reliable inferences about cognitive 
(dys-)function may not be based on tumor location alone.15 In our sample of mainly 
GBMs, we did not observe a one-to-one relationship between tumor location and the 
personalized selection of tests, e.g., Letter Fluency and Shifting Attention tests were 
selected in patients with occipital tumors. The relative value of selection approaches 
(uniform, location-specific, personalized) within the context of prediction of PD may 
be compared in one larger sample in the future.
The absence of a gold standard concerning the cut off for CD, irrespective of 
the selection approach, in settings where cognition is used as a predictive instead of 
an outcome measure also warrants further investigation. The used RCI is a suitable 
measure for change as it conveys a cautious estimation of decline. Selecting three 
tests per patient is in accordance with previous approaches5,8 and preserves briefness 
required for repeated NPA in the HGG population. We must note that the widely 
adopted RANO criteria for HGG are based on current evidence22 and will likely evolve 
in the future.
Cognitive performance can fluctuate over time due to factors (un-)related to 
disease activity, such as temporary corticosteroid use29 or depressive symptoms.30 It 
has however been suggested that the main cause of cognitive decline over time is the 
tumor itself.13 Cognitive stability in eight out of 10 progression-free patients in this 
study also suggests that such factors did not disturb cognitive performance strongly 
(RCI’s remained>−1) or in a personalized pattern. The group with both CD and PD did 
seem to comprise a relatively large proportion of patients using AED’s, although in the 
majority of cases due to a pre-surgical insult. It was also the only group that comprised 
patients with KPS < 90 at time of final NPA/ PD. Clinical status may have interplayed with 
cognitive functioning around the time of PD. We were unable to adopt post-surgical 
decline in KPS or a combined cognition-KPS classification in the statistical model due to 
sample size, but analysis of hazard rates associated with CD irrespective of (K)PS decline 
could be a next step in future research.
Sample characteristics should be taken into account in interpreting our results. 
We note that our sample primarily comprised patients with GBM, and the majority 
of AA patients did not show PD. Moreover, 50% of patients who were invited to 
participate in this study declined participation, e.g., due to anticipated intensity of 
repeated NPA. Patients in good clinical condition at time of inclusion might therefore be 
overrepresented. Furthermore, only 12% of the included patients had low educational 
level. Different cognitive courses might exist between groups who differ on these 
variables.
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Results from the personalized prediction model warrant further investigation to 
establish relevance in clinical practice. Personalized NPA may serve as a noninvasive 
method to complement decision making processes, such as timing of second-line 
therapy in case of unclear or seemingly limited tumor growth. Conducting targeted 
NPA between MRI scans may also allow for early detection of recurrent disease activity, 
e.g., in patients whose radiological evaluation is conducted over longer intervals due 
to other relatively favorable prognostic features.
CONCLUSION
In conclusion, our prediction model based on a personalized selection of three 
neuropsychological tests showed CD before or at time of PD in the majority of patients 
with HGG. Eighty percent of progression-free survivors showed stable cognitive 
performance. Patients demonstrating CD showed five times higher chance of PD 
compared to stable performers. Personalized, longitudinal NPA may provide a targeted 
and sensitive addition to monitoring of both cognitive and disease status without 
overburdening patients or care trajectories.
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Supplementary Table 1. Description of neuropsychological tests
Test Content Scores and 
computation
CNS VS Verbal Memory 
(VEM) Test
Fifteen words are presented, one at a 
time. Subject subsequently identifies 
presented words among new words.
Total items correct
CNS VS Visual Memory 
(VIM) Test
Fifteen abstract images are 
presented, one at a time. Subject 
subsequently identifies presented 
images among new images.
Total items correct
CNS VS Finger Tapping Test 
(FTT): Motor speed
Subject presses space bar as quickly 
as possible for 10 secs (index finger, 
three trials per side).
Taps right average + 
taps left average
CNS VS Symbol Digit Coding 
(SDC) Test: Psychomotor 
speed
Participant matches numbers with 
corresponding symbols for two 
minutes.
Correct responses – 
incorrect responses
CNS VS Stroop Test: 
Interference
Part 1: subject presses space bar 
when a word is presented.
Part 3: subject presses space bar if 
the color of the word does not match 
the meaning of the word.
(Reaction time Part 3 
– Reaction time Part 
1) / Reaction time 
Part 1
CNS VS Shifting Attention 
Test (SAT): Cognitive 
flexibility
Subject matches geometric objects 
by shape or color for two minutes.
Correct responses – 
Errors
CNS VS Continuous 
Performance Test (CPT): 
Vigilance
Subject responds to target letter 
among distractors for 5 minutes.
Average reaction time 
of responses to B
Digit Span Forward (DSFW) 
†: Attention
Subject repeats series of digits of 
increasing length.
Total items correct
Digit Span Backward 
(DSBW) †: Acoustic working 
memory
Subject repeats series of digits of 
increasing length in reverse order
Total items correct
Letter Fluencya: verbal 
(lexical) ability, executive 
control
Subject names words starting with 
a specific letter for 1 minute (3 trials 
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Binnenwerk_Productie.indd   169 1/18/2021   11:39:04 AM
170
Chapter 8
The research described in this dissertation aimed to 1) contribute to our understanding 
of the nature of cognitive (dys-)function in patients with primary brain tumors 
undergoing surgical resection, 2) illustrate the value of postoperative cognitive 
measures for prognostic purposes, and 3) improve the alignment between needs 
and questions in clinical care and scientific research, by using clinically applicable and 
intuitive methodologies.
In part II (Chapters 2-5), we investigated the prevalence of and patterns in 
cognitive dysfunction, as well as their correlates, in patients with non-functioning 
pituitary adenoma (NFPA, Chapter 2) glioma (Chapter 4) and meningioma (Chapter 
5) one day before and, in Chapter 2 and 5, three months after surgical resection. We 
investigated the specific influence of APOE ε4 allele carrier status on pre-surgical 
cognitive impairment and cognitive change up to 12 months after resection in patients 
with newly diagnosed glioma or meningioma in Chapter 3.
Part III (Chapters 6 and 7) addressed the prognostic value of cognitive measures. 
In Chapter 6, we investigated whether cognitive impairment during early adjuvant 
treatment predicted survival duration in glioblastoma patients independent of known 
clinical prognostic factors. Chapter 7 describes a longitudinal study that investigated 
whether decline on a personalized set of three neuropsychological tests predicted 
radiological disease progression according to RANO criteria in patients with anaplastic 
astrocytoma and glioblastoma.
The following section provides an overview and discussion of the core findings on 
the formulated goals, methodological considerations, and an evaluation of challenges 
and opportunities in current clinical practice and for future research.
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1. Understanding the manifestation of cognitive dysfunction and its 
predictors (Part II of the dissertation)
1.1 Prevalence and course of cognitive dysfunction before and after treatment
Preoperative cognitive (dys-)function
Chapters 2-5 illustrate that patients with meningioma, glioma and NFPA show 
considerable risk of cognitive dysfunction before treatment. Our patient samples 
performed worse than sociodemographically similar healthy controls on the majority of, 
if not all, cognitive tests of the CNS Vital Signs battery (Chapter 2 NFPA, Chapter 3 glioma 
and meningioma).We consistently observed cognitive impairment in at least half of 
patients before surgical intervention across diagnoses. Specifically, 56% of patients with 
NFPA in Chapter 2 showed impairment on at least one cognitive domain, while 57% of 
diffuse glioma patients in Chapter 4 and 55% of meningioma patients in Chapter 5 were 
assigned to clusters that characterized profiles with impairment. Although dysfunction 
may overall be more mild in meningioma,1 our results suggest that similar percentages 
of meningioma and glioma patients harbor a cognitive profile with actual impairment 
before surgical intervention. At the same time, we also note that a substantial number 
of patients (44% of NFPA, 43% of glioma, 45% of meningioma) presented with a generally 
intact cognitive profile, despite the presence of a symptomatic tumor. Factors that may 
contribute to the (variance in) cognitive performances and profiles are discussed in 
section 1.3 Predictors of cognitive performances and profiles.
Postoperative cognitive (dys-)function
Postoperative status
Despite the mostly benign clinical course of NFPA and meningioma, and the general 
assumption that their resection is beneficial to cognition,1 since a primary driver of 
dysfunction is removed,2 the rates of impairment (Chapter 2) and impaired profiles 
(Chapter 5) three months after surgery were similar to those before surgery. Specifically, 
63% of patients with NFPA showed clinical impairment on at least one domain of 
CNS Vital Signs and 45% of patients with meningioma were assigned to clusters that 
characterized profiles with impairment.
In regard to malignant tumors, Chapter 6 strongly supports previous research3,4 by 
showing that high grade glioma patients are often cognitively impaired after surgery. As 
many as 99 out of 114 patients (87%) showed impairment on at least one test measure, 
and 38 patients (33%) showed impairment on at least half of the tests. Although the 
glioma itself is also viewed as the main disrupter of cognition,5 its removal does not 
necessarily result in relief of cognitive dysfunction.
8




We investigated the relatively unknown individual courses of cognitive 
functioning of NFPA patients from before up to three months after endonasal 
endoscopic transsphenoidal surgery by using a Reliable Change Index (RCI). This 
RCI measure provides a more accurate indication of the change in performances of 
individual patients than previously used measures, such as differences in raw scores or 
standardized scores, as it takes both practice effects and (varying) test-retest reliability 
into account. Interestingly, the individual courses in the sample varied substantially, with 
equal proportions of patients (28%) showing cognitive decline or improvement, and 8% 
showing both improvement and decline. These individual variances were masked by 
group results that indicated overall performance stability over time. Cognition in NFPA 
patients has usually been studied on group level only, with studies suggesting overall 
improvement.6,7 Our results show that we need to be aware that, similar to other PBT,4,8 
not all individual patients with NFPA benefit from surgery on a cognitive level and that 
group results cannot be directly translated into predictions for individual patients.
In the APOE-study in Chapter 3 (a more elaborate discussion of this study can 
be found under section 1.3), we investigated the longitudinal course of cognitive 
functioning from the postsurgical assessment up to 12 months after surgery of glioma 
and meningioma with Longitudinal Multilevel Modelling, that estimates individual 
differences in patients’ performances over time. We observed (small) overall 
improvements from the pre-surgical to 12 months postsurgical assessment on the 
majority of cognitive measures, with the exception of sustained attention (Continuous 
Performance test), visual memory (Visual memory test), attention and working memory 
(Digit Span Forward and Backward). Interestingly, the longitudinal course did not differ 
significantly between patients with meningioma and glioma (WHO grade II-IV), except 
for letter fluency and only in the interval from pre- to 3 months post- surgery. The 
similar trajectories may be partly attributable to the fact that glioma patients with 
disease progression and/or poorer clinical status do not return for follow ups (also 
reflected in the 17% of glioblastoma patients in Chapter 6 that did not return as early 
as 3 months after resection), thus making our follow up glioma sample biased towards 
fitter, possibly younger, patients.
1.2 The nature of cognitive dysfunction: cognitive performances and profiles
The way in which cognitive dysfunction manifests, i.e., to what extent different domains 
are affected, can be studied in various ways. In Chapter 2, we applied a common 
approach by studying group- and individual level performances on domains separately. 
Similar to - relatively scarce - (prospective) literature on patients with pituitary adenoma 
who underwent resection,7,9-12 NFPA patients showed pronounced disruption on tests of 
executive functioning. In light of studies using non-computerized (i.e., paper-and-pencil) 
testing in other PBT groups,13,14 this finding supports the proposed vulnerability of more 
complex functions that involve larger distributed networks5,15 to tumor disruption, 
regardless of the exact pathophysiology.
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In Chapters 4 and 5, we provide a different framework by exploring patterns 
in impaired performances across cognitive tests with Latent Class Analysis (LCA). An 
overview of the pre-surgical impairment profiles identified in these studies can be found 
in Figure 1. It appears that the high prevalence on the domain executive function found 
in previous studies16,17 can manifest in multiple cognitive profiles in both meningioma 
and glioma patients. In our research, it could present as isolated dysfunction or in 
combination with susceptibility to impairment of other functions. Memory impairment, 
that is also often found with a high prevalence,18 may rather be restricted to a smaller 
number of profiles (isolated memory dysfunction and global dysfunction), for which 
chances of impairment may be very high.
Comparing cognitive profiles in meningioma and glioma patients
As can be seen in Figure 1, we observed both similar and distinct profiles of cognitive 
impairment in our meningioma and glioma patients. The profiles found in both groups 
involve seemingly opposite ends of the cognitive spectrum; the “intact” profile (low 
chances of impairment across tests) and the “global disruption” profile (high chances 
of impairment across tests). Striking are the similar proportions of patients that these 
profiles present in (±45% “intact”, 13%”global” in both samples). Even with differences 
in pathophysiology and population characteristics (such as sex), meningioma and glioma 
patients scheduled to undergo surgical resection can thus show these similar profiles 
in similar rates.
Besides these two “opposed” profiles that presented in both samples, we found 
profiles illustrating different natures (which specific functions were affected) and 
severities of impairment (how many measures were affected and the probabilities of 
impairment) that presented in either the glioma or meningioma sample. Similar to 
the finding that preoperative deficits in separate cognitive domains can be related 
to tumor type,19 so may some cognitive profiles. For example, a broad impairment 
profile with apparent underlying speed-related problems was present in glioma, but not 
meningioma. This finding fits in the general framework for consequences of brain injury 
(as opposed to compression), in which mental slowing is a key problem that contributes 
to problems in other domains.20 Still, direct statistical comparisons of the diagnostic 
groups are imperative to investigate these differences further.
Cognitive profiles after surgery
Chapter 5 additionally investigated cognitive impairment profiles three months after 
surgery within the meningioma sample. Besides an “intact” profile that was similar in 
nature and proportion as the one before surgery, most post-surgical profiles (“verbal 
memory”, “executive-speed”, “(psycho-)motor-attention”, “diffuse”) appeared 
somewhat different from the ones identified before surgery. We emphasize here that 
pre- and postsurgical samples had comparable sample characteristics. This finding leads 
us to hypothesize that, although the prevalence of cognitive dysfunction may be similar 
8
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after meningioma resection as before, the nature of dysfunction, and possibly problems 
that patients encounter in daily functioning, may be different.
It is important to note as well that about two-thirds of meningioma patients 
classified as “intact” before surgery, were also classified as “intact” after surgery, 
indicating stable unimpaired functioning. The other one-third apparently had 
deteriorated, as they were classified in one of the impairment clusters after surgery. 
Some patients seemingly showed new deficits in addition to existing ones, e.g., 29% 
patients went from the psychomotor-executive profile to the executive-speed profile. 
Conversely, 26-38% of patients from the pre-surgically impaired clusters was classified 
as “intact” after surgery, indicating that they had shown recovery. An important finding 
that also reflects the added value of LCA, is that we found patients who showed a 
qualitatively different cognitive profile, e.g., 19% of patients with a “(pyscho-)motor-
executive” profile before surgery showed a “verbal memory” profile at after.
1.3 Predictors of cognitive performances and profiles
Findings from Chapters 2-5 support the proposed multi-dimensionality2 of factors 
influencing cognition in PBT. Moreover, an insight we gained beyond what is known 
from literature is that some factors previously related to separate cognitive domains 
may actually discriminate between an intact versus a (broadly) impaired cognitive 
profile, while others may help to discriminate between different impaired profiles. In 
this section, we discuss the predictive value of the investigated patient, disease and 
germline genetic factors.
Patient factors
Sociodemographics: consistent prediction of intact cognition
Even though test performances used in our studies were already standardized for effects 
of age and educational level found in healthy individuals,21 these factors seem to show 
additional influences on cognition in PBT patients (Chapter 4 and 5). Intact and milder 
profiles (isolated executive dysfunction in glioma, isolated verbal memory dysfunction 
in meningioma) were related to younger age compared to more severely disrupted 
profiles. This suggests that, with higher age, the chance of more severe dysfunction 
that involves multiple domains may be higher. The nature of the dysfunction may still 
vary.
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In meningioma patients, 50% of the “intact” cluster had a high education level. 
Educational attainment may reflect lifetime exposures that are related to higher 
cognitive reserve,22 i.e., a higher ability of the brain to actively cope with damage by 
means of compensatory processes,23 apart from tumor characteristics that can already 
influence reorganization.24 Sociodemographic factors are easy to collect as part of a 
clinical examination, and may be used for a quick indication about a patient’s (relative) 
likelihood of having an intact cognitive profile and thereby unimpaired communicative 
and decision-making ability.25,26
Symptoms of depression: low burden in patients with an intact profile
It is known that various biological (e.g., inflammatory27 and neurotrophic)28 and 
behavioral (e.g., apathy)29,30 depression markers can mediate cognitive fitness. In Chapter 
5, we found postoperative scores on the Depression facet of the Hospital Anxiety and 
Depression Scale to be significantly lower in the patient cluster that showed an “intact” 
profile compared to all other clusters. The “(psycho-)motor-attention” cluster showed 
the highest Depression score. We can explain this finding when we take into account 
that psychomotor slowing is a diagnostic criterion for depression in the DSM-V,31 and 
that disruption of (networks involved in) sustained and divided attention32 has been 
reported in depressed individuals. Moreover, as some of the biological and behavioral 
processes found in depression are also linked to tumor activity,33 and co-occuring 
cognitive impairment and depression has been linked to worse survival outcome,34 
monitoring depressive symptoms of patients at clinical follow up is warranted.
Disease factors
Tumor characteristics: discriminating between impaired profiles before surgery
Smaller tumor volume was related to an intact pre-surgical cognitive profile in both 
of our samples in Chapters 4 and 5, which supports previous findings in glioma,35 
meningioma36 and cerebral metastases.37 Mass effect can apparently disrupt cognitive 
networks independent from other tumor features, such as infiltrative potential. We also 
note that the degree of peritumoral edema may play an additional role here as well,38,39 
but we did not investigate this.
Further in accordance with findings on separate tests,17,40,41 there was a propensity 
towards high grade lesions (WHO III/IV) in the “globally disrupted” cognitive profile 
of glioma patients. Low grade lesions (WHO II) were most common in the “intact” 
profile. This difference may be partly attributed to differences in growth patterns. 
Slower growing, low grade lesions allow for 1) more functional remapping - by involving 
perilesional areas or more remote areas in the same or the contralateral hemisphere - 
and 2) for some function to persist in the tumoral tissue.24 WHO grade was not related 
to cognitive profiles in our meningioma sample. This may be due to a less pronounced 
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difference in growth pattern between benign and atypical meningioma, but we also 
note that the number of atypical tumors was small (8%).
Our findings with regard to the predictive value of tumor locations in glioma 
(Chapter 4) are in part supported by previous investigation, but are also somewhat 
different. One example regards the effect of lateralization. Habets concluded from 
several empirical investigations15,35 that left hemispheric glioma were associated with 
worse cognitive deficits on tests.5 We found left hemispheric glioma to be associated 
with an isolated executive impairment profile, while right hemispheric glioma were 
related to a speed-related impairment profile that affected more domains. At first 
sight, this appears contradictory. At the same time, executive dysfunction is related 
to left hemispheric lesions.17 and a speed-profile fits to reporting42 of patients with 
right hemispheric damage (from stroke) showing more pronounced slowing of 
information processing than patients with left hemispheric lesions. We also note 
that neuropsychological tests often carry a language component (e.g. instructions, 
responses) apart from the test content, and this may also partly explain stronger 
disruption in left hemispheric lesions. Frontal lobe glioma were more common in the 
global disruption profile in glioma patients, which warrants awareness that glioma 
infiltrating networks involving the frontal lobe may have a widespread influence on 
patients’ cognition beyond, e.g., executive functions.
Substantial inconsistencies exist in literature on the relationship between tumor 
lateralization and the degree of cognitive dysfunction in the meningioma population. Our 
finding in Chapter 5 that left-sided meningioma were related to the global impairment 
profile before surgery are in line with several studies reporting more deficits in this 
group before and or after treatment14,39,43, although other studies found no significant 
differences as compared to right sided lesions.36,44,45 Interestingly, meningioma located 
at the supratentorial skull base were as prevalent in the intact as the globally disrupted 
profile in our study, whereas previous investigation found a relationship between 
skull base adhesion and worse performance on cognitive tests.43 These different 
findings call for more investigation into the relationship between anatomical locations 
of meningioma and pre-surgical cognition. We note that anatomical locations of 
meningioma are usually broadly categorized for research purposes, and that further 
distinctions, e.g., within infratentorial locations and supratentorial skull base locations, 
may reveal specific deficits that were not captured in our and previous studies. Still, 
with the exception of bilateral tumor location, most meningioma location variables 
were not predictive of postsurgical cognitive profiles. Location may play a smaller role 
at this time point compared to before surgery, especially if the pre-surgical effect was 
mediated by local edema.
Suprasellar extension and pituitary hypofunction in NFPA
In Chapter 2, we found no effect of suprasellar growth of NFPA on cognitive 
performances. This finding contradicts reporting by Psaras and colleagues, who 
found that removal of the suprasellar extension was the primary factor contributing 
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to cognitive improvement after surgery.12 NFPA frequently present with suprasellar 
extension that can compress adjacent structures, such as the third ventricle and 
hypothalamus, and subsequently induce cognitive (e.g., memory) dysfunction.46,47 We 
hypothesize that the Hardy-Wilson category of tumor extension, although relatively 
easily obtained from coronal MRI as part of regular anatomical classification, may not 
be precise enough for predicting cognition. A 3D volumetric report of the suprasellar 
portion of the tumor may be more appropriate.
Patients with loss of functioning of the pituitary-adrenal and/or pituitary-thyroid 
axes performed better on verbal memory than those without loss of functioning 
in these axes. Usually, dysfunction of these hormonal axes is related to decreased 
memory function, 48,49 making this a remarkable finding. Still, taking into account that 
all patients were receiving suppletion at time of cognitive assessment, this could have 
boosted memory performance as compared to other patients with subtotal (i.e., milder) 
hypofunction not receiving suppletion.
Symptomatology at time of presentation: possibly differential effects in glioma 
and meningioma
Notably, the effect of treatment with anti-epileptic drugs (AED) on pre-surgical 
cognition was different in glioma and meningioma patients (see Chapter 4 versus 
5); It was a predictor of an intact cognitive profile in glioma, but of an impaired 
(“psychomotor-executive”) profile in meningioma. This finding contradicts reporting that 
epilepsy (treatment) is related to worse cognition in both diagnoses.14,50 Mechanisms 
of tumor-related epilepsy are plentiful and are assumed to vary between infiltrative, 
intra-axial tumors versus distortive, extra-axial tumors.51 Moreover, epilepsy in glioma 
is also indicative of low grade lesions,52 which in turn are associated with less cognitive 
disturbances than high grade lesions.17 Still, as AED use independently contributed to 
discrimination between pre-surgical cognitive profiles in our studies, there may be an 
interplay between the mechanism(s) of epilepsy and/or its treatment and functioning 
of networks that subserve cognition.
Cognitive complaints reported by patients at time of presentation were not 
indicative of the degree or nature of “objective” pre-surgical cognitive dysfunction in our 
glioma sample (as measured with tests). However, in meningioma patients, the “intact” 
pre-surgical profile was related to a very low proportion of cognitive complaints (only 
6%, compared to, e.g., 32% in the group with global disruption). It is known that the level 
of subjective cognitive function as indicated on self-report instruments is only weakly 
related to objective performances on tests in PBT.53,54 This may be due to the difference 
in what and how these approaches measure cognition (i.e., objective performances on 
neuropsychological tasks in a controlled setting or subjective experience of functioning 
in daily tasks). At the same time, whereas objective testing may be less ecologically valid, 
the internal validity of subjective reporting can suffer under a possible lack of insight of 
patients into their own level of functioning that isnot uncommon in (right sided) frontal 
and anterior temporal lesions.55 Still, for clinicians, it is important to note that, in the 
triad of objective measuring vs. self report on instruments vs. spontaneous reporting, 
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meningioma patients who spontaneously report cognitive problems at time of clinical 
presentation are more likely to display a profile with objective impairments.
APOE ε4: no evidence for effects on cognitive functioning before and shortly after 
treatment
Literature on APOE allelic variation and cognition in PBT lacks investigations of 
pre-treatment status. Our first hypothesis in Chapter 3 was that APOE ε4 carrying 
meningioma and glioma patients would show worse cognitive performances and more 
impairment than non-carrying patients before surgery. This hypothesis was based 
on ApoE4’s facilitation of maladaptive responses to CNS damage and less efficient 
modulation of myelin formation and repair,56-59 that proposedly negatively modulates 
cognitive functioning.60-62 Our findings showed no significant differences between 
carriers and non-carriers. We hypothesize that, as tumor-related injury develops more 
gradually over the years, carriers may have been able to compensate for the reactive 
changes and the less efficient network organization,61,63 thereby showing similar 
performances as compared to their non-carrying counterparts. A key question to be 
studied here is whether deviant functional brain activation patterns can be observed in 
ε4 carrying PBT patients with similar task performance(s) as non-carriers. In addition, 
it is argued that the ε4 relates to a “cognitive phenotype” because of effects on white 
matter integrity.61 We did not adopt ε4 carrier status in our pre-surgical LCA’s, because 
genotyping was only available for a subset of patients (until September 2017), but its 
relationship with cognitive profiles can be investigated in future studies.
We expected the longitudinal course of cognition in carriers to be worse than in 
non-carriers, based on the interaction between APOE ε4 and oncological treatment 
effects64,65 as well as findings on cognitive performances in patients treated for (non-)
CNS cancers.62,66,67 However, in our study, PBT patients who carried the APOE ε4 allele 
did not show a significantly worse trajectory of cognitive functioning over the course 
of surgical and adjuvant treatment, at least in the first year after surgery.
Previous studies that did find a negative relationship between ε4 allele presence 
and cognition, assessed performances years after completing treatment.68,69 E4’s 
interaction with anti-tumor treatment may manifest in cognition on the longer term. 
This may especially be true for glioma undergoing a long trajectory of adjuvant 
treatment with concurrent chemoradiation followed by chemotherapy. Still, research 
into germ-line genetic factors in relation to cognitive performance of PBT patients is 
in a relatively early stage.70 Investigations of APOE at later follow ups in large patient 
samples that allow for stratification according to possibly relevant genetic (e.g, COMT)70 
and patient moderators (e.g., sex71 and smoking),72 and involving functional imaging 
should shed more light on its relevance.
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2. THE PROGNOSTIC VALUE OF COGNITIVE MONITORING IN 
POST-SURGICAL CARE FOR HIGH GRADE GLIOMA (PART III OF 
THE DISSERTATION)
Clinical characteristics, primarily patient age and functional performance status 
(Karnofsky Performance Status, KPS)73,74 are often used to explain heterogeneity in 
survival outcomes that exists in patient groups with similar histological diagnosis. The 
prognostic value of these factors lies in their indication of physical fragility and, in case 
of KPS, also disease activity.75 Still, their effects on survival outcome can be confounded 
by other factors,76 such as (salvage) treatment decisions. Fact is that survival outcome 
is still heterogeneous within subgroups of patients stratified by clinical prognostic 
factors.74
Cognitive performance - and changes therein - are also increasingly viewed as 
a possible reflection of the degree of disruption of cerebral networks due to tumor-
induced infiltration, mass effect and edema (i.e., parameters of disease activity). 
Attention towards its value in prognostic stratification, mostly in high grade glioma, is 
therefore growing.76 Still, several important questions regarding the use of cognitive 
parameters for prognostic purposes have to be addressed:
First, it should be evaluated for what purpose(s) we can use measures of cognition. 
In part III, we investigated its value for early prognostic stratification (knowing which 
patients may be at risk for shorter survival and therefore warrant extra vigilance in 
clinical follow up), and for longitudinal disease monitoring (using cognitive monitoring 
as an addition to general follow-up care). Second, as high-grade glioma and their 
cognitive effects are heterogeneous, we should ask how we should assess cognition 
for prognostic purposes. This primarily involves decisions on assessment content and 
whether neuropsychological evaluation should involve uniform testing with a core test 
set, e.g., based on overall vulnerabilities in the population, or if there should be some 
form of assessment personalization based on patient or tumor characteristics.
2.1 Early refinement of prognosis
It is well known that, over the course of treatment for glioma, patients can show decline 
in cognitive functioning or develop new cognitive deficits.2,77 These deficits may be 
the result of treatment related damage and toxicity,64,78 but there are also indications 
that early post-surgical deficits before adjuvant treatment may already indicate poorer 
prognosis.79 In Chapter 6, we focused on the question whether impairment on measures 
obtained in the early adjuvant treatment phase for glioblastoma, when patients return 
to the outpatient clinic for standard care appointments, can be used for prognostic 
stratification. In a sample of 114 patients, impaired performances on tests measuring 
executive control and simple processing speed (Stroop tests I and III, reaction times) 
predicted substantial reductions in survival time of ±25%. This effect existed even 
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when controlling for the effects of known prognostic factors KPS and age, but also for 
the effect of salvage treatment, which is a factor that has been left out of studies on 
cognition and survival thus far. Furthermore, as the presence of early impairments was 
related to less salvage treatment administration, the importance of taking incorporating 
this factor for survival prediction with cognitive measures is further emphasized.
In conclusion, patients’ cognitive status on two uniform tests, that take around 
5 minutes to administer, at an early postsurgical clinical evaluation may be an easily 
obtainable prognostic indicator.
2.2 Longitudinal, personalized monitoring
A challenge in using cognitive change over time as a tool for predicting (subsequent) 
disease progression, is that the cognitive functions that are most sensitive to changes 
in disease activity differ between, and can therefore be hard to capture in, individual 
patients. Some studies have attempted to capture individual variability in sensitivity, 
for example by tailoring test selection to tumor location.80 Still, as glioma tend to affect 
brain functioning outside their direct location,24 a location-based selection may not 
fully cover the existing individual variation. Additional methodological challenges in 
longitudinal monitoring are the absence guidelines for how to measure change in 
cognitive performances in individual patients specifically for prognostic purposes , and 
which cut off value for “cognitive decline” we should use here.
The study described in Chapter 7 was unique in 1) its approach to the personalized 
selection of tests used in follow up monitoring, and 2) its use of the Reliable Change 
Index to measure change as part of a prognostic longitudinal study. We hypothesized 
that immediate post-surgical improvements in cognition may provide important 
information about which cognitive domains are most sensitive to tumor presence, and 
therefore tumor recurrence at a later time point. Patients underwent three-monthly 
assessments together with standard clinical follow-up until radiological progression 
was established or up to 24 months after surgery.
For each patient, we opted to select the three functions for which they showed 
the most relief - the highest RCI values - within 3 months after surgery for follow up 
monitoring in our analyses. We calculated changes in performance on the three 
personalized tests using the first postsurgical assessment (T3) as baseline (e.g., interval 
T6-T3, T9-T3, etc), with an RCI of ≤-1 on at least two of the three tests in an interval 
considered cognitive decline. We found that the majority (60%) of patients with 
progressive disease (PD) displayed decline on their personalized set of tests before or 
at time of radiological PD, and that the majority (80%) of patients with stable disease 
during follow up remained stable on their set of tests. Moreover, the chance of PD in 
case of cognitive decline on this set was 5 times as high in case of stable performance. 
This effect was higher than the one found in previous investigation in a HGG sample 
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with uniform testing81 (also using three tests) and similar to the one found in a tumor 
location-based selection of tests in a heterogeneous PBT sample (using five tests).80
We conclude from this study that patients’ change on a brief, personalized 
assessment may serve as a noninvasive indicator of disease status over time, and should 




A limitation across our studies concerns the content of the neuropsychological 
assessment. For integration in the clinical trajectory, a balance had to be guarded 
between keeping the assessment short enough for integration with other standard 
care appointments (e.g., MRI, consultation with treating clinicians) and the importance 
of testing a range of cognitive domains. Computerized testing has multiple advantages 
in this matter, as it can be less time consuming (the assessment itself, but also due 
to automatic score computation), items are picked at random (thereby automatically 
presenting alternate test forms for repeated assessments), and precise measurement 
of reaction times.82 At the same time, multiple limitations can be noted regarding the 
tests of the CNS Vital Signs battery specifically.
First, the memory tests of the test battery assess immediate and delayed 
recognition of verbal and visual material, but there is no assessment of the learning 
curve nor of free recall. These functions may in fact be the most important facets 
to test83 as they show high dysfunction rates and stronger prognostic value than 
recognition.79 Our estimation of memory problems may be lower than is actually the 
case in the true PBT population.
In general, computerized tests may put a higher strain on information processing 
speed than traditional paper and pencil tests. In translating tests to computerized 
versions, the item presentation and/or the response is often timed, while in the 
‘traditional’ version this may not be the case. For example, we can compare the CNS 
Vital Signs’ Verbal Memory test and Stroop tests to non-computerized counterparts 
Hopkins Verbal Learning Test and Stroop test. In the original forms, patients do not have 
to respond within a couple of seconds to each item, as opposed to the computerized 
forms. In the original Stroop test, the total time it takes for a patient to complete the 
test is recorded, but no item average. What this means is that there is a risk with CNS 
Vital Signs that mental slowing affects performances on tests that claim to measure 
other functions. At the same time, we do note that our LCA (Chapter 5) showed that 
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there are distinct clusters with and without impairment on simple processing speed, 
indicating that mental slowing may not automatically disrupt all CNS Vital Signs tests.
A majority of tests in our protocol have a language component with regard to 
their items, the required response, or both. However, we did not specifically test 
language abilities, such as naming and language reception. Aphasia symptoms can be 
a presenting symptom of PBT. It can also occur temporarily after tumor resection84 in 
varying degrees. Language testing is recommended, especially in case of specific lesion 
locations,84 as subtle problems in language reception or expression may affect test 
performance without the cognitive ability itself being disrupted.
Assessment timing
In order to ensure uniformity in timing of the assessments and facilitate integration, 
our pre-surgical assessment took place one day before surgery, which is the day of 
hospitalization. Although this timing had advantages from a logistical standpoint, we 
note that anxiety regarding undergoing surgery may have influenced cognition, although 
there was no evidence found for this in an earlier study in a subset of patients from 
this cohort.85 Furthermore, as patients undergo multiple appointments the same day, 
assessment sometimes needed to be cut short, thereby providing incomplete data. If 
assessment took place after multiple appointments, fatigue could also have influenced 
patients’ performances.
 The assessments in the studies described in this thesis were repeated up 
to 3 or 12 months after surgery. As mentioned in Chapter 3, late effects of adjuvant 
treatment can continue beyond these time points.78 Specifically with regard to the 
interaction between these late effects and APOE ε4 allele carrier status, longer-term 
follow up assessments may have provided additional information. Measurements at 24 
months post-surgery are currently part of the research protocol at the Neurosurgery 
department of Elisabeth-Tweesteden Hospital, but due to later implementation (2015 
onwards) and a lower proportion of (glioma) patients who return or this measurement, 
this time point was not adopted in our current studies.
3.2. Patient samples
Several biases may exist in the patient samples of the described studies. First, 
all patients underwent surgical resection. This means that our results cannot be 
generalized to patients following a different care path, e.g., those undergoing biopsy 
and/or systemic treatment only or those with (incidentally discovered) tumors in a wait-
and-see trajectory. The latter group of patients are currently understudied, even though 
they likely also show cognitive dysfunction86 possibly depending on tumor location.87 
In a new research program at the ETZ (Topklinische Zorg en Onderzoek 2020-2024), 
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neuropsychological testing and advanced MR imaging will also be routinely performed 
in patients who do not undergo surgery.
We also address potential sample bias due to participation refusal for follow ups, 
e.g., for relatively intense follow up like in Chapter 7. As mentioned, as much as 50% of 
patients asked to participate in our disease monitoring study in Chapter 7 refused for 
various reasons, including the anticipated intensity of follow up. If patients feel that 
three-monthly assessments are too burdensome, this may reflect patient or disease 
characteristics, such fatigue or distress. In addition, drop out between measurements 
over time, as seen in Chapters 2, 3, 5-7 is a common phenomenon in patients with 
cancer. As many as 31 of 179 glioblastoma patients in Chapter 6 who underwent pre-
surgical assessment did not return 3 months after surgery due to deterioration in 
clinical status or early death. This suggests that missing cases on follow up assessments 
were not simply random. We acknowledge that our post-surgical (glioma) samples in 
Chapter 3 and 6 are probably biased towards younger, fitter patients. At the same 
time, as T0 and T3 measurements were part of regular clinical care, the dropout may 
reflect the ‘natural’ flow of patients who show early clinical deterioration and for whom 
prognostication and cognitive assessment may not be as relevant.
4. CHALLENGES AND OPPORTUNITIES IN CLINICAL PRACTICE 
AND FUTURE RESEARCH
4.1 Alignment between clinical care and research - using clinically 
intuitive methodological approaches
Multiple factors may play into under-recognition of cognitive dysfunction in care,88,89 
including a lack of awareness and prioritization by both patients and staff. To show the 
potential value of neuropsychological assessment for daily neurosurgical care, we stress 
the importance of aligning methodology in research with what clinicians actually want 
to know and, closely related, if the derived results are intuitive for a clinical setting. This 
concerns instances where we measure cognition as a part of treatment outcome as 
well as instances where it is used for the purpose of predicting disease outcomes.
One example of the latter is that, for clinicians who want early prognostic 
information for patients with dismal survival outcome, it makes more sense to know 
how a characteristic relates to survival duration as opposed to how it relates to (chances 
of) of death. A method like Accelerated Failure Time modeling is relatively underused 
in medical research. However, it allows for derivation of a Time Ratio that is directly 
interpretable for health professionals who may not be familiar with risk indicators. If 
the question is whether cognitive decline from one time point to the other reflects an 
event like increased tumor activity, reporting a Hazard Ratio can provide the necessary 
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information, as it conveys an increase in chance of the event on which clinicians could 
act at that time.
In regard to cognition as an outcome, we addressed that investigating profiles 
as opposed to test performances may provide a better understanding of cognition on 
a fundamental level. There are multiple arguments as to why investigating profiles is 
also more clinically applicable. A neuropsychologist may look at a patient’s integrated 
cognitive profile instead of looking at one test when evaluating the need for further 
assessment, strategy training or rehabilitation. Knowing to which cognitive profile a 
specific patient or disease characteristic is related is in that case also most relevant. 
Moreover, it is crucial for neuropsychologists to know which tests are and which tests 
are not sensitive to dysfunction in a specific patient population. The fact that a large 
proportion of patients shows impairment on a specific test in a population does not 
necessarily mean that the test is sensitive in the sense that it discriminates between 
different cognitive profiles. Methods such as LCA allow us to simultaneously provide 
an integrative analysis of (trajectories of) latent cognitive profiles and estimation of 
contributions of different tests to the discrimination between these profiles.
4.2 Considerations for clinical practice
Implications of cognitive deficits in patients for clinicians
In order to improve the recognition of cognitive dysfunction,90 it is important for 
clinicians to be aware of how common cognitive deficits are. Our findings indicate 
that over 50% of patients scheduled to undergo resection display objective cognitive 
impairment. About 10% may display impairment across domains and the other 40% 
may show various severities and natures of impairment that also depend on patient and 
disease characteristics. Surgical treatment of PBT does not necessarily resolve cognitive 
dysfunction, but dysfunctions may be different after the tumor is removed.
As mentioned, cognitive deficits can widely affect daily functioning of patients. At 
the same time, the presence and type of cognitive dysfunction a patient harbors is also 
relevant for various aspects of a clinician’s job. For example, patient communication 
should be approached differently in memory dysfunction versus mental slowing. 
Different objective dysfunctions may also relate to different problems in daily life, and 
this could be taken into account in patient informing. For example, deficits in mental 
and psychomotor speed may also affect a patient’s driving ability. Discussing such 
practical implications of cognitive deficits can help manage expectations of patients 
and adjust their goals after treatment. In addition, specific dysfunctions can impair a 
patient’s ability to engage in decision making regarding treatment.26 As decision making 
in neurosurgical care moves more towards a shared consensus between physician and 
patient, the latter issue will become increasingly important in the future. It should be 
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noted overall that not all patients experience objective deficits as a problem.91 Assessing 
the subjective level of burden due to cognitive dysfunction is therefore relevant.
Adaptability and efficient use of assessment
A core testing protocol for the PBT population has been recommended by the RANO 
group92 for the purpose of cognition as outcome evaluation, but this set is probably not 
enough the capture the full extent of (dys-)function. In outcome assessment, it may be 
useful to administer such a core set along with patient- or disease-specific additions, 
e.g., tests of language in case of tumors in eloquent areas,84 or of processing speed in 
case of right-sided lesions or older patients.93,94 For predicting the degree and nature of 
dysfunction in PBT patients, clinicians should be aware of characteristics on patient as 
well as disease level before surgery. After surgery, patient characteristics, such as age, 
educational attainment and depressive symptoms, may be more useful for estimating 
risks of cognitive impairment than disease factors, such as tumor location. Importantly, 
many useful characteristics may already be obtained as part of routine care. Pre-surgical 
cognitive fitness is quite a strong predictor of post-surgical performances16,95 and in 
some patients with malignant tumors, it also reflects their best cognitive state during 
their disease.96 Therefore, a broad pre-surgical assessment does seem particularly 
relevant, with possible targeting of potential risk domains at later follow ups.
Obtaining cognitive data requires extra effort in the care trajectory. Using the 
data to its full potential is therefore important. As mentioned in the introduction of 
this dissertation, cognitive functioning is related to many facets of daily life. For neuro-
oncologists, it can be of particular interest that routinely obtained cognitive measures 
can serve prognostic purposes as well. If cognition is used as additional means for 
disease monitoring, our studies support that assessment needs to balance efficiency 
with accuracy of testing. Broad or uniform testing may therefore be less appropriate 
here. Broad testing protocols may be deemed feasible for longitudinal follow up,96 but 
they are strenuous for already vulnerable patients, may ultimately decrease motivation 
for participation, and are simply harder to integrate in the care trajectory. Moreover, 
50% of tests in a general battery may not be sensitive to progression.96 As mentioned, 
a limited set of specific tests may serve as early postoperative prognostic indicator 
(Chapter 6), and a set of personalized tests appears to convey an indication as to 
whether a patient is at increased risk for disease progression (Chapter 7). Cognitive 
follow ups that we obtain for prognostic purposes could therefore be shorter and more 
targeted than those used as outcome measurement.
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4.3 Directions for future research
Cognition is a difficult phenomenon to study due to 1) the brain networks that 
underlie the various functions are complex and not yet fully characterized, and 2) 
its vulnerability to disruption in response to disease-, treatment- and patient-level 
factors. As a consequence, a multidisciplinary approach is critical for adequate study 
and understanding. We identify potential targets for future research.
Exploring dynamic patient characteristics for optimizing cognitive fitness
Many of the predictors we researched in our studies constitute static disease or patient 
characteristics (age, educational attainment, lesion location). However, physical and 
behavioral modifiable features of the roughly 50% of patients who were unlikely to 
suffer impairment could be investigated as part of a more rehabilitation-focused view 
on cognition. Depressive symptomatology is an example of such a factor, but other 
characteristics, e.g., physical activity, may also be relevant. Gehring and colleagues 
showed in a recent Randomized Controlled Trial that patients with WHO grade II/III 
glioma who participated in a 6 months home-based exercise intervention (of moderate 
to vigorous intensity 3 times a week) showed better scores on measures of attention and 
information processing speed, verbal memory and executive functioning.97 Moreover, 
dietary patterns98 and obesity99 may be also related to cognitive trajectories. Some 
information about potential dynamic factors is generally obtained as part of routine 
clinical care. Self report, experience sampling methods or, regarding exercise, wearables 
may also provide opportunities for measurement.
Novel approaches to studying cognition
From “decline” and “improvement” to “qualitative change”
A second opportunity regards our frame of reference when it comes to research into 
cognition over time. Traditionally, the central question posed is whether PBT patients 
show improvement, decline and/or stability in functioning over time in cognitive 
domains. Findings from Chapter 5 suggest that some patients change over time from 
one cognitive profile to another cognitive profile, and this has implications for our 
approach to studying cognitive change. For example, if a patient shifts from a profile 
with executive dysfunction to a profile with memory dysfunction, this cannot simply be 
judged as a “decline” or an “improvement”. Instead, it engenders a qualitative change 
in the cognitive profile. Such qualitative changes cannot be captured with traditional 
analyses. Longitudinal applications of classification models, such as latent transition 
analysis, can allow for the investigation of a patient’s probability for transitioning 
from one cognitive profile to another one over the course of surgical and oncological 
treatment. Results from such analyses are likely to provide new insights that are also 
clinically intuitive.
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Data-driven development of a classification tool
Collecting sufficiently large datasets to perform data-driven analyses or model-
based clustering in PBT research is not just a logistical challenge, but also requires 
data collection and funding over a timespan of multiple years often beholden to large 
treatment centers or multi-center collaborations that come with their own challenges. 
However, common prediction methods applicable to modest datasets cannot capture 
the interdependency between various dimensions of brain tumor symptoms, such as 
cognition, but also mood anfatigue, that have proven to be hard to explain thusfar. 
Machine learning applications that are data-driven (as opposed to model-based) are 
increasingly recognized for their value in (predictive) personalized neurosurgical care.100 
Machine learning may serve clinical practice through development of a classifier tool 
to predict cognitive functions, e.g., as also done for the detection of dementia in 
primary care.90 Such a tool could use routinely obtained characteristics to estimate a 
patient’s cognitive risk before and after surgery. Currently, efforts are made towards 
integration of machine learning methods in predicting cognitive outcomes for data 
from PBT patients who underwent craniotomy at Elisabeth-Tweesteden Hospital under 
the Topklinische Zorg en Onderzoek 2020-2024 protocol, and their added value will be 
investigated as part of new research projects over the coming years.
5. CONCLUSION
Cognitive dysfunction is a common symptom of benign and malignant primary brain 
tumors that may linger after treatment with roughly similar prevalence at group level, 
but possibly with qualitatively different manifestations in the individual patient. Patient- 
and disease-level characteristics each contribute to can specific cognitive deficits or 
profiles, whereas the influence of APOE allelic variation may be limited, at least before 
and in the first year after diagnosis. Brief, targeted cognitive measures after surgery may 
aid in early prognostic refinement and in longitudinal disease monitoring. We propose to 
broaden the framework for studying cognition in three main ways; 1) from investigation 
of test performances to cognitive profiles that combine performances on various tests, 
2) from improvement, stability and decline in performances over time to qualitative 
changes in cognition over time, and 3) from outcome measure to a measure with a 
multifaceted value that potentially includes refinement of prognosis. Opportunities for 
future research may lie in usage of sophisticated data-driven analyses that can provide 
an integrated account of cognitive profiles and aim to deliver (classification) tools for 
clinical practice.
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Discussie van de bevindingen in dit proefschrift en aanbevelingen voor 
onderzoek en klinische praktijk
AANLEIDING VOOR HET ONDERZOEK
Primaire hersentumoren zijn tumoren die ontstaan uit het hersenweefsel, zoals 
gliaweefsel, hypofyseweefsel of de hersenvliezen. Primaire hersentumoren zeldzaam,1 
maar zorgen voor een relatief grote druk op de gezondheidszorg.2 Een van de redenen 
hiervoor is de intensieve, multidisciplinaire behandeling die de patiënten ondergaan. 
Daarnaast spelen de significante lichamelijke en psychologische morbiditeit die gepaard 
gaat met aanwezigheid en behandeling van een hersentumor een rol.
Verstoring van cognitief functioneren is een van de meest voorkomende 
symptomen is bij patiënten met zowel goedaardige als kwaadaardige hersentumoren. 
Een cognitieve stoornis is geen geïsoleerd symptoom; het kan een negatieve uitwerking 
kan hebben op dagelijks functioneren van patiënten, bijvoorbeeld op werk,3,4 op 
kwaliteit van leven5 en zelfs bekwaamheid voor medische besluitvorming.6,7 Echter 
worden cognitieve stoornissen veelal niet herkend in de kliniek, onder andere 
omdat ze moeilijk op te merken zijn in korte consulten en doorgaans geen prioriteit 
zijn in de spreekkamer.8 Tenslotte is monitoring van cognitief functioneren met 
neuropsychologische tests vaak geen onderdeel van de standaard zorg.9
Om het belang van neuropsychologisch onderzoek als onderdeel van de zorg voor 
patiënten met hersentumoren te onderbouwen, werden de volgende doelen binnen 
dit proefschrift opgesteld:
1) Bijdragen aan onze kennis over en begrip van cognitieve problematiek 
bij patiënten met primaire hersentumoren die chirurgische behandeling 
ondergaan,
2) De waarde van postoperatieve metingen van cognitief functioneren voor 
prognostische doeleinden (i.e., het voorspellen van ziekte uitkomsten) 
illustreren,
3) De aansluiting tussen wetenschappelijk onderzoek en vragen en behoeften 
in de klinische praktijk te verbeteren door gebruik van klinisch intuïtieve 
onderzoeksmethoden.
De studies in dit proefschrift zijn gericht op patiënten die een operatie ondergingen voor 
een primaire hersentumor bij de afdeling Neurochirurgie van het Elisabeth-Tweesteden 
Ziekenhuis, Tilburg.
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In het eerste deel van het proefschrift onderzochten we de prevalentie van 
en patronen in cognitieve stoornissen in patiënten met een niet-functionerend 
hypofyse adenoom (Hoofdstuk 2), glioom (Hoofdstuk 4) en meningeoom (Hoofdstuk 
5) vóór en drie maanden na operatie. Daarbij werd ook gekeken naar welke patiënt- 
en ziektekenmerken van belang zijn in de voorspelling van cognitie. In Hoofdstuk 3 
werd specifiek gekeken naar de invloed van dragerschap van het APOE-ε4 allel op 
cognitief functioneren tot 12 maanden na operatie (Hoofdstuk 3) bij patiënten met 
een meningeoom of glioom.
In het tweede deel van het proefschrift onderzochten we de waarde van cognitieve 
maten voor verschillende prognostische doeleinden. Hoofdstuk 6 illustreert een 
onderzoek naar de vraag of cognitieve verstoring tijdens vroege fase van adjuvante 
behandeling gerelateerd is aan een kortere overlevingsduur bij patiënten met een 
glioblastoom. Hoofdstuk 7 beschrijft een longitudinale studie waarbij onderzocht 
werd of cognitieve achteruitgang op een gepersonaliseerde set neuropsychologische 
testen radiologische groei van een hooggradig glioom (anaplastisch astrocytoom of 
glioblastoom) kan voorspellen.
Discussie van de bevindingen
Prevalentie en verloop van cognitieve problemen voor en na behandeling
De resultaten van onze onderzoeken illustreren dat patiënten met een primaire 
hersentumor significant risico lopen op cognitieve verstoringen. Vóór operatie toonde 
56% van patiënten met een niet-functionerend hypofyse adenoom (NFHA, Hoofdstuk 
2) een stoornis op minstens één cognitief domein. 57% en 55% van de patiënten 
met respectievelijk een meningeoom (Hoofdstuk 5) of glioom (Hoofdstuk 4) toonde 
een cognitief profiel dat gekenmerkt werd door de aanwezigheid van een stoornis 
op minstens één cognitieve functie. Aangenomen wordt dat cognitieve problematiek 
milder is in goedaardige tumoren, zoals meningeomen, dan in kwaadaardige tumoren, 
zoals gliomen.10 Onze resultaten duiden er juist op dat stoornissen in gelijke mate 
kunnen voorkomen vóór start van behandeling.
In tegenstelling tot de algemene verwachting dat verwijdering van een 
(goedaardige) tumor leidt tot cognitieve verbetering, was de prevalentie van cognitieve 
stoornissen drie maanden na operatie niet significant gedaald ten opzichte van het 
preoperatieve meetmoment; 63% van NFHA patiënten en 45% van meningeoom 
patiënten toonde nog één of meerdere cognitieve stoornissen. In glioblastoom patiënten 
(Hoofdstuk 6), de meest kwaadaardige vorm van een glioom, was de prevalentie drie 
maanden na operatie zelfs 87%.
Onze resultaten bevestigen daarnaast ook eerder onderzoek11 dat aantoont 
dat de keuze voor analyses op groepsniveau (gebruik van gemiddelde scores van de 
steekproef) of patiëntniveau (gebruik van individuele scores per patiënt) de resultaten, 
en daarmee de boodschap van wetenschappelijk onderzoek kunnen beïnvloeden. 
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In Hoofdstuk 2 vonden wij bijvoorbeeld dat patiënten met NFHA als groep stabiele 
cognitieve prestaties op de testen leverden over de tijd (geen significante verandering 
in het groepsgemiddelde). Echter viel op dat er 28% van de individuele patiënten 
klinisch relevante vooruitgang lieten zien, gemeten met de Reliable Change Index.12 
Nog eens 28% van de patiënten toonde klinische relevante achteruitgang. In deze groep 
patiënten maskeerde dus het resultaat op groepsniveau de uiteenlopende trajecten die 
individuele patiënten lieten zien. Clinici moeten dus voorzichtig zijn met het vertalen 
van groepsresultaten naar patiënten die gezien worden in de praktijk.
Welke cognitieve profielen bestaan?
De vraag welke cognitieve functies (het meest) aangedaan zijn kan op verschillende 
manieren onderzocht worden. In voorgaande studies werden verschillende cognitieve 
functies telkens apart onderzocht en voorspeld. Echter negeert deze aanpak een 
belangrijk aspect van cognitieve functies – en daarmee ook van cognitieve stoornissen 
– , namelijk dat cognitieve functies onderlinge samenhang tonen, omdat zij deels 
op dezelfde mechanismen berusten.13,14 Een ‘basisfunctie’ als verwerkingssnelheid 
is bijvoorbeeld belangrijk voor complexere functies, zoals het vermogen om te 
schakelen tussen opdrachten. In Hoofdstuk 4 (gliomen) en 5 (meningeomen) pasten 
wij Latente Klassen Analyse (LCA) toe om patronen te onderzoeken in prestaties over 
verschillende cognitieve testen heen, waarbij onderlinge samenhang tussen functies 
in acht genomen kan worden. Met behulp van deze analysemethode vonden wij 
verschillende “stoornisprofielen”. De pre-operatieve profielen gevonden in glioom- en 
meningeoompatiënten zijn weergegeven in Figuur 1.
Voor operatie
Twee stoornisprofielen kwamen voor in beide diagnosen; een intact profiel (lage 
kansen op stoornissen op alle cognitieve testen) en een globaal verstoord profiel (hoge 
kansen op stoornissen op alle cognitieve testen). Deze profielen lijken twee uiteinden 
van het cognitieve spectrum te illustreren. De andere profielen leken meer specifiek 
voor meningeoompatiënten (een profiel met verstoring van executieve functies en 
verwerkingssnelheid en een profiel met verstoring van psychomotorische en executieve 
functies) of voor glioompatiënten (een profiel met geïsoleerde verstoring van executieve 
functies, een profiel met geïsoleerde verstoring van visuele en verbale geheugenfuncties 
en een profiel met stoornissen op verschillende domeinen die snelheid gerelateerd 
lijken).
Na operatie
In Hoofdstuk 5 werden ook postoperatieve cognitieve-stoornisprofielen binnen de 
groep patiënten met een meningeoom. Ook na operatie kwam een intact profiel naar 
voren. De andere profielen die op dit meetmoment gevonden werden zagen er anders 
uit dan vóór operatie; een profiel met geïsoleerde verstoring van verbaal geheugen, 
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een profiel met verstoring van executieve, verwerkingssnelheid én psychomotorische 
functies, een profiel met verstoring van psychomotorische en aandachtsfuncties en een 
profiel met diffuse verstoring, waarbij simpele motoriek en visueel geheugen relatief 
bespaard bleven.
Bij het vergelijken van de pre- en postoperatieve profielen viel op dat er een groep 
patiënten herstel liet zien; zij gingen bijvoorbeeld van een verstoord profiel naar het 
intacte profiel. Daarnaast was er een groep patiënten die juist verslechtering liet zien; 
bijvoorbeeld een overgang van het intacte profiel naar een verstoord profiel. Tenslotte 
was een belangrijke bevinding dat een aantal patiënten een kwalitatief ander profiel 
liet zien na operatie; zij gingen bijvoorbeeld van een psychomotorisch-executief profiel 
naar een geheugen profiel.
Uit deze resultaten concluderen wij dat de cognitieve problematiek na operatie, 
en daarmee wellicht problemen in dagelijks functioneren, anders kunnen zijn dan 
voor operatie. In het volgen van cognitie over de tijd moeten onderzoekers en clinici 
zich ervan bewust zijn dat, naast vooruitgang en achteruitgang, er ook kwalitatieve 
veranderingen op kunnen treden in cognitie.
Welke factoren zijn relevant in het voorspellen van cognitie?
De bevindingen van Hoofdstukken 2-5 bevestigen dat factoren op zowel patiënt- 
als ziekteniveau cognitie van patiënten met primaire hersentumoren kunnen 
beïnvloeden. Een belangrijk inzicht uit onze LCA studies is dat er factoren zijn die lijken 
te onderscheiden tussen intact versus verstoord cognitief functioneren, terwijl andere 
factoren meer lijken te onderscheiden tussen verschillende verstoringen.
Patiëntkenmerken
Scores op de neuropsychologische testen waren gecontroleerd voor effecten van 
leeftijd, opleidingsniveau en geslacht, die in de gezonde populatie zijn aangetoond.15,16 
Resultaten van Hoofdstuk 4 (gliomen) en 5 (meningeomen) tonen aan dat leeftijd en 
opleidingsniveau nog additionele effecten hebben op cognitie bij hersentumorpatiënten, 
waarbij jongere leeftijd en hoog opleidingsniveau voorspellend waren voor een intact 
cognitief profiel. In Hoofdstuk 5 werd gevonden dat meningeoompatiënten met 
een intact cognitief profiel na operatie een significant lagere score toonden op een 
zelfrapportagelijst voor depressie symptomatologie dan patiënten met verstoorde 
cognitieve profielen.
Stemming en sociodemografische informatie zijn relatief eenvoudig te verzamelen 
in het kader van reguliere zorg en kan een snelle indicatie geven van de kans dat een 
patiënt een intact cognitief profiel heeft.
Tumorkenmerken
Verschillende tumorkenmerken hingen samen met cognitief functioneren, met name 
vóór operatie. Een lager tumorvolume hing samen met een intact cognitief profiel in 
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meningeoom- én glioompatiënten. Dit kan verklaard worden door minder schade aan 
en/of verdrukking van het hersenweefsel. Eenzelfde effect werd gevonden voor de 
tumorgraad, waarbij laaggradige gliomen vaker voorkwamen bij patiënten met het 
intacte profiel. Deze bevinding past in het beeld dat laaggradige gliomen minder schade 
veroorzaken en meer ruimte laten voor functionele reorganisatie in het brein.17 De 
locatie van de tumor lijkt met name juist onderscheid te maken tussen verstoorde 
profielen (bilaterale lokalisatie bij meningeomen hing bijvoorbeeld samen met het 
“executief-snelheid” profiel, infiltratie van de frontaalkwab bij gliomen hing samen 
met het “globaal verstoord” profiel). In Hoofdstuk 2 kwam naar voren dat uitval van 
de hypofyse-bijnier as (cortisol) en/of hypofyse-schildklier as (schildklierhormoon) 
samenhing met een beter verbaal geheugen in patiënten met een niet-functionerend 
hypofyse adenoom. Dit effect kan wellicht verklaard worden doordat patiënten met 
uitval suppletie ontvingen ten tijde van de neuropsychologische testen. Suprasellaire 
groei gemeten met de Hardy-Wilson categorisatie was niet gerelateerd aan cognitieve 
prestaties, wat erop kan duiden dat deze klinisch gebruikte methode niet sensitief 
genoeg is om cognitie te voorspellen.
Tumorkenmerken worden veelal verzameld als onderdeel van reguliere zorg. 
Sommige kenmerken lijken informatie geven over de kans op een intact cognitief profiel, 
terwijl andere lijken te onderscheiden tussen verschillende verstoringen.
Vroege symptomen
Gebruik van anti-epileptica vóór operatie hing samen met een intact cognitief profiel 
bij glioompatiënten. Enerzijds is dit in contradictie met eerder onderzoek dat juist 
slechtere prestaties vindt bij patiënten die deze medicatie gebruiken.18,19 Anderzijds 
is epilepsie, en dus anti-epilepticagebruik, indicatief voor een laaggradige tumor. Bij 
meningeomen was anti-epileptica gebruik juist voorspellend voor een psychomotorisch- 
executief profiel. Meningeoompatiënten die geen cognitieve klachten rapporteerden 
ten tijde van de diagnose hadden een hogere kans op een intact cognitief profiel. Bij 
glioompatiënten vonden wij geen effect van deze factor.
Symptomatologie is bekend ten tijde van vroege diagnostiek. De relatie met 
cognitie kan verschillend zijn van voor verschillende typen tumoren.
Dragerschap van het APOE ε4 allel
Het polymorfe gen APOE codeert voor apolipoproteine E (ApoE). Dit glycoproteïne 
is betrokken bij processen die belangrijk zijn voor herstel en plasticiteit in het 
centrale zenuwstelsel. Eerder onderzoek toont aan dat ApoE4, dat tot uiting komt 
door dragerschap van het APOE ε4 allel, minder effectief herstel bevorderd dan 
andere vormen van ApoE en zelfs schadelijke reacties kan oproepen bij letsel in het 
brein.20 Deze effecten lijken te kunnen doorwerken in cognitief functioneren van o.a. 
patiënten met ischemische beroerte en kanker buiten het centrale zenuwstelsel.21,22 
Bij hersentumorpatiënten is echter beperkt onderzoek gedaan naar de potentiële 
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negatieve effecten van APOE op cognitie, en concentreren studies zich op reeds 
behandelde patiënten met kwaadaardige tumoren.23-25
In onze prospectieve longitudinale studie met glioom- en meningeoompatiënten 
vonden wij géén effect van APOE ε4 allel dragerschap op cognitieve prestaties vóór start 
van behandeling. Onze hypothese is dat bij relatief traag groeiende hersentumoren kans 
is voor het brein om toch aan te passen aan de schadelijke effecten van ApoE4. Het 
kan zijn dat er wel afwijkende activatiepatronen bestaan in ε4 dragers in vergelijking 
met niet-dragers.26 Dit zou met functionele beeldvorming (fMRI) kunnen worden 
bestudeerd.
In tegenstelling tot eerder gepubliceerd onderzoek bij glioompatiënten die (> 
4 jaar geleden) chirurgische en adjuvante behandeling hadden ondergaan,24 vonden 
wij geen negatief effect van APOE ε4 allel dragerschap op het beloop van cognitie 
functioneren van onze patiënten over de tijd (tot 3 en 12 maanden na operatie). 
Hiervoor zijn een aantal methodologische verklaringen, waaronder het feit dat onze 
studie cognitieve meting tijdens en kort na adjuvante behandeling plaatsvonden. 
De schadelijke effecten van chemo- en radiotherapie kunnen na dit tijdstip nog 
doorwerken.27,28 Het kan dus zijn dat de effecten van APOE op cognitie ook pas later 
manifesteren. Daarnaast kan het ook zo zijn dat de effecten zich vooral bij bepaalde 
groepen manifesteren. Vervolgstudies zouden daarom in grote steekproeven kunnen 
stratificeren voor potentiële moderatoren, zoals geslacht, leeftijd en andere genetische 
kenmerken.29-31
Studie naar genetische determinanten van cognitie in hersentumorpatiënten is 
momenteel nog beperkt. Alhoewel onze studie geen effect van APOE ε4 dragerschap 
aantoonde, is meer onderzoek naar dit en andere genetische kenmerken relevant om 
(late) cognitieve uitkomsten bij deze populatie te voorspellen.















































































































































































































































































































































































































































































































































































































Binnenwerk_Productie.indd   204 1/18/2021   11:39:07 AM
205
Summary in Dutch
De prognostische waarde van cognitieve data in zorg voor patiënten met een hoog-
gradig glioom
Verschillende tumor-specifieke (bijvoorbeeld maligniteit) en patiënt-specifieke 
kenmerken (bijvoorbeeld functionele status en leeftijd) kunnen informatie verschaffen 
over het gedrag van de tumor en de prognose van patiënten.32,33 Cognitieve prestaties 
- en veranderingen daarin - worden steeds meer onderzocht als aanvullende marker 
van tumoractiviteit, omdat prestaties onder invloed staan van bijvoorbeeld infiltratieve 
groei, druk op omliggend hersenweefsel en reactief oedeem.34 Vroege metingen van 
cognitieve prestaties lijken aanvullende informatie te kunnen geven over bijvoorbeeld 
overlevingsduur, onafhankelijk van de eerder genoemde kenmerken.34 In Hoofdstuk 
6 en 7 sluiten aan bij twee vragen die momenteel open staan in het onderzoek naar 
het gebruik van klinisch verkregen cognitieve metingen in het voorspellen van ziekte 
uitkomsten, namelijk 1) voor welk(e) prognostisch doeleinde(n) cognitieve metingen 
gebruikt kunnen worden, en 2) hoe we cognitie dienen te meten als het gebruikt wordt 
als voorspellende factor in plaats van een uitkomst.
In Hoofdstuk 6 onderzochten we op de vraag of stoornissen in de vroege adjuvante 
behandelfase, gemeten op één afspraak als onderdeel van reguliere klinische follow-
up, kunnen worden gebruikt voor vroege prognostische stratificatie van glioblastoom 
patiënten. Hiervoor gebruikte wij het, in medisch onderzoek relatief onbekende, 
Accelerated Failure Time model, dat het effect van een risicofactor kan vertalen in een 
verschil in overlevingsduur. Onze resultaten toonden aan dat patiënten met een stoornis 
op testen van executief functioneren (Stroop test deel III) en reactiesnelheid (Stroop test 
deel I) ongeveer 25% kortere overlevingstijd hadden dan patiënten zonder dergelijke 
stoornissen, zelfs na het controleren voor klinische kenmerken en extra behandeling 
na ziekteprogressie.
Verstoring in prestatie op slechts cognitieve twee testen, gemeten bij een regulier 
zorgmoment 3 maanden na operatie, is een eenvoudig te verkrijgen maat die clinici 
al op een vroeg moment kan informeren relatieve verschillen in overlevingsduur van 
patiënten.
Hoofdstuk 7 beschrijft een studie waarbij onderzocht werd of verandering in 
het cognitief functioneren over de tijd als aanvullende marker gebruikt kan worden 
om groei van een hooggradig glioom te voorspellen. In deze studie werd cognitie 
driemaandelijks gemeten op dezelfde dag als de MRI scan die in de reguliere zorg 
gebruikt wordt en gouden standaard geldt om tumorgroei te monitoren. Uniek in deze 
studie is dat voor iedere patiënt een gepersonaliseerde selectie gemaakt werd van 3 
tests waarop zij gemonitord werden. Deze selectie werd gebaseerd op de functies 
waarop patiënten direct na verwijdering van de tumor het meest op vooruitgingen. 
Onze hypothese was dat de functies die het meest herstellen als de tumor verwijderd, 
ook het snelst achteruitgaan als de tumor terugkeert.
In 25 patiënten met een anaplastich astrocytoom of glioblastoom vonden wij 
dat cognitieve achteruitgang (een achteruitgang op 2 van de 3 gepersonaliseerde 
testen gemeten met de eerder genoemde Reliable Change Index) vastgesteld werd 
Binnenwerk_Productie.indd   205 1/18/2021   11:39:07 AM
206
Appendix I
ten tijde van of zelfs vóór groei van de tumor vastgesteld op de MRI scan in 60% van de 
patiënten. Patiënten waarbij de tumor stabiel bleef, bleven ook overwegend cognitief 
stabiel (80% geen achteruitgang). De kans van tumorgroei op de MRI scan was 5 keer 
hoger in patiënten die cognitieve achteruitgang toonden op hun testen dan in patiënten 
die stabiel waren.
Veranderingen in prestaties op een korte, gepersonaliseerde set cognitieve 
testen kunnen een aanvullende rol spelen in het monitoren en op tijd herkennen van 
tumorprogressie na behandeling.
Concluderend, meting van cognitief functioneren:
1) kan zowel in een vroeg stadium prognostische informatie geven (“welke 
patiënten hebben risico op kortere overleving?”) als over de tijd heen 
aanvullende informatie geven over terugkeer van de tumor (“welke patiënten 
hebben op korte termijn een groter risico op ziekteprogressie?”),
2) kan gedaan worden met korte, gerichte testprotocollen (met een uniforme of 
gepersonaliseerde testselectie) op reguliere zorgmomenten. Hierdoor blijft 
de druk op kwetsbare patiënten en het zorgtraject beperkt.
Uitdagingen en kansen voor de (aansluiting tussen) klinische praktijk en onderzoek
Het is belangrijk dat in wetenschappelijk onderzoek kritisch geëvalueerd wordt in 
hoeverre de gebruikte methodologie aansluit bij wat clinici willen weten en, daaraan 
gerelateerd, of de resultaten die voortkomen uit de methodologie klinisch intuïtief 
gerapporteerd (kunnen) worden.
Voor het voorspellen van de prognose van een patiënt met een ongeneeslijke 
hersentumor is het voor een clinicus bijvoorbeeld relevanter om te weten hoe een 
karakteristiek, zoals een vroege cognitieve stoornis, samenhangt met de overlevingsduur 
dan met de kans op overlijden. Doorgaans worden echter nog methoden toegepast 
die juist het laatste rapporteren. Hoofdstuk 6 toont aan dat het Accelerated Failure 
Time framework een klinisch intuïtief alternatief kan bieden aan reguliere methoden 
in overlevingsstudies. Een methode die cognitieve profielen opspoort in data, zoals 
LCA uit Hoofdstuk 4 en 5, geeft niet alleen een natuurgetrouwer beeld van cognitief 
functioneren dan het apart onderzoeken van cognitieve domeinen, het sluit ook beter 
aan bij de manier waarop klinisch neuropsychologen in de praktijk bij een individuele 
patiënt evalueren welke sterktes en zwaktes aanwezig zijn waarop ingespeeld kan 
worden.
Voor clinici is het belangrijk om bewust te zijn dat cognitieve stoornissen 
veel voorkomen én verschillende facetten van functioneren van patiënten kunnen 
beïnvloeden. Echter heeft de aanwezigheid van en het type cognitieve stoornissen 
ook uitwerking op verschillende aspecten van het werk van clinici. De aanwezigheid van 
geheugenproblematiek zal bijvoorbeeld andere eisen stellen aan de consultvoering dan 
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de aanwezigheid van globale cognitieve verstoring of problematiek met mentaal tempo. 
Daarnaast hebben cognitieve stoornissen invloed op de capaciteit voor besluitvorming. 
Aangezien het patiëntperspectief steeds groter belang krijgt in besluitvorming rondom 
neurochirurgische behandeling, zal dit laatste aspect meer aandacht vragen in zowel 
onderzoek als praktijk.
De manier waarop cognitie getest dient te worden behoeft in de toekomst meer 
aandacht. Vanuit internationale werkgroepen, waaronder de Response Assessment 
in Neuro-Oncology group, is een consensus geformuleerd over een set van cognitieve 
functies die in patiënten met hersentumoren onderzocht dient te worden.35 Echter 
behoeft de inhoud van neuropsychologisch onderzoek enige flexibiliteit, bijvoorbeeld 
op basis van het doel dat gediend wordt. Bij het meten van cognitie als uitkomstmaat, 
tonen onze studies aan dat een brede evaluatie vóór en na operatie van belang is, omdat 
uiteenlopende problematiek gevonden kan worden. Door breed te testen kan een zo 
volledig mogelijk beeld verkregen worden van sterktes en zwaktes van patiënten, en 
veranderingen daarin over de tijd. Een testbatterij kan hierbij ook aangepast worden 
op o.a. de locatie van de tumor, bijvoorbeeld extra testen van executief functioneren 
bij een tumor in de frontaalkwab. Bij het meten van cognitie als voorspeller van ziekte 
uitkomsten, volstaat juist wellicht een beperkter, maar gerichter, neuropsychologisch 
onderzoek. De inhoud van het onderzoek kan hier per patiënt helemaal verschillen.
Uit dit proefschrift komen enkele potentiële richtingen voor toekomstig 
wetenschappelijk onderzoek naar voren. Een van deze richtingen leidt naar de 
verkenning van factoren die beschermend lijken te werken voor cognitief functioneren. 
Uit ons onderzoek kwamen een aantal patiënt- en ziektekenmerken naar voren die 
samenhingen met een intact profiel. Echter waren dit overwegend statische factoren, 
zoals leeftijd en opleidingsniveau. Dynamische predictoren van intact cognitief 
functioneren kunnen handvatten bieden voor verbetering cognitie van patiënten 
die aanvankelijk een verstoord profiel tonen. In ons onderzoek kon bijvoorbeeld 
depressieve symptomatologie een onderscheid tussen het intacte en de verstoorde 
profielen. Eerder is ook aangetoond dat, bijvoorbeeld fysieke activiteit tot verbetering 
kan leiden in verschillende cognitieve functies.36
Om beter aan te sluiten bij de kliniek moet in wetenschappelijk onderzoek ook 
rekening gehouden worden met het feit dat er, naast verslechtering en verbetering 
van cognitief functioneren, ook kwalitatieve veranderingen kunnen optreden die niet 
in een van die twee categorieën vallen. Deze kwalitatieve veranderingen kunnen niet 
eenvoudig met traditionele statistiek onderzocht worden. Daarom is het van belang 
dat meer complexe statistische methoden, waaronder machine learning, betrokken 
worden in onderzoek naar cognitie bij hersentumor patiënten. Momenteel wordt in 
het Elisabeth-Tweesteden ziekenhuis als onderdeel van Topklinische Zorg en Onderzoek 
2020-2024 (TZO) projecten (zie: https://www.etz.nl/Over-ETZ/Thema/TZO) gewerkt aan 
de ontwikkeling van een classificatie tool die op basis van aangevoerde data predicties 
kan doen over cognitieve uitkomsten voor individuele patiënten.




Verstoring van cognitief functioneren is een veelvoorkomend symptoom van primaire 
hersentumoren. Verstoringen blijven na behandeling even prevalent op groepsniveau, 
maar kunnen een kwalitatief andere uiting hebben in de individuele patiënt. Patiënt- 
en ziektekarakteristieken dragen bij aan specifieke cognitieve stoornissen, terwijl 
de invloed van variatie in APOE allel dragerschap wellicht beperkt is. Kort, gericht 
neuropsychologisch onderzoek na operatie kan helpen bij zowel vroege prognostische 
verfijning als bij monitoring van de ziekte over tijd. We stellen voor om het framework 
voor onderzoek naar cognitie op meerdere manieren te verbreden; 1) van onderzoek van 
prestaties op aparte testen naar onderzoek van profielen, die prestaties op verschillende 
tests combineren, 2) van “verbetering, stabiliteit en verslechtering” van prestaties 
naar “kwalitatieve veranderingen” in cognitie over de tijd, en 3) van (secundaire) 
uitkomstmaat naar een maat met een veelzijdige toegevoegde waarde. Mogelijkheden 
voor toekomstig onderzoek kunnen liggen in het gebruik van geavanceerde, data-driven 
analyses die gericht zijn op het leveren van bruikbare (classificatie) instrumenten voor 
de klinische praktijk.
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